{
    "data": [
        {
            "title": "Quanta Services to Participate in Two Institutional Investor Conferences in March | PWR Stock News",
            "description": "<article class=\"article\"><div class=\"xn-content\"><p class=\"prntac\"><i>Jefferies Power, Energy, Clean Energy, and Utilities Conference 2026</i></p><p class=\"prntac\"><i>Daiwa Investment Conference Tokyo 2026</i></p><p><span class=\"legendSpanClass\"><location idsrc=\"xmltag.org\" value=\"LU/us.tx.houstn\">HOUSTON</location></span>, <span class=\"legendSpanClass\">Feb. 27, 2026</span> /PRNewswire/ -- Quanta Services, Inc. (NYSE: <a class=\"symbol-link\" href=\"/overview/PWR/\" title=\"View PWR stock overview\">PWR</a>) announced today that company management will participate in two institutional investor conferences in March, including the Jefferies Power, Energy, Clean Energy, and Utilities Conference 2026 in <location idsrc=\"xmltag.org\" value=\"LU/us.ny.nyc\">New York City</location> and the Daiwa Investment Conference Tokyo 2026. </p><div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\"><p><a href=\"https://mma.prnewswire.com/media/334505/quanta_services_logo.html\" rel=\"nofollow noopener\" target=\"_blank\"><img alt=\"Quanta Services Logo. (PRNewsFoto/Quanta Services, Inc.)\" loading=\"lazy\" src=\"https://mma.prnewswire.com/media/334505/quanta_services_logo.jpg\" title=\"Quanta Services Logo. (PRNewsFoto/Quanta Services, Inc.)\"/></a></p></div><p><b><i>Jefferies Power, Energy, Clean Energy, and Utilities Conference 2026<br/></i></b>Duke <location idsrc=\"xmltag.org\" value=\"LU/us.tx.austin\">Austin</location>, Chief Executive Officer, and Jayshree Desai, Chief Financial Officer, will meet with institutional investors during the conference on March 3, 2026 in <location idsrc=\"xmltag.org\" value=\"LU/us.ny.nyc\">New York City</location>. Mr. <location idsrc=\"xmltag.org\" value=\"LU/us.tx.austin\">Austin</location> and Ms. Desai will also participate in a fireside chat hosted by Jefferies analyst Julien Dumoulin-Smith on the same day at 2:45 p.m. Eastern time, which will be broadcast live over the Internet. Live webcast links and archived replays of this presentation will be available in the \"News &amp; Events\" area of the Investor Relations section of Quanta's website (<a href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629219-1&amp;h=3380947856&amp;u=https%3A%2F%2Finvestors.quantaservices.com%2Fnews-events&amp;a=https%3A%2F%2Finvestors.quantaservices.com%2Fnews-events\" rel=\"nofollow noopener\" target=\"_blank\">https://investors.quantaservices.com/news-events</a><u>)</u>.</p><p><b><i>Daiwa Investment Conference Tokyo 2026<br/></i></b>Kip Rupp, Vice President – Investor Relations, will meet with institutional investors in <location idsrc=\"xmltag.org\" value=\"LU/jp..tokyo\">Tokyo</location> during the conference on March 2 and 3, 2026.</p><p><b>About Quanta Services<br/></b>Quanta Services is an industry leader in providing specialized infrastructure solutions to the utility, power generation, load center, communications, pipeline, and energy industries. Quanta's comprehensive services include designing, installing, repairing and maintaining energy, load center and communications infrastructure. With operations throughout <location idsrc=\"xmltag.org\" value=\"LC/us\">the United States</location>, <location idsrc=\"xmltag.org\" value=\"LC/ca\">Canada</location>, <location idsrc=\"xmltag.org\" value=\"LC/au\">Australia</location> and select other international markets, Quanta has the manpower, resources and expertise to safely complete projects that are local, regional, national or international in scope. For more information, visit <a href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629219-1&amp;h=2764480197&amp;u=http%3A%2F%2Fwww.quantaservices.com%2F&amp;a=www.quantaservices.com\" rel=\"nofollow noopener\" target=\"_blank\">www.quantaservices.com</a>.</p><div><table border=\"0\" cellpadding=\"1\" cellspacing=\"0\" class=\"prnbcc\"><tr><td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">Contact:</span></p></td><td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">Kip Rupp, CFA, IRC</span></p></td></tr><tr><td class=\"prngen3\" colspan=\"1\" rowspan=\"1\"><br/></td><td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">Sean Eastman</span></p></td></tr><tr><td class=\"prngen3\" colspan=\"1\" rowspan=\"1\"><br/></td><td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">Quanta Services, Inc.</span></p></td></tr><tr><td class=\"prngen3\" colspan=\"1\" rowspan=\"1\"><br/></td><td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">(713) 629-7600 </span></p></td></tr></table></div><p> </p><p>SOURCE Quanta Services, Inc.</p></div></article>",
            "link": "https://www.stocktitan.net/news/PWR/quanta-services-to-participate-in-two-institutional-investor-sqvrvjhap5hw.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 14:49:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Director/PDMR Shareholding | SHEL Stock News",
            "description": "<article class=\"article\"><table style=\"border-collapse: collapse; width:648px; border-collapse:collapse ;\"><tr><td colspan=\"5\" style=\"width:576.043px;;vertical-align: middle ; \"><b>NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU AND UK MARKET ABUSE REGIMES</b></td></tr><tr><td style=\"width:126.042px;;vertical-align: bottom ; \"> </td><td style=\"width:141.104px;;vertical-align: bottom ; \"> </td><td style=\"width:114.542px;;vertical-align: bottom ; \"> </td><td style=\"width:94.417px;;vertical-align: bottom ; \"> </td><td style=\"width:99.9375px;;vertical-align: bottom ; \"> </td></tr><tr><td colspan=\"5\" style=\"width:576.043px;;vertical-align: middle ; \">February 27, 2026</td></tr><tr><td style=\"width:126.042px;;vertical-align: middle ; \"> </td><td style=\"width:141.104px;;vertical-align: bottom ; \"> </td><td style=\"width:114.542px;;vertical-align: bottom ; \"> </td><td style=\"width:94.417px;;vertical-align: bottom ; \"> </td><td style=\"width:99.9375px;;vertical-align: bottom ; \"> </td></tr><tr><td colspan=\"5\" style=\"width:576.043px;;vertical-align: middle ; \">Shell plc announces that each of the following Persons Discharging Managerial Responsibilities (“PDMRs”) have received the number of shares as set out below. A percentage of the PDMR’s annual bonus is delivered in cash and a percentage is delivered in shares. Shares are subject to a three-year holding period, which continues to apply after PDMRs leave employment.</td></tr><tr><td style=\"width:126.042px;;vertical-align: bottom ; \"> </td><td style=\"width:141.104px;;vertical-align: bottom ; \"> </td><td style=\"width:114.542px;;vertical-align: bottom ; \"> </td><td style=\"width:94.417px;;vertical-align: bottom ; \"> </td><td style=\"width:99.9375px;;vertical-align: bottom ; \"> </td></tr><tr><td style=\"width:126.042px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: bottom ; \">PDMR</td><td style=\"width:141.104px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">Date Acquired</td><td style=\"width:114.542px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">Share Type</td><td style=\"width:94.417px;;text-align: right ;  vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">Number of shares acquired</td><td style=\"width:99.9375px;;text-align: right ;  vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">Purchase price per Share</td></tr><tr><td style=\"width:126.042px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: bottom ; \">Wael Sawan</td><td style=\"width:141.104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">26 February 2026</td><td style=\"width:114.542px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">SHEL (LSE)</td><td style=\"width:94.417px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> 23,980 </td><td style=\"width:99.9375px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> GBP 30.11 </td></tr><tr><td style=\"width:126.042px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: bottom ; \">Sinead Gorman</td><td style=\"width:141.104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">26 February 2026</td><td style=\"width:114.542px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">SHEL (LSE)</td><td style=\"width:94.417px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> 15,841 </td><td style=\"width:99.9375px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> GBP 30.11 </td></tr><tr><td style=\"width:126.042px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: bottom ; \">Philippa Bounds</td><td style=\"width:141.104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">26 February 2026</td><td style=\"width:114.542px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">SHEL (LSE)</td><td style=\"width:94.417px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> 6,892 </td><td style=\"width:99.9375px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> GBP 30.11 </td></tr><tr><td style=\"width:126.042px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: bottom ; \">Peter Costello</td><td style=\"width:141.104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">26 February 2026</td><td style=\"width:114.542px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">SHEL (LSE)</td><td style=\"width:94.417px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> 3,060 </td><td style=\"width:99.9375px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> GBP 30.11 </td></tr><tr><td style=\"width:126.042px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: bottom ; \">Andrew Smith</td><td style=\"width:141.104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">26 February 2026</td><td style=\"width:114.542px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">SHELL (AMS)</td><td style=\"width:94.417px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> 6,853 </td><td style=\"width:99.9375px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> EUR 34.57 </td></tr><tr><td style=\"width:126.042px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: bottom ; \">Rachel Solway</td><td style=\"width:141.104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">26 February 2026</td><td style=\"width:114.542px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">SHEL (LSE)</td><td style=\"width:94.417px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> 6,892 </td><td style=\"width:99.9375px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> GBP 30.11 </td></tr><tr><td style=\"width:126.042px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: bottom ; \">Cederic Cremers</td><td style=\"width:141.104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">25 February 2026</td><td style=\"width:114.542px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">SHELL (AMS)</td><td style=\"width:94.417px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> 5,321 </td><td style=\"width:99.9375px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> EUR 34.18 </td></tr><tr><td style=\"width:126.042px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: bottom ; \">Machteld de Haan</td><td style=\"width:141.104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">25 February 2026</td><td style=\"width:114.542px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">SHELL (AMS)</td><td style=\"width:94.417px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> 4,979 </td><td style=\"width:99.9375px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> EUR 34.18 </td></tr><tr><td style=\"width:126.042px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: bottom ; \">Robin Mooldijk</td><td style=\"width:141.104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">25 February 2026</td><td style=\"width:114.542px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \">SHELL (AMS)</td><td style=\"width:94.417px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> 3,648 </td><td style=\"width:99.9375px;;text-align: right ;  vertical-align: middle; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; \"> EUR 34.18 </td></tr><tr><td style=\"width:126.042px;;vertical-align: bottom ; \"> </td><td style=\"width:141.104px;;vertical-align: bottom ; \"> </td><td style=\"width:114.542px;;vertical-align: bottom ; \"> </td><td style=\"width:94.417px;;vertical-align: bottom ; \"> </td><td style=\"width:99.9375px;;vertical-align: bottom ; \"> </td></tr><tr><td colspan=\"4\" style=\"width:476.105px;;vertical-align: middle ; \">The Notification of Dealing Form for each PDMR can be found below.</td><td style=\"width:99.9375px;;vertical-align: bottom ; \"> </td></tr><tr><td style=\"width:126.042px;;vertical-align: bottom ; \"> </td><td style=\"width:141.104px;;vertical-align: bottom ; \"> </td><td style=\"width:114.542px;;vertical-align: bottom ; \"> </td><td style=\"width:94.417px;;vertical-align: bottom ; \"> </td><td style=\"width:99.9375px;;vertical-align: bottom ; \"> </td></tr><tr><td style=\"width:126.042px;;vertical-align: bottom ; \"> </td><td style=\"width:141.104px;;vertical-align: bottom ; \"> </td><td style=\"width:114.542px;;vertical-align: bottom ; \"> </td><td style=\"width:94.417px;;vertical-align: bottom ; \"> </td><td style=\"width:99.9375px;;vertical-align: bottom ; \"> </td></tr><tr><td style=\"width:126.042px;;vertical-align: middle ; \">Julie Keefe</td><td style=\"width:141.104px;;vertical-align: bottom ; \"> </td><td style=\"width:114.542px;;vertical-align: bottom ; \"> </td><td style=\"width:94.417px;;vertical-align: bottom ; \"> </td><td style=\"width:99.9375px;;vertical-align: bottom ; \"> </td></tr><tr><td colspan=\"2\" style=\"width:267.146px;;vertical-align: middle ; \">Deputy Company Secretary</td><td style=\"width:114.542px;;vertical-align: bottom ; \"> </td><td style=\"width:94.417px;;vertical-align: bottom ; \"> </td><td style=\"width:99.9375px;;vertical-align: bottom ; \"> </td></tr><tr><td style=\"width:126.042px;;vertical-align: bottom ; \"> </td><td style=\"width:141.104px;;vertical-align: bottom ; \"> </td><td style=\"width:114.542px;;vertical-align: bottom ; \"> </td><td style=\"width:94.417px;;vertical-align: bottom ; \"> </td><td style=\"width:99.9375px;;vertical-align: bottom ; \"> </td></tr><tr><td style=\"width:126.042px;;vertical-align: middle ; \"><b>ENQUIRIES</b></td><td style=\"width:141.104px;;vertical-align: bottom ; \"> </td><td style=\"width:114.542px;;vertical-align: bottom ; \"> </td><td style=\"width:94.417px;;vertical-align: bottom ; \"> </td><td style=\"width:99.9375px;;vertical-align: bottom ; \"> </td></tr><tr><td colspan=\"2\" style=\"width:267.146px;;vertical-align: middle ; \">Shell Media Relations</td><td style=\"width:114.542px;;vertical-align: bottom ; \"> </td><td style=\"width:94.417px;;vertical-align: bottom ; \"> </td><td style=\"width:99.9375px;;vertical-align: bottom ; \"> </td></tr><tr><td colspan=\"3\" style=\"width:381.688px;;vertical-align: middle ; \">International, UK, European Press: +44 20 7934 5550</td><td style=\"width:94.417px;;vertical-align: bottom ; \"> </td><td style=\"width:99.9375px;;vertical-align: bottom ; \"> </td></tr><tr><td style=\"width:126.042px;;vertical-align: middle ; \"> </td><td style=\"width:141.104px;;vertical-align: bottom ; \"> </td><td style=\"width:114.542px;;vertical-align: bottom ; \"> </td><td style=\"width:94.417px;;vertical-align: bottom ; \"> </td><td style=\"width:99.9375px;;vertical-align: bottom ; \"> </td></tr></table><p><br/></p><table style=\"border-collapse: collapse; width:433pt; border-collapse:collapse ;\"><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>1. Details of the person discharging managerial responsibilities/person closely associated</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>First Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Wael</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Last Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Sawan</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>2. Reason for the notification</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Position/status</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Chief Executive Officer</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Initial notification/ amendment</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Initial notification</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Full name of the entity</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Shell plc</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Legal Entity Identifier code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">21380068P1DRHMJ8KU70</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Description of the financial instrument</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Ordinary shares of <money>€0.07</money> each</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Identification Code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">GB00BP6MXD84</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Nature of the transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Delivery of <percent>50%</percent> of bonus in shares</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Currency</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">GBP</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">30.11</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">23,980.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">722,037.80</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Aggregated information</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \"> </td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">23,980.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">30.11</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">722,037.80</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Date of transaction </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">26/02/2026</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Place of transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Outside a trading venue</td></tr></table><p><br/></p><table style=\"border-collapse: collapse; width:433pt; border-collapse:collapse ;\"><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>1. Details of the person discharging managerial responsibilities/person closely associated</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>First Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Sinead</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Last Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Gorman</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>2. Reason for the notification</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Position/status</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Chief Financial Officer</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Initial notification/ amendment</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Initial notification</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Full name of the entity</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Shell plc</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Legal Entity Identifier code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">21380068P1DRHMJ8KU70</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Description of the financial instrument</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Ordinary shares of <money>€0.07</money> each</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Identification Code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">GB00BP6MXD84</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Nature of the transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Delivery of <percent>50%</percent> of bonus in shares</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Currency</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">GBP</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">30.11</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">15,841.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">476,972.51</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Aggregated information</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \"> </td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">15,841.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">30.11</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">476,972.51</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Date of transaction </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">26/02/2026</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Place of transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Outside a trading venue</td></tr></table><p><br/></p><table style=\"border-collapse: collapse; width:433pt; border-collapse:collapse ;\"><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>1. Details of the person discharging managerial responsibilities/person closely associated</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>First Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Philippa</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Last Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Bounds</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>2. Reason for the notification</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Position/status</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Chief Legal Officer</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Initial notification/ amendment</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Initial notification</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Full name of the entity</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Shell plc</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Legal Entity Identifier code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">21380068P1DRHMJ8KU70</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Description of the financial instrument</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Ordinary shares of <money>€0.07</money> each</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Identification Code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">GB00BP6MXD84</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Nature of the transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Delivery of <percent>50%</percent> of bonus in shares</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Currency</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">GBP</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">30.11</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">6,892.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">207,518.12</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Aggregated information</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \"> </td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">6,892.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">30.11</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">207,518.12</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Date of transaction </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">26/02/2026</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Place of transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Outside a trading venue</td></tr></table><p><br/></p><table style=\"border-collapse: collapse; width:433pt; border-collapse:collapse ;\"><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>1. Details of the person discharging managerial responsibilities/person closely associated</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>First Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Peter</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Last Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Costello</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>2. Reason for the notification</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Position/status</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">President, Upstream</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Initial notification/ amendment</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Initial notification</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Full name of the entity</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Shell plc</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Legal Entity Identifier code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">21380068P1DRHMJ8KU70</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Description of the financial instrument</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Ordinary shares of <money>€0.07</money> each</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Identification Code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">GB00BP6MXD84</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Nature of the transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Delivery of <percent>25%</percent> of bonus in shares</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Currency</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">GBP</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">30.11</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">3,060.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">92,136.60</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Aggregated information</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \"> </td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">3,060.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">30.11</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">92,136.60</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Date of transaction </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">26/02/2026</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Place of transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Outside a trading venue</td></tr></table><p><br/></p><table style=\"border-collapse: collapse; width:433pt; border-collapse:collapse ;\"><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>1. Details of the person discharging managerial responsibilities/person closely associated</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>First Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Andrew</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Last Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Smith</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>2. Reason for the notification</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Position/status</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">President, Trading and Supply</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Initial notification/ amendment</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Initial notification</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Full name of the entity</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Shell plc</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Legal Entity Identifier code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">21380068P1DRHMJ8KU70</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Description of the financial instrument</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Ordinary shares of <money>€0.07</money> each</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Identification Code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">GB00BP6MXD84</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Nature of the transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Delivery of <percent>50%</percent> of bonus in shares</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Currency</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">EUR</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">34.57</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">6,853.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">236,908.21</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Aggregated information</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \"> </td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">6,853.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">34.57</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">236,908.21</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Date of transaction </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">26/02/2026</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Place of transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Outside a trading venue</td></tr></table><p><br/></p><table style=\"border-collapse: collapse; width:433pt; border-collapse:collapse ;\"><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>1. Details of the person discharging managerial responsibilities/person closely associated</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>First Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Rachel</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Last Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Solway</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>2. Reason for the notification</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Position/status</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Chief Human Resources and Corporate Officer</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Initial notification/ amendment</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Initial notification</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Full name of the entity</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Shell plc</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Legal Entity Identifier code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">21380068P1DRHMJ8KU70</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Description of the financial instrument</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Ordinary shares of <money>€0.07</money> each</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Identification Code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">GB00BP6MXD84</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Nature of the transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Delivery of <percent>50%</percent> of bonus in shares</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Currency</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">GBP</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">30.11</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">6,892.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">207,518.12</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Aggregated information</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \"> </td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">6,892.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">30.11</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">207,518.12</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Date of transaction </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">26/02/2026</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Place of transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Outside a trading venue</td></tr></table><p><br/></p><table style=\"border-collapse: collapse; width:433pt; border-collapse:collapse ;\"><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>1. Details of the person discharging managerial responsibilities/person closely associated</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>First Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Cederic</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Last Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Cremers</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>2. Reason for the notification</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Position/status</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">President, Integrated Gas</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Initial notification/ amendment</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Initial notification</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Full name of the entity</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Shell plc</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Legal Entity Identifier code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">21380068P1DRHMJ8KU70</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Description of the financial instrument</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Ordinary shares of <money>€0.07</money> each</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Identification Code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">GB00BP6MXD84</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Nature of the transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Delivery of <percent>50%</percent> of bonus in shares</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Currency</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">EUR</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">34.18</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">5,321.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">181,871.78</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Aggregated information</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \"> </td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">5,321.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">34.18</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">181,871.78</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Date of transaction </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">25/02/2026</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Place of transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Outside a trading venue</td></tr></table><p><br/></p><table style=\"border-collapse: collapse; width:433pt; border-collapse:collapse ;\"><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>1. Details of the person discharging managerial responsibilities/person closely associated</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>First Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Machteld</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Last Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">de Haan</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>2. Reason for the notification</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Position/status</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">President, Downstream, Renewables and Energy Solutions</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Initial notification/ amendment</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Initial notification</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Full name of the entity</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Shell plc</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Legal Entity Identifier code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">21380068P1DRHMJ8KU70</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Description of the financial instrument</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Ordinary shares of <money>€0.07</money> each</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Identification Code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">GB00BP6MXD84</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Nature of the transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Delivery of <percent>50%</percent> of bonus in shares</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Currency</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">EUR</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">34.18</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">4,979.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">170,182.22</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Aggregated information</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \"> </td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">4,979.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">34.18</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">170,182.22</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Date of transaction </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">25/02/2026</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Place of transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Outside a trading venue</td></tr></table><p><br/></p><table style=\"border-collapse: collapse; width:433pt; border-collapse:collapse ;\"><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>1. Details of the person discharging managerial responsibilities/person closely associated</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>First Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Robin</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Last Name(s)</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Mooldijk</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>2. Reason for the notification</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Position/status</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">President, Projects &amp; Technology</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Initial notification/ amendment</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Initial notification</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Full name of the entity</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Shell plc</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Legal Entity Identifier code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">21380068P1DRHMJ8KU70</td></tr><tr><td colspan=\"2\" style=\"width:577.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted</b></td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Description of the financial instrument</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Ordinary shares of <money>€0.07</money> each</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Identification Code</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">GB00BP6MXD84</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Nature of the transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Delivery of <percent>25%</percent> of bonus in shares</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Currency</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">EUR</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">34.18</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">3,648.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">124,688.64</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Aggregated information</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \"> </td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Volume </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">3,648.00</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Price</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; vertical-align: middle ; \">34.18</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Total</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">124,688.64</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Date of transaction </b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">25/02/2026</td></tr><tr><td style=\"width:202.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; \"><b>Place of transaction</b></td><td style=\"width:374.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: middle ; \">Outside a trading venue</td></tr></table><img alt=\"\" class=\"__GNW8366DE3E__IMG\" loading=\"lazy\" src=\"https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE2NzI4NSM0MDIzNTAxMTIjMjI0ODQ2OA==\"/> <br/><img alt=\"\" loading=\"lazy\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml-eu.globenewswire.com/media/NmQwMWIyZmItZDEyMi00ZWQ2LWE0NmMtMzUxOWE0ZjQ5ZGU1LTEyNjAwMjEtMjAyNi0wMi0yNy1lbg==/tiny/Shell-plc.png\"/></article>",
            "link": "https://www.stocktitan.net/news/SHEL/director-pdmr-540d8xsmgj4f.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 15:43:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "RETRANSMISSION: QIMC Identifies Second Hydrogen-Associated Structural Zone at 313m, Supporting Multi-Zone H2 System at West Advocate in Nova Scotia | QIMCF Stock News",
            "description": "<article class=\"article\"><p><b>Vertical Structural Continuity Emerging in DDH-26-01</b><br/><b>Nova Scotia Introduces Purpose-Built Natural Hydrogen Legislation</b></p><p>Montreal, Quebec--(Newsfile Corp. - February 27, 2026) - Québec Innovative Materials Corp. (CSE: QIMC) (OTCQB: <a class=\"symbol-link\" href=\"/overview/QIMCF/\" title=\"View QIMCF stock overview\">QIMCF</a>) (FSE: 7FJ) (\"QIMC\" or the \"Company\") reports that drill hole DDH-26-01 has intersected a second hydrogen-associated structural zone at approximately 313 metres depth at its West Advocate Project, Nova Scotia. This interval from approximately 313 metres to 330 metres depth is distinct from the previously reported 40-metre hydrogen-bearing fault corridor encountered between 142 and 191 metres.</p><p>The identification of two vertically separated hydrogen-associated structural zones within a single borehole supports the interpretation of a structurally controlled, multi-zone natural hydrogen system and further strengthens QIMC's H2 geological model. Drilling at DDH-26-01 remains ongoing toward the planned total depth of 650 metres.</p><p>This development coincides with the Government of Nova Scotia's introduction of the Powering the Economy Act (Bill No. 193), proposed legislation that regulates natural hydrogen as a subsurface energy resource within the Province. This legislative development directly enhances investment certainty and long-term planning capability and demonstrates the Province's and Premier Houston's commitment to establishing Nova Scotia as a hub for responsible clean energy development. The Company's exploration at West Advocate involves no hydraulic fracturing and no reservoir stimulation.</p><p><b>What This Means for Investors</b></p><p>DDH-26-01 has now intersected hydrogen-associated structural intervals at approximately 142 metres and 313 metres depth within a single borehole, supporting the interpretation of a multi-zone, structurally controlled natural hydrogen system rather than an isolated occurrence. In natural hydrogen exploration, structural repetition across depth is a recognized indicator of system continuity and scale. This result further strengthens QIMC's working geological model and provides a defined, systematic, data-driven pathway for the next phases of its Nova Scotia natural hydrogen exploration program.</p><p><b>CEO Commentary</b></p><p>John Karagiannidis, President &amp; CEO of QIMC, stated:</p><p>\"Intersecting a second hydrogen-associated structural zone at 320 metres while Hole 1 continues drilling toward 650 metres significantly strengthens our geological interpretation of West Advocate as a structurally controlled, multi-zone system. We are observing vertically separated brecciated intervals within a single borehole that exhibit geochemical characteristics consistent with hydrogen-bearing environments.</p><p>The Province of Nova Scotia's introduced regulatory framework provides the clarity necessary to responsibly advance multi-well exploration strategies and support long-term planning and investment. As we continue defining structural continuity through drilling and logging, this regulatory certainty underpins our disciplined, systematic approach and we commend the Province for its proactive clean energy leadership.\"</p><p><b>Project Geologist Commentary</b></p><p>Edward Procyshyn, Project Geologist, commented:</p><p>\"Drill logging has identified within the second structural fault zone three separate brecciated shear zones that are progressively more altered and sheared downhole. With progressive alteration, the breccia fragments become more completely replaced by finely crystalline massive dark carbon-graphite and dark mica. Each underlying shear zone is more highly altered than the overlying shear zone. The middle and lower altered shear zones were most highly altered and develop dark, very finely granular, massive carbon-rich intervals 0.5 to 1 metre thick. These highly altered core intervals contain the highest measured hydrogen gas values.</p><p>The host rock within the structural fault zone is also progressively altered as the intensity of shear deformation increases downhole. Thinly bedded, finely granular siltstone, dark carbonaceous mudstone, and fanglomerate are progressively recrystallized to form, within the structural fault zone, massive white, very fine-grained porcelain-like units cut by darker web to lenticular fractures. As shear fracturing and alteration increase in intensity downhole, the intervening porcellanite-like host changes colour from white to pale green and finally to darker greenish grey, indicating mineralogical changes due to increasing conditions of alteration.\"</p><p>Edward Procyshyn continued:</p><p>\"The progressive hydrothermal alteration of this structural fault shear zone supports the model that white native hydrogen is being increasingly generated at lower crustal levels by degassing of a magmatic system and being transported by advective hydrothermal fluids into the fault-related shear structures. This suggests that the degassing may be generated by injection of mantle plumes into the upper crust within the West Advocate area and that this process may have contributed significant amounts of white hydrogen gas that was and is presently being measured in the intersected structural zones and at surface in the soil-gas samples.</p><p>The very low to absent quantities of methane contained in the measured gases support the concept that hydrogen is being generated from crustal sources in a naturally occurring hydrogen system rather than from a conventional hydrocarbon occurrence.\"</p><p><b>Gas Monitoring Observations at 313m</b></p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"text-align: start; width: 100%; border-collapse: collapse;\"><tbody><tr><td style=\"vertical-align: top;\">Parameter</td><td style=\"width: 50%; vertical-align: top;\">Observation<br/><br/></td></tr><tr><td style=\"vertical-align: top;\">Hydrogen (H₂)</td><td style=\"width: 50%; vertical-align: top;\">Elevated concentrations detected<br/><br/></td></tr><tr><td style=\"vertical-align: top;\">Oxygen (O₂)</td><td style=\"width: 50%; vertical-align: top;\">Depleted relative to atmospheric levels<br/><br/></td></tr><tr><td style=\"vertical-align: top;\">Methane (CH₄)</td><td style=\"width: 50%; vertical-align: top;\">None detected<br/><br/></td></tr><tr><td style=\"vertical-align: top;\">Hydraulic fracturing / stimulation</td><td style=\"width: 50%; vertical-align: top;\">Not conducted<br/><br/></td></tr></tbody></table><p> </p><p>Measurements were collected in ambient atmospheric air near the borehole collar and during core handling and are subject to atmospheric dilution.</p><p><b>2026 Drill Program: Five-Hole Campaign</b></p><p>DDH-26-01 is the first hole in a planned five-hole 2026 drill program designed to systematically evaluate structural hydrogen corridors at West Advocate and adjacent targets.</p><ul><li><p>Hole 1 (DDH-26-01): Drilling continues toward planned 650 metres depth.</p></li><li><p>Hole 2 (DDH-26-02): Planned from same pad; oriented N297° with 55° plunge to the northwest.</p></li><li><p>Hole 3 (DDH-26-03): Eatonville Road area along the Reid Line; planned to 700 metres depth.</p></li><li><p>Holes 4 &amp; 5 (DDH-26-04 and DDH-26-05): Bennett Hill targets testing the broader regional structural hydrogen corridor.</p></li></ul><p><b>Nova Scotia Legislation</b></p><p>Nova Scotia's proposed legislation reflects a broader recognition by governments that natural hydrogen warrants a dedicated regulatory framework, a development that directly benefits companies with active exploration programs in the province. QIMC is a publicly listed companies with a scientifically rigorous, active drill program specifically targeting structurally hosted natural hydrogen systems in North America.</p><p><b>About Québec Innovative Materials Corp. (QIMC)</b></p><p>Québec Innovative Materials Corp. (CSE: QIMC) (OTCQB: <a class=\"symbol-link\" href=\"/overview/QIMCF/\" title=\"View QIMCF stock overview\">QIMCF</a>) (FSE: 7FJ) is a mining exploration and development company dedicated to unlocking the potential of North America's abundant natural resources. With properties in Ontario, Quebec, Nova Scotia, and Minnesota (USA), QIMC specializes in the exploration of white (natural) hydrogen and high-grade silica assets. QIMC is committed to sustainable development, environmental stewardship, and innovation, with the objective of supporting clean energy solutions for the AI-driven and carbon-neutral economy.</p><div id=\"contactInfo\"><p><b>For More Information, Please Contact:</b></p><p><b>QUEBEC INNOVATIVE MATERIALS CORP.</b><br/>John Karagiannidis<br/>President &amp; Chief Executive Officer<br/>Email: <a href=\"mailto:info@qimaterials.com\" rel=\"nofollow noopener\">info@qimaterials.com</a><br/>Tel: +1 514-726-7058</p></div><p><b>Regulatory Disclaimer</b></p><p><i>Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this press release and has neither approved nor disapproved its contents. Technical Note: Hydrogen readings reported are based on real-time field measurements from the first 350 metres of Hole 1 using calibrated monitoring equipment at the borehole collar with an upper measurement range of approximately 1,000 ppm. True structural width and regional continuity remain subject to further drilling and structural interpretation. Drilling remains ongoing to the planned 650 metre depth.</i></p><p><i><b>Forward-Looking Statements</b></i></p><p><i>This press release contains \"forward-looking statements\" and \"forward-looking information\" within the meaning of applicable Canadian securities legislation. These statements are based on expectations, estimates, and projections as of the date of this press release and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements of the Company to differ materially from those expressed or implied.</i></p><p><i>Forward-looking statements are generally identified by words such as \"expects,\" \"anticipates,\" \"believes,\" \"intends,\" \"estimates,\" \"projects,\" \"potential,\" and similar expressions, or by statements that events or conditions \"will,\" \"may,\" \"could,\" or \"should\" occur.</i></p><p><i>Although the Company believes that the forward-looking information contained herein is reasonable as of the date of this press release, such information is subject to change and no assurance can be given that future results will be achieved. The Company undertakes no obligation to update forward-looking statements except as required by applicable law.</i></p><p id=\"corporateNewsLogoContainer\"><img alt=\"Corporate Logo\" id=\"corporateNewsLogo\" loading=\"lazy\" src=\"https://images.newsfilecorp.com/files/7968/285642_81bd210cd4914a31_logo.jpg\"/></p><p id=\"corporateLinkBack\">To view the source version of this press release, please visit <a href=\"https://api.newsfilecorp.com/redirect/xEjnXFK8az\" rel=\"nofollow noopener\">https://www.newsfilecorp.com/release/285642</a></p><p><img alt=\"\" loading=\"lazy\" src=\"https://api.newsfilecorp.com/newsinfo/285642/375\"/></p></article>",
            "link": "https://www.stocktitan.net/news/QIMCF/retransmission-qimc-identifies-second-hydrogen-associated-structural-gpqmsf2j58rq.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 14:41:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Stonegate Capital Partners Updates Coverage on BlackSky Technology, Inc. (BKSY) 4Q25 | BKSY Stock News",
            "description": "<article class=\"article\"><p>Dallas, Texas--(Newsfile Corp. - February 27, 2026) - BlackSky Technology, Inc. (NYSE: <a class=\"symbol-link\" href=\"/overview/BKSY/\" title=\"View BKSY stock overview\">BKSY</a>): Stonegate Capital Partners Updates Coverage on BlackSky Technology, Inc. (NYSE: <a class=\"symbol-link\" href=\"/overview/BKSY/\" title=\"View BKSY stock overview\">BKSY</a>). <a class=\"symbol-link\" href=\"/overview/BKSY/\" title=\"View BKSY stock overview\">BKSY</a> reported revenue, adj      EBITDA, and EPS of <money>$35.2M</money>, <money>$8.8M</money>, and (<money>$0.02)</money>, respectively. This compares to our/consensus estimates of <money>$41.1M</money>/<money>$36.1M</money>, <money>$11.1M</money>/<money>$7.2M</money>, and (<money>$0.18)</money>/(<money>$0.28)</money>. Imagery and Software Analytical      Services revenue declined to <money>$14.5M</money> (-<percent>17%</percent> y/y), with management remaining cautious amid EOCL-related budget uncertainty. Mission Solutions rose to <money>$9.5M</money> (vs. <money>$1.0M</money> last year) on a new      international Gen-3 contract and milestone deliveries. Professional and Engineering Services slipped to <money>$11.2M</money> from <money>$11.9M</money> y/y due to project timing. Adjusted EBITDA increased to <money>$8.8M</money> from      <money>$7.4M</money> on higher revenue and cost discipline, while gross margin improved to <percent>72.6%</percent> from <percent>65.3%</percent> in 3Q25.</p> <p>      To view the full announcement, including downloadable images, bios, and more, <a href=\"https://api.newsfilecorp.com/redirect/xEjnLIK8aK\" rel=\"nofollow noopener\">click here</a>.    </p> <p> <b>Key Takeaways:</b> </p> <ul> <li><money>$240M</money>+ new awards lifted backlog to <money>$345M</money>, mostly international Gen-3.      </li> <li>FY26 guidance implies continued investment in scaling capacity.      </li> <li>Adjusted EBITDA increased to <money>$8.8M</money> and gross margin expanded to <percent>72.6%</percent>, supported by improved mix and cost discipline.      </li> </ul> <p style=\"text-align: center;\"> <a href=\"https://api.newsfilecorp.com/redirect/7n1KRiMkeP\" rel=\"nofollow noopener\"><img alt=\"Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/285641_figure1.png\" loading=\"lazy\" src=\"https://images.newsfilecorp.com/files/7294/285641_figure1.png\"/></a> </p> <p style=\"text-align: center;\"> <i>Click image above to view full announcement.</i> </p> <hr style=\"border-width: 1px 0px 0px; border-right-style: initial; border-bottom-style: initial; border-left-style: initial; border-right-color: initial; border-bottom-color: initial; border-left-color: initial; border-top-style: solid; border-top-color: rgba(0, 0, 0, 0.1);\"/> <p> <strong>About Stonegate<br/></strong>Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach      services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.    </p> <div id=\"contactInfo\"><p> <b>Contacts:</b> </p> <p>      Stonegate Capital Partners<br/>      (214) 987-4121<br/> <a href=\"mailto:info@stonegateinc.com\" rel=\"nofollow noopener\">info@stonegateinc.com</a> </p></div> <p>      Source: <a href=\"https://api.newsfilecorp.com/redirect/ejYn8hMvzz\" rel=\"nofollow noopener\">Stonegate, Inc.</a></p> <p id=\"corporateLinkBack\">      To view the source version of this press release, please visit <a href=\"https://api.newsfilecorp.com/redirect/87wK3SOj5L\" rel=\"nofollow noopener\">https://www.newsfilecorp.com/release/285641</a> </p><p><img alt=\"\" loading=\"lazy\" src=\"https://api.newsfilecorp.com/newsinfo/285641/375\"/></p></article>",
            "link": "https://www.stocktitan.net/news/BKSY/stonegate-capital-partners-updates-coverage-on-black-sky-technology-xhyjqvizdq69.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 14:28:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "The Marketing Cloud Expands its AI-Enablement Platform Agent Cloud with Major Partner Integrations and Enterprise Features  | STGW Stock News",
            "description": "<article class=\"article\"><p><i><strong>New specialized AI agents from Limbik and Glystn, enhanced model support, and platform improvements accelerate adoption</strong></i></p><p><strong id=\"dateline\">NEW YORK CITY, NEW YORK / <a href=\"https://www.accessnewswire.com/\" rel=\"nofollow noopener\">ACCESS Newswire</a> / February 27, 2026 / </strong><a href=\"https://pr.report/j3vd\" rel=\"nofollow noopener\">The Marketing Cloud</a>, a Stagwell company (NASDAQ:<a class=\"symbol-link\" href=\"/overview/STGW/\" title=\"View STGW stock overview\">STGW</a>), today announced significant expansions to Agent Cloud, its secure AI-driven, unified platform that simplifies access to the world's leading AI tools and purpose-built marketing assistants. Since its October 2025 launch, Agent Cloud has expanded AI integrations and enterprise controls while driving real impact, growing monthly agent interactions by <percent>30%</percent> to more than 25,000 per month, supporting 500+ custom built agents, and increasing daily engagement time by <percent>25%</percent>.</p><p>Building on Agent Cloud's debut with leading AI partners including OpenAI's ChatGPT, Anthropic's Claude, Google's Gemini and creative models NanoBanana and Veo, as well as xAI's Grok, the latest updates address critical enterprise needs while expanding Agent Cloud's specialized capabilities through strategic partnerships with leading AI companies Glystn, Limbik, Parallel, and Walt AI, alongside major platform enhancements that improve user experience and administrative control.</p><a href=\"https://app.accessnewswire.com/imagelibrary/2e762058-8acb-45ff-9be6-ca6cd54cd992/1142047/stagwell-pic-022626.jpg\" rel=\"nofollow noopener\"><img loading=\"lazy\" src=\"https://app.accessnewswire.com/imagelibrary/2e762058-8acb-45ff-9be6-ca6cd54cd992/1142047/stagwell-pic-022626.jpg\" style=\"width:253px;text-align:center;margin:0.9em auto;\"/></a><div></div><div></div><div></div><div></div><div></div><div></div><div></div><p>Agent Cloud now features newly launched AI integrations designed for advanced marketing intelligence:</p><ul><li><p><strong>Glystn Social Intelligence</strong> - Converts scattered social media signals into clear, actionable insights by analyzing real conversations from TikTok and Instagram, uncovering emerging cultural and consumer trends through semantic searches and identifying the specific creators driving trend spaces</p></li><li><p><strong>Glystn Creator Discovery</strong> - Enables comprehensive creator search and analysis across TikTok and Instagram through conversational queries, analyzing content, engagement patterns, and authenticity while vetting creators for brand safety considerations and competitor partnerships</p></li><li><p><strong>Limbik Resonance Agent</strong> - Leverages six years of behavioral data across 6,600+ audience segments in 60+ countries to predict message resonance in real-time, often delivering insights within 10 seconds</p></li><li><p><strong>Parallel AI Deep Research Integration</strong> - Transforms complex research queries into comprehensive, analyst-grade intelligence reports through automated web exploration and multi-step synthesis with inline citations and confidence metrics, delivering actionable insights on competitors and industry trends within minutes</p></li><li><p><strong>Walt AI Database Intelligence Integration</strong> - Unlocks client data and marketing databases for instant insights through natural language queries powered by ReasonBase™ semantic layer technology, enabling questions like, \"Which campaigns drove the highest ROI last quarter?\" with accurate answers and deterministic SQL generation across platforms like Snowflake and BigQuery</p></li></ul><p>Other platform improvements include comprehensive budget management with organization-level caps and role-based spending controls, alongside significant user experience enhancements including universal model switching that allows seamless transitions between Claude, OpenAI, Gemini, and Grok while preserving conversation context, plus universal file support for documents across all models.</p><p>\"These advancements represent our commitment to continuous innovation based on real user needs,\" said Elspeth Rollert, CEO at The Marketing Cloud. \"Since launch, we've seen tremendous user adoption across the marketing spectrum, especially from agencies who need both specialized AI capabilities and enterprise-grade controls. Agent Cloud continues to be the platform that combines leading AI models with the security and flexibility that modern marketers require to drive outcomes.\"</p><p>\"Agent Cloud has been pivotal in advancing our AI transformation,\" said Brent Diggins, Managing Director of Performance+Intelligence at Allison Worldwide. \"Its flexible, enterprise-grade platform with robust governance and ethical safeguards has enabled us to accelerate workflows, boost productivity, and meet the evolving needs of our teams and clients worldwide. The ability to build and deploy custom AI assistants makes Agent Cloud a true differentiator.\"</p><p>Agent Cloud enhancements are available immediately to existing users, with new specialized agents accessible through the platform's unified interface. To learn more and request a demo, visit <a href=\"https://pr.report/j3ve\" rel=\"nofollow noopener\">www.themarketingcloud.com</a>.</p><p><strong>About The Marketing Cloud</strong><br/>The Marketing Cloud (formerly Stagwell Marketing Cloud) is a data-driven suite of AI-powered SaaS and service solutions built for the modern marketer. Powered by proprietary data and advanced tools spanning research, communications, creative, and media, it enables organizations to achieve measurable business outcomes by making smarter decisions, faster. The Marketing Cloud was born out of Stagwell's (NASDAQ:<a class=\"symbol-link\" href=\"/overview/STGW/\" title=\"View STGW stock overview\">STGW</a>) award-winning network, known for delivering creative performance for ambitious brands.</p><p><strong>About Stagwell</strong><br/>Stagwell is the global challenger network transforming marketing through AI. We deliver scaled creative performance for the world's most ambitious brands, connecting culture-moving creativity with leading-edge technology to harmonize the art and science of marketing. Led by entrepreneurs, our specialists in 45+ countries are unified under a single purpose: to drive effectiveness and improve business results for our clients. Join us at <a href=\"https://pr.report/hxjf\" rel=\"nofollow noopener\">www.stagwellglobal.com</a>.</p><p><strong>Media Contact:</strong><br/>Alyssa Bourne-Peters<br/>PR Director, North America<br/><a href=\"mailto:Alyssa.Bourne-Peters@themarketingcloud.com\" rel=\"nofollow noopener\">Alyssa.Bourne-Peters@themarketingcloud.com</a><br/>+1 917-592-9795</p><p><strong>SOURCE:</strong> Stagwell</p><br/><br/>View the original <a href=\"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/the-marketing-cloud-expands-its-ai-enablement-platform-agent-clo-1142047\" rel=\"nofollow noopener\">press release</a> on ACCESS Newswire<br/><br/><img height=\"0\" loading=\"lazy\" src=\"https://app.accessnewswire.com/img.ashx?id=1142047\" width=\"0\"/></article>",
            "link": "https://www.stocktitan.net/news/STGW/the-marketing-cloud-expands-its-ai-enablement-platform-agent-cloud-jhrrih08jxi0.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 14:30:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "CarMax Launches First-of-Its-Kind Car Shopping and Selling Experience in ChatGPT App Store | KMX Stock News",
            "description": "<article class=\"article\"><p><strong>Retailer brings nationwide inventory and online offer capabilities to OpenAI with the new CarMax App in ChatGPT</strong></p><p>RICHMOND, VA, Feb.  27, 2026  (GLOBE NEWSWIRE) -- CarMax, Inc. (NYSE: <a class=\"symbol-link\" href=\"/overview/KMX/\" title=\"View KMX stock overview\">KMX</a>), the nation’s largest retailer of used cars, today announced a first-of-its-kind milestone by becoming the first U.S. auto retailer with an <a href=\"https://www.globenewswire.com/Tracker?data=QUetxV7T2iQ-G0OIZV9UWPSkt3-ybqf1LXuW2fEqmNe1CiTLXKxAiVgWnsAPEIdMEbrF1912HgFDhA7giO9wkM2uMm7Jfo9Vh2HAMZU__PfOyjO2CirHfdbI9goz-1y9NBu1vQshjsNdWiW2PsTleQ==\" rel=\"nofollow noopener\" target=\"_blank\">app </a>in the ChatGPT app store that supports car shopping. The new online experience allows consumers to search for vehicles, explore listings, and get vehicle value information within ChatGPT, creating a new way for customers to begin their car buying and selling journeys.</p> <p><b>Key Takeaways: </b></p> <p> </p> <ul><li style=\"margin-top:0in; margin-bottom:0in;\">CarMax is the first U.S. car retailer to launch an app in ChatGPT, providing customers a new fast and easy way to shop for their next vehicle.</li><li style=\"margin-top:0in; margin-bottom:0in;\">By bringing its nationwide inventory of more than 45,000 vehicles and recent offer experience into ChatGPT, CarMax acknowledges that shoppers are turning to AI and is stepping up to meet users at this new frontier.  </li><li style=\"margin-top:0in; margin-bottom:0in;\">This app offers a new AI-powered way to make car shopping and selling easier and more approachable from the very first step.</li></ul> <p> </p> <p><b>What is the New CarMax ChatGPT App Experience?</b></p> <p>CarMax is the first U.S. car retailer to make both the car buying and selling experience available within ChatGPT’s app store. The new CarMax integration helps customers navigate their car shopping journey by combining the conversational, generative nature of the AI platform with CarMax’s extensive inventory and vehicle information. Additionally, car sellers can leverage the app to get access to a fast and easy offer on their car.</p> <p> </p> <ul><li style=\"margin-top:0in; margin-bottom:0in;\">Vehicle search: In the app, customers can discover and shop CarMax’s live inventory using conversational language tailored to their needs. They can simply describe what they’re looking for, such as “an SUV with a third row under <money>$25,000</money>” or “a small AWD car with good tech,” and browse matching cars from CarMax’s nationwide selection of vehicles.</li><li style=\"margin-top:0in; margin-bottom:0in;\">Vehicle offers: Customers can ask within the app about their current vehicle’s value and receive instant information about CarMax offers on their make and model with a direct path to CarMax’s online offer tool.</li></ul> <p> </p> <p><b>Making Car Shopping and Selling Easier with AI</b></p> <p>This launch builds on CarMax’s continued work to make car buying and selling clearer and easier for everyone through innovative technology. CarMax has been leveraging AI technology for years and has its own 24/7 virtual assistant Skye embedded in its website that manages tens of thousands of customer conversations each week and is trained to guide shoppers by helping them compare features, locate financing information, and find vehicles that match their needs. Whether customers begin their journey on CarMax.com or through AI-powered search tools, CarMax continues to support them at every step by simplifying the shopping and selling experience.</p> <p>“Used car shopping online can often feel overwhelming,” explains Diane Cafritz, CarMax Chief Innovation &amp; People Officer. “By bringing CarMax’s nationwide inventory and shopping tools into ChatGPT, we’re giving customers a simple, reliable way to explore their options within a platform they are already using. This integration is another step in making the car-shopping experience more seamless than ever before.”</p> <p>This integrated approach reflects CarMax’s commitment to making the entire car shopping journey easier and more approachable – whether customers are just starting their search, comparing options, or preparing to sell. As a brand, CarMax is evaluating user engagement to inform expansions into this new ecosystem as OpenAI continues to make apps more readily available to users.</p> <p>About CarMax</p> <p> </p> <ul><li style=\"margin-top:0in; margin-bottom:0in;\">Founded more than 30 years ago, CarMax set out to fundamentally change the way people buy used cars — offering the honesty and transparency customers deserve. It was the original disruptor to introduce a true \"no-haggle\" car-buying model, setting a new standard for the industry.   <ul><li style=\"margin-top:0in; margin-bottom:0in;\">Today, CarMax has grown into the nation's largest retailer of used cars with 255 stores nationwide and more than 28,000 associates, and is proud to have been recognized for 21 consecutive years as one of the Fortune 100 Best Companies to Work For®.</li></ul> </li><li style=\"margin-top:0in; margin-bottom:0in;\">At CarMax, customers are in the driver’s seat. Whether shopping online, in-store, or a combination of both, CarMax makes the process seamless and empowering — offering guidance at every step so customers feel confident in their purchase.</li><li style=\"margin-top:0in; margin-bottom:0in;\">CarMax gives customers the flexibility to buy a vehicle online and either pick it up quickly in-store through express pickup or have it delivered to their home or workplace with home delivery (available within a 60-mile radius of select stores).</li><li style=\"margin-top:0in; margin-bottom:0in;\">Customers can shop CarMax's nationwide inventory of more than 45,000 cars with upfront pricing, and have the option to ship to the customer’s local store (fee and restrictions may apply), with no pressure to buy.</li><li style=\"margin-top:0in; margin-bottom:0in;\">CarMax offers customers peace of mind with its 10-day Money Back Guarantee and a <a href=\"https://www.carmax.com/car-buying-process/maxcare-service-plans\" rel=\"nofollow noopener\" target=\"_blank\">30-day limited warranty</a> with no mileage limitation and no deductible. State-specific warranties apply in CT, MA, MN, NJ, NY, and RI. CarMax also offers the option to purchase one of its MaxCare extended service plans for additional coverage beyond the limited warranty. </li><li style=\"margin-top:0in; margin-bottom:0in;\">For customers trading in or selling, CarMax will buy their car — even if they don’t buy a vehicle from CarMax. Sellers can receive an online offer in two minutes or less, which is good for seven days to compare options. Customers can sell their vehicle from the comfort of their home or office with an at-home pickup, which is available for the majority of CarMax customers (availability may vary by location, and a fee could apply). For those who prefer an in-store experience, CarMax also offers express drop-off, where sellers can drop off their vehicle at a CarMax location and finalize their sale in under 30 minutes.</li><li style=\"margin-top:0in; margin-bottom:0in;\">For more information, visit <a href=\"https://www.carmax.com/\" rel=\"nofollow noopener\" target=\"_blank\">carmax.com</a>.</li></ul> <p> </p> <img alt=\"\" class=\"__GNW8366DE3E__IMG\" loading=\"lazy\" src=\"https://www.globenewswire.com/newsroom/ti?nf=OTY2MjkwNSM3NDU5Mzc5IzIxODc5NTM=\"/> <br/><img alt=\"\" loading=\"lazy\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NWE0MzkxZjctNGNhZS00YTE3LTg0NjgtZTcxMWJkNzBjMjExLTExOTk1MDYtMjAyNi0wMi0yNy1lbg==/tiny/CarMax.png\"/><br/><p></p><pre>Public RelationsCarMax(855) 887-2915PR@CarMax.com</pre></article>",
            "link": "https://www.stocktitan.net/news/KMX/car-max-launches-first-of-its-kind-car-shopping-and-selling-1wgjnji0m1ed.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 15:36:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Brookfield Renewable Completes Annual Filings | BEP Stock News",
            "description": "<article class=\"article\"><p align=\"justify\">BROOKFIELD, News, Feb.  27, 2026  (GLOBE NEWSWIRE) -- Brookfield Renewable (NYSE: <a class=\"symbol-link\" href=\"/overview/BEP/\" title=\"View BEP stock overview\">BEP</a>, <a class=\"symbol-link\" href=\"/overview/BEPC/\" title=\"View BEPC stock overview\">BEPC</a>; TSX: <a class=\"symbol-link\" href=\"/overview/BEP/\" title=\"View BEP stock overview\">BEP</a>.UN, <a class=\"symbol-link\" href=\"/overview/BEPC/\" title=\"View BEPC stock overview\">BEPC</a>) announced today the filing of its 2025 annual reports, including audited financial statements for the year ended December 31, 2025, on Forms 20-F with the SEC on EDGAR as well as with Canadian securities regulatory authorities on SEDAR+.</p> <p align=\"justify\">These documents are available at <a href=\"https://www.globenewswire.com/Tracker?data=NfwscYAshCdCsgYZA0nXAwM1s8WoIub_0HFnozJ4HYj7HBPvT0m51EjDXldMHcsBi-55YxulHIKWpxazCVWgHD5Nb-OlmB7zWEIICoZGwAk=\" rel=\"nofollow noopener\" target=\"_blank\">bep.brookfield.com</a> (or for Brookfield Renewable Corporation, at <a href=\"https://www.globenewswire.com/Tracker?data=NfwscYAshCdCsgYZA0nXA5t_7wjY7_6_hwKW25OteQKKYeGFq1R0CJ3rOluxmgS4AZVJYyhXYIN0P65UlUfribQHvyUoPnQdgvCLArrs8ryv2flUXLeTVZi5PNCO1TPO\" rel=\"nofollow noopener\" target=\"_blank\">bep.brookfield.com/bepc</a>), on the SEC’s website at <a href=\"https://www.globenewswire.com/Tracker?data=Ll6XP4JqH-TKw8fvATxSlb3DED9_5uR55MKFvsDRnMo3CXFLBv6vPKdHUaRCudaphotju9qGmilvp0iOE227cg==\" rel=\"nofollow noopener\" target=\"_blank\">www.sec.gov</a> and on SEDAR+’s website at <a href=\"https://www.globenewswire.com/Tracker?data=Ll6XP4JqH-TKw8fvATxSlU8HOSfNuDS1y-zKs1p9_YAzJlGdZLcFRL1EyFC5HvPtpw11l7Z0_yEskuE9zNHNs9HN5L4-r72zHcwwZBx9PTg=\" rel=\"nofollow noopener\" target=\"_blank\">www.sedarplus.ca</a>. Hard copies will be provided to unitholders and shareholders free of charge upon request.</p> <p align=\"justify\"><strong>Brookfield Renewable</strong></p> <p align=\"justify\">Brookfield Renewable operates one of the world’s largest publicly traded platforms for renewable power and sustainable solutions. Our renewable power portfolio consists of hydroelectric, wind, utility-scale solar, distributed solar, and storage facilities and our sustainable solutions assets include our investment in a leading global nuclear services business and investments in carbon capture and storage capacity, agricultural renewable natural gas, materials recycling and eFuels manufacturing capacity, among others.</p> <p align=\"justify\">Investors can access the portfolio either through Brookfield Renewable Partners L.P. (NYSE: <a class=\"symbol-link\" href=\"/overview/BEP/\" title=\"View BEP stock overview\">BEP</a>; TSX: BEP.UN), a Bermuda-based limited partnership, or Brookfield Renewable Corporation (NYSE, TSX: <a class=\"symbol-link\" href=\"/overview/BEPC/\" title=\"View BEPC stock overview\">BEPC</a>), a Canadian corporation.</p> <p align=\"justify\">Brookfield Renewable is the flagship listed renewable power and transition company of Brookfield Asset Management, a leading global alternative asset manager headquartered in New York, with over <money>$1 trillion</money><strong> </strong>of assets under management.</p> <table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\"><tr><td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>Contact information:</strong><br/></td><td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong> </strong></td></tr><tr><td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>Media:</strong></td><td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>Investors:</strong></td></tr><tr><td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>Simon Maine</strong></td><td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>Alex Jackson</strong></td></tr><tr><td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>+44 7398 909 278</strong></td><td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>+1 416 649-8172</strong></td></tr><tr><td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><a href=\"mailto:simon.maine@brookfield.com\" rel=\"nofollow noopener\" target=\"_blank\"><strong>simon.maine@brookfield.com</strong></a><br/></td><td style=\"text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><a href=\"mailto:alexander.jackson@brookfield.com\" rel=\"nofollow noopener\" target=\"_blank\"><strong>alexander.jackson@brookfield.com</strong></a><br/></td></tr></table> <p><br/></p> <img alt=\"\" class=\"__GNW8366DE3E__IMG\" loading=\"lazy\" src=\"https://www.globenewswire.com/newsroom/ti?nf=OTY2Mjg4NSM3NDU5Mjk3IzIwOTg0NTk=\"/> <br/><img alt=\"\" loading=\"lazy\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MTcxNDI5MTMtZGE2My00MzgxLTg4YmYtMmZkOTM2MTZiYzBjLTExMTAwMzAtMjAyNi0wMi0yNy1lbg==/tiny/Brookfield-Renewable-Partners-.png\"/></article>",
            "link": "https://www.stocktitan.net/news/BEP/brookfield-renewable-completes-annual-gxiahohqudi4.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 14:30:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Flex LNG - Filing of 2025 Annual Report on Form 20-F | FLNG Stock News",
            "description": "<article class=\"article\"><div class=\"xn-content\"><p><span class=\"legendSpanClass\"><location idsrc=\"xmltag.org\" value=\"LU/bm..hamton\">HAMILTON, Bermuda</location></span>, <span class=\"legendSpanClass\">Feb. 27, 2026</span> /PRNewswire/ -- Flex LNG Ltd (the \"Company\") announces that its annual report on Form 20-F for the year ended December 31, 2025 (the \"Annual Report\") has been filed with the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location> Securities and Exchange Commission (the \"Commission\").</p><p>The attached Annual Report can also be downloaded from the Company's website, <a href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629168-1&amp;h=2577468126&amp;u=http%3A%2F%2Fwww.flexlng.com%2Fcategory%2Fannual-reports%2F&amp;a=www.flexlng.com%2Fcategory%2Fannual-reports%2F\" rel=\"nofollow noopener\" target=\"_blank\">www.flexlng.com/category/annual-reports/</a> and is available on the website of the Commission, <a href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629168-1&amp;h=526736123&amp;u=http%3A%2F%2Fwww.sec.gov%2F&amp;a=www.sec.gov\" rel=\"nofollow noopener\" target=\"_blank\">www.sec.gov</a>.  Additionally, shareholders can request a hard copy of our complete audited financial statements free of charge by writing us at:</p><p>FLEX LNG Ltd.<br/>Par-La-Ville Place<br/>14 Par-La-Ville Road<br/><location idsrc=\"xmltag.org\" value=\"LU/bm..hamton\">Hamilton, Bermuda</location></p><p>Or submitting the contact form request the report at <a href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629168-1&amp;h=2834337672&amp;u=http%3A%2F%2Fwww.flexlng.com%2Finvestor-contact-2%2F&amp;a=www.flexlng.com%2Finvestor-contact-2%2F\" rel=\"nofollow noopener\" target=\"_blank\">www.flexlng.com/investor-contact-2/</a> </p><p>For more information please contact:</p><p>Knut Traaholt, Chief Financial Officer of Flex LNG Management AS<br/>Telephone: +47 23 11 40 00<br/>Email: <a href=\"mailto:IR@flexlng.com\" rel=\"nofollow noopener\" target=\"_blank\">IR@flexlng.com</a></p><p><b>About Flex LNG</b></p><p>Flex LNG is a shipping company focused on the growing market for Liquefied Natural Gas (LNG). Our fleet consists of thirteen LNG carriers on the water and all our vessels are state-of-the-art ships with the latest generation two-stroke propulsion (MEGI and X-DF). These modern ships offer significant improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. Flex LNG is listed on the New York Stock Exchange under the ticker <a class=\"symbol-link\" href=\"/overview/FLNG/\" title=\"View FLNG stock overview\">FLNG</a>.</p><p>This information was brought to you by Cision <a href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629168-1&amp;h=2112969659&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener\" target=\"_blank\">http://news.cision.com</a></p><p>The following files are available for download:</p><div><table border=\"0\" cellpadding=\"1\" cellspacing=\"0\"><tr><td class=\"prngen1\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\"><a class=\"prnews_a\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629168-1&amp;h=3176625947&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F22886%2F4314408%2F3957254.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F22886%2F4314408%2F3957254.pdf\" rel=\"nofollow noopener\" target=\"_blank\">https://mb.cision.com/Main/22886/4314408/3957254.pdf</a></span></p></td><td class=\"prngen1\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">Flex LNG - 20F 2025</span></p></td></tr></table></div><p>SOURCE Flex LNG</p></div></article>",
            "link": "https://www.stocktitan.net/news/FLNG/flex-lng-filing-of-2025-annual-report-on-form-20-ouj76ix13iyf.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 14:59:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Voting Rights and Capital | SHEL Stock News",
            "description": "<article class=\"article\"><p><b>Total Voting Rights</b></p> <p>In conformity with the Disclosure Guidance and Transparency Rules, we hereby notify the market of the following:</p> <p>Shell plc's capital as at February 27, 2026, consists of 5,663,769,613 ordinary shares of <money>€0.07</money> each. Shell plc holds no shares in Treasury.</p> <p>The figure, 5,663,769,613, may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Shell plc under the FCA's Disclosure Guidance and Transparency Rules.</p> <p>Note: This announcement is made pursuant to Disclosure Guidance and Transparency Rule 5.6.1 and as such, the above figure includes shares purchased by Shell plc as part of its share buy-back programme but not yet cancelled.</p> <p>Enquiries</p> <p><br/>Shell Media Relations<br/>International +44 (0)207 934 5550; U.S. and Canada: <a href=\"https://www.globenewswire.com/Tracker?data=3OH7-YMf0fW0cADfbDXs8k0xD5nEdXKSOhF_c18KnaWvVO65y3bvmCdEV-bPxXTZim_6WTr055MZuTo5DRwJoKTFbUe-dX2crYugBEd7A0fTeODOl3BlyWp5b3l6PXgevDzD2cSeKM1kD_qQlIVF7ub5i4UYUqls-HEZ6Ki4SYSizaPUSi-9EuqXtsNvdz-0sgkcLJgf4wGRl2ozt2TirYOcq0jdM-wC3dvZ86NpE9_Gn7Cuu3sFHAm-WXLD-_XY-cq-NpMY31XE4Vblp5Tfoy6vguyH1mYXCt-zpOQ6NLeXFLKW2sjv7I7IbMWyaXjnAwbpDPBlu3sKaCeqnUAq7g==\" rel=\"nofollow noopener\" target=\"_blank\"><b>Contact form</b></a></p> <img alt=\"\" class=\"__GNW8366DE3E__IMG\" loading=\"lazy\" src=\"https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE2NzI3NyM0MDIzNTAwODcjMjI0ODQ2OA==\"/> <br/><img alt=\"\" loading=\"lazy\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml-eu.globenewswire.com/media/ZjJiZmFiOTItNWZkNC00YjAxLWI0YjctNmMyN2MwMTgzNTIyLTEyNjAwMjEtMjAyNi0wMi0yNy1lbg==/tiny/Shell-plc.png\"/></article>",
            "link": "https://www.stocktitan.net/news/SHEL/voting-rights-and-npini55p6rpl.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 15:19:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Kingman Begins Phase III Drilling to Test Southwick Vein Step-Out at Mohave | KGSSF Stock News",
            "description": "<article class=\"article\"><p>Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - <i><b>Kingman Minerals Ltd. (TSXV: KGS) (OTCQB: <a class=\"symbol-link\" href=\"/overview/KGSSF/\" title=\"View KGSSF stock overview\">KGSSF</a>) (FSE: 47A) (\"Kingman\" or the \"Company\")</b></i> is pleased to announce that the Altar Drilling crew has mobilized to site and assembled the drill rig at the first planned collar location (P3-05 / P3-06) for Phase III diamond drilling at the Mohave Project in Arizona.</p><p>The Phase III program is designed to test along-strike continuity of the mineralized corridor in line with the Company's structural interpretation and magnetic vector inversion (MVI) model.</p><p style=\"text-align: center;\"><a href=\"https://images.newsfilecorp.com/files/9368/285644_6d01a37f24ee89da_001full.jpg\" rel=\"nofollow noopener\"><img alt=\"Cannot view this image? Visit: https://images.newsfilecorp.com/files/9368/285644_6d01a37f24ee89da_001.jpg\" loading=\"lazy\" src=\"https://images.newsfilecorp.com/files/9368/285644_6d01a37f24ee89da_001.jpg\" style=\"border-width: 0px;\"/></a></p><p style=\"text-align: center;\"><i>Figure 1 - Drill rig positioned at the first Phase III collar location (P3-05 / P3-06), Mohave Project, Arizona.</i><br/><br/>To view an enhanced version of this graphic, please visit:<br/><a href=\"https://images.newsfilecorp.com/files/9368/285644_6d01a37f24ee89da_001full.jpg\" rel=\"nofollow noopener\">https://images.newsfilecorp.com/files/9368/285644_6d01a37f24ee89da_001full.jpg</a></p><p>Brad Peek, QP and Director of the Company states: \"<i>Phase III comprises four drill locations - three locations southeast of the Rosebud Mine and one to the northwest. All holes are designed to intersect the projected step-out extension of the Southwick vein system beyond the historic mine area. At the southeastern pads, paired holes at -45° and -60° are oriented to intersect the projected vein extension at depth.\"</i></p><p>The HQ diamond drill holes are totaling 814.7 metres (2,673 feet) of planned drilling. The Phase III drill collar locations are summarized in Table 1.</p><p><i>Table 1:</i> <i>Proposed Phase III Drill Program (NAD83)</i></p><table border=\"0\" cellpadding=\"3\" cellspacing=\"0\" style=\"width: 100%; border-collapse: collapse; border-width: 1px; border-style: solid; border-\"><tbody><tr><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\"><b>Hole </b><br/><b>ID</b></td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\"><b>UTM East </b><br/><b>(m)</b></td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\"><b>UTM North </b><br/><b>(m)</b></td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\"><b>Elev. </b><br/><b>(m)</b></td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\"><b>Azimuth </b><br/><b>(°)</b></td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\"><b>Dip </b><br/><b>(°)</b></td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\"><b>Depth</b><br/><b>(m)</b></td></tr><tr><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">P3-01</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">235952</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">3947654</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">973</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">45</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">-45</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">28.3</td></tr><tr><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">P3-02</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">235952</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">3947654</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">973</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">45</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">-60</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">96.9</td></tr><tr><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">P3-03</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">235950</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">3947610</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">966</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">45</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">-45</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">139.9</td></tr><tr><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">P3-04</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">235950</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">3947610</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">966</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">45</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">-60</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">97.8</td></tr><tr><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">P3-05</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">235963</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">3947582</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">962</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">45</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">-45</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">111.6</td></tr><tr><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">P3-06</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">235963</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">3947582</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">962</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">45</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">-60</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">145.1</td></tr><tr><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">MH-08</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">235827</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">3947942</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">1024</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">260</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">-45</td><td style=\"border-width: 1px; border-style: solid; border- width: 14.3%; text-align: center; font-size: 10px;\">195.1</td></tr></tbody></table><p style=\"text-indent: 5%;\"></p><p><b>Qualified Person</b></p><p>The technical information contained in this news release has been reviewed and approved by Brad Peek, M.Sc., CPG, a Qualified Person as defined under National Instrument 43-101 - Standards of Disclosure for Mineral Projects. Mr. Peek is a Director of Kingman Minerals Ltd.</p><p><b>ABOUT</b></p><p>Kingman Minerals Ltd. (TSXV: KGS) is a publicly traded exploration and development company focused on precious metals in North America. The Company's flagship project comprises the fully owned historic Rosebud Mine, located in the Music Mountains, Mohave County, Arizona. High-grade gold and silver veins were discovered in the area in the 1880s and were mined mainly in the late 1920s and 1930s. Underground development on the Rosebud property included a 400-foot main shaft and approximately 2,500 feet of drifts, raises and crosscuts. </p><div id=\"contactInfo\"><p><b>For further information please contact:</b></p><p><b>Simon D. Studer</b><br/>Interim CEO, President &amp; Director<br/><a href=\"mailto:simondavidstuder@gmail.com\" rel=\"nofollow noopener\">simondavidstuder@gmail.com</a><br/>Phone: +41 77 459 16 20</p><p><b>Corporate Office<br/></b>Tel:  +1 (604) 685-7720<br/>Email:  <a href=\"mailto:info@kingmanminerals.com\" rel=\"nofollow noopener\">info@kingmanminerals.com</a></p></div><p>Web:  <a href=\"https://api.newsfilecorp.com/redirect/XEz1XiMaWk\" rel=\"nofollow noopener\">www.kingmanminerals.com</a></p><p><i>Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. </i></p><p><i><b>Cautionary Statement Regarding Forward-Looking Information </b>This news release contains forward-looking information within the meaning of applicable securities laws, including statements regarding the planned scope, timing and execution of the Phase III drilling program, and the potential continuity or extension of the Southwick vein system based on geological and geophysical interpretation. Forward-looking information is based on current expectations and assumptions but involves risks and uncertainties that could cause actual results to differ materially, including drilling conditions, geological variability, contractor performance, permitting requirements, and market conditions. The Company undertakes no obligation to update such information except as required by law.</i></p><p id=\"corporateNewsLogoContainer\"><img alt=\"Corporate Logo\" id=\"corporateNewsLogo\" loading=\"lazy\" src=\"https://images.newsfilecorp.com/files/9368/285644_6d01a37f24ee89da_logo.jpg\"/></p><p id=\"corporateLinkBack\">To view the source version of this press release, please visit <a href=\"https://api.newsfilecorp.com/redirect/DOyagHPXYv\" rel=\"nofollow noopener\">https://www.newsfilecorp.com/release/285644</a></p><p><img alt=\"\" loading=\"lazy\" src=\"https://api.newsfilecorp.com/newsinfo/285644/375\"/></p></article>",
            "link": "https://www.stocktitan.net/news/KGSSF/kingman-begins-phase-iii-drilling-to-test-southwick-vein-step-out-at-kitplwh07aok.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 15:19:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Advanced Gold Acquires 100% Interest in Silver Belle Nevada CRD Claims | AUHIF Stock News",
            "description": "<article class=\"article\"><p>Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - <b>Advanced Gold Exploration Inc. (CSE: AUEX) (FSE: ZF2) (OTC Pink: <a class=\"symbol-link\" href=\"/overview/AUHIF/\" title=\"View AUHIF stock overview\">AUHIF</a>)</b> (\"<b>Advanced Gold</b>\" or the \"<b>Company</b>\") is pleased to announce that it has entered into a mineral property purchase and sale agreement dated February 26, 2026 (the \"<b>Agreement</b>\") with Stream Metals LLC and Kadenwood Development Corp. (collectively, the \"<b>Vendors</b>\") to acquire a <percent>100%</percent> interest in the Silver Belle Project (the \"<b>Project</b>\") located in Eureka County, Nevada.</p><p>The Project consists of approximately 100 unpatented lode mining claims (2,000 acres) situated within the prolific Eureka Mining District of Nevada, an area well known for high-grade carbonate replacement deposit (\"<b>CRD</b>\") style mineralization and historic silver-lead-zinc production.</p><p>The Project is in one of Nevada's most productive carbonate-hosted mineral belts, proximal to several historic and modern mining operations. The Company believes the Project demonstrates geological characteristics consistent with CRD-style mineralization and intends to conduct modern exploration, including geologic mapping, sampling, and geophysical targeting, to evaluate the potential for high-grade replacement and feeder structures at depth.</p><p>Historic records from the district document high-grade mineralization, including reported silver and base metal head grades from prior mining operations in the area. Mineralization is characterized by silver with associated lead, zinc and antimony hosted in favorable carbonate stratigraphy typical of CRD systems.</p><p>Advanced Gold president Arndt Roehlig, states, \"Data interpreted of the Project has confirmed the site's status as a \"rediscovery\" target, highlighted by documented historical production of silver. Located in the historic Diamond District of Eureka County, the Project consists of a 2,000-acre claim block situated on the Eureka-Battle Mountain mineral belt. Despite its location in one of the world's most productive mining jurisdictions, the Project has seen no modern exploration, with all historical work restricted to the shallow oxidized cap of a much larger, untested potential CRD system.\"</p><p>A documented 1937 smelter return from the Silver Bell Mining Co. underscores the metal content of the Project's underground workings. A 21-short-ton shipment sent to the ASARCO Smelter in Salt Lake City returned a silver grade of <b>1,611 g/t (47 oz/ton)</b>. In addition to silver, the shipment contained significant base metal concentrations, including <b><percent>37%</percent> Lead, <percent>10%</percent> Zinc, and <percent>1%</percent> Copper</b>. The presence of 3,000 g/t Antimony further confirms the Project's position within the antimony-enriched portion of the Diamond Range CRD belt, consistent with regional metallogenic zoning typical of large-scale systems. </p><p>Historical infrastructure at the site includes a shaft, multiple adits, and approximately 500 feet of underground development.  The deeper, higher-temperature sulphide-rich CRD core-where the highest tonnages are typically found-remains untested. The Project sits within a wide-open structural corridor with clear expansion potential both along strike to the north and south, and down-dip to the west where the limestone host rock thickens.</p><p>The high-grade nature of the Project mineralization is related to classic CRD architecture, characterized by reactive limestone-quartzite contacts and intrusive-driven hydrothermal fluids. These systems are highly prized by modern explorers for their ability to host vertically extensive mineralized shoots and very large ounce counts within relatively small surface footprints. All historical grade data and shipment records cited herein are verified by the <b>USGS MRDS deposit record (M232256).</b></p><p><b>Transaction Terms</b></p><p>In accordance with the terms of the Agreement, the Company shall acquire the Project from the Vendors. As consideration for the Project, the Company shall: (A) pay an aggregate of <money>$25,000</money> in cash to the Vendors upon execution of the Agreement (the \"<b>Effective Date</b>\"), an additional <money>$100,000</money> in cash on the date of the closing (the \"<b>Closing Date</b>\") of the transactions contemplated by the Agreement, and a final cash payment of <money>$50,000</money> on or before the sixth anniversary of the Closing Date; and (B) issue to the Vendors an aggregate of 1,500,000 common shares (the \"<b>Common Shares</b>\") in the capital of the Company on the Closing Date, and issue an aggregate of 1,500,000 Common Shares to the Vendors on or before the sixth anniversary of the Closing Date.</p><p>In addition, in connection with the transaction contemplated by the Agreement, Stream Metals will be entitled to a <percent>1.5%</percent> net smelter returns royalty (the \"<b>Royalty</b>\"). The Company has the option to purchase the Royalty (reducing the Royalty to <percent>0%</percent>) by making a cash payment to Stream Metals in the amount of US<money>$1,500,000. T</money>he completion of the transaction contemplated by the Agreement remains subject to the approval of all regulatory and other approvals, including the approval of the Canadian Securities Exchange. All securities issued pursuant to the Agreement will be subject to a statutory hold period of four months and one day from the issuance thereof, as applicable, in accordance with applicable securities laws.</p><p><b>Proposed Private Placement</b></p><p>In addition, the Company wishes to announce that it intends to complete a non-brokered private placement through the issuance of up to 5,000,000 units (each, a \"<b>Unit</b>\") in the capital of the Company at a price of <money>$0.20</money> per Unit for aggregate gross proceeds of up to <money>$1,000,000</money> (the \"<b>Offering</b>\").</p><p>Each Unit shall be comprised of one common share (each, a \"<b>Common Share</b>\") in the capital of the company and one-half of one whole transferable Common Share purchase warrant (each whole warrant, a \"<b>Warrant</b>\"). Each Warrant shall entitle the holder thereof to acquire one Common Share at a price of <money>$0.30</money> per Common Share for a period of two (2) years from the date of issuance.</p><p>All securities issued pursuant to the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation. The gross proceeds of the Offering shall be used for general corporate and working capital purposes.</p><p>The closing of the Offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and other approvals, including the approval of the Canadian Securities Exchange. The Company may pay certain eligible finders a cash commission of up to <percent>8%</percent> cash or warrants of the gross proceeds received from subscribers introduced to the Company by such finder.</p><p>Closing of the transaction remains subject to customary conditions and regulatory approvals.</p><p><b>Qualified Person</b></p><p>Jim Atkinson, MSc., P. Geo., the Chairman and a director of the Company, and a non-independent Qualified Person (\"<b>QP</b>\") as such term is defined by National Instrument 43-101 - <i>Standards of Disclosure for Mineral Projects</i>, has reviewed and approved the geological information reported in this news release. The QP has not completed sufficient work to verify the historic information on the Project, particularly with regards to historical sampling and regional government-mapped geology. However, the QP assumes that sampling and analytical results were completed to industry standard practices. The information provides an indication of the exploration potential of the Property but may not be representative of expected results.</p><p><b>ABOUT ADVANCED GOLD</b></p><p>Advanced Gold Exploration is a Canadian mineral exploration company with a portfolio of Canadian gold and copper properties. The company's expertise is in identifying and acquiring undervalued properties with significant historical work, which it believes it can enhance their economic value at today's prices. The company's purpose is to bring immediate and long-term value to its partners and shareholders<b>. </b>Visit <a href=\"https://api.newsfilecorp.com/redirect/JkYMPI7OY8\" rel=\"nofollow noopener\">www.advancedgoldexploration.com</a> for more information.</p><p><b>On behalf of the Board of Directors,</b> </p><p><i>Arndt Roehlig, President, CEO, Director</i></p><div id=\"contactInfo\"><p><b>Contact Information</b></p><p>Arndt Roehlig<br/>CEO, President, Director, Advanced Gold Exploration Inc.<br/>Email: <a href=\"mailto:arndtroehlig@gmail.com\" rel=\"nofollow noopener\">arndtroehlig@gmail.com</a><br/>Tel: (604) 318-1034</p></div><p><b>Forward-Looking Information and Cautionary Statements</b></p><p><i>This news release may contain \"forward-looking information\" within the meaning of applicable securities laws relating to the trading of the Company's securities and the focus of the Company's business. Any such forward-looking statements may be identified by words such as \"expects\", \"anticipates\", \"intends\", \"contemplates\", \"believes\", \"projects\", \"plans\" and similar expressions. Forward-looking statements in this news release include statements regarding the Company's ability to increase the value of its current and future mineral exploration properties and, in connection therewith, any long-term shareholder value, the Company's ability to mitigate or eliminate exploration risk, and the Company's intention to develop a portfolio of historic gold properties. Readers are cautioned not to place undue reliance on forward-looking statements. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will continue its business as described above. Readers are encouraged to refer to the Company's annual and quarterly management's discussion and analysis and other periodic filings made by the Company with the Canadian securities regulatory authorities under the Company's profile on SEDAR+ at <a href=\"https://api.newsfilecorp.com/redirect/GzqKkH0VWJ\" rel=\"nofollow noopener\">www.sedarplus.ca</a>. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law.</i></p><p id=\"corporateLinkBack\">To view the source version of this press release, please visit <a href=\"https://api.newsfilecorp.com/redirect/Q2pMesEBpM\" rel=\"nofollow noopener\">https://www.newsfilecorp.com/release/285647</a></p><p><img alt=\"\" loading=\"lazy\" src=\"https://api.newsfilecorp.com/newsinfo/285647/375\"/></p></article>",
            "link": "https://www.stocktitan.net/news/AUHIF/advanced-gold-acquires-100-interest-in-silver-belle-nevada-crd-qv9zr0wwmirw.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 15:20:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Palamina Announces Colt Silver Corp. Spin Out Transaction | PLMNF Stock News",
            "description": "<article class=\"article\"><p>Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - <b>Palamina Corp. (TSXV: PA) (OTCQB: <a class=\"symbol-link\" href=\"/overview/PLMNF/\" title=\"View PLMNF stock overview\">PLMNF</a>)</b> (\"<b>Palamina</b>\" or the \"<b>Company</b>\") is pleased to announce that the Board of Directors of the Company has unanimously approved a spin out transaction (the \"<b>Spin Out Transaction</b>\"), whereby Palamina will distribute a certain number of common shares of a newly created wholly owned subsidiary named Colt Silver Corp. (\"<b>Colt Silver</b>\") to the shareholders of Palamina pursuant to a plan of arrangement under section 182 of the <i>Business Corporations Act </i>(Ontario) (the \"<b>Arrangement</b>\"). Colt Silver owns the Company's seven silver-copper projects in northeastern and southeastern Peru (the \"<b>Assets</b>\"). As part of the Spin Out Transaction, the Company will complete a series of private placement financings (the \"<b>Financings</b>\") and apply for listing of the common shares of Colt Silver on the TSX Venture Exchange (\"<b>TSXV</b>\") as a Tier 2 mining issuer. </p><p><b>Reasons for the Transaction </b></p><ul><li><p>Palamina began acquiring these projects in 2017 where most have been acquired through staking where there are no underlying payments and funds go into the ground. </p></li><li><p>Through this strategic spin out, Palamina shareholders will receive immediate shareholder value of 0.33 of a share of Colt Silver per each Palamina share owned</p></li><li><p>Palamina shareholders will continue to retain the same ownership percentage of Palamina as they hold currently </p></li><li><p>Shareholders will have exposure to two public companies, one focused on Palamina's gold assets and one focussed on Colt Silver's silver and copper assets</p></li><li><p>enhanced management focus and expertise on the different mineral exploration assets</p></li></ul><p><b>Terms of the Transaction </b></p><p>Palamina, Colt Silver and Palamina Finco Corp. (\"<b>Finco</b>\") will enter into an arrangement agreement (\"<b>Arrangement Agreement</b>\") whereby:</p><ul><li><p>Colt Silver will immediately complete a private placement offering of convertible debentures for up to <money>$500</money>k in gross proceeds (the \"<b>Debenture Offering</b>\"), that bear interest at a rate of <percent>5%</percent> per annum and will automatically convert into common shares of Colt Silver immediately prior to the effective date of the plan of arrangement (the \"<b>Arrangement</b>\") based on a price of <money>$0.10</money> per share</p></li><li><p>Finco will complete a private placement financing of subscription receipts for up to <money>$2.25M</money> in gross proceeds (the \"<b>Subscription Receipt Offering</b>\"), which subject to meeting all conditions, will automatically convert into common shares of Finco and then be exchanged for common shares of Colt Silver immediately prior to the effective date of the Arrangement at a rate of <money>$0.15</money> per share</p></li><li><p>Palamina will complete the Arrangement whereby Palamina shareholders will receive 0.33 shares of Colt Silver for every one (1) share held in Palamina</p></li><li><p>Pursuant to the Arrangement, holders of Palamina warrants following closing will be entitled to exercise their warrants for one (1) share of Palamina and 0.33 shares of Colt Silver  </p></li><li><p>Palamina will retain <percent>10%</percent> of issued and outstanding common shares of Colt Silver (the \"<b>Resulting Issuer</b>\") upon completion of the Arrangement</p></li><li><p>Upon completion of the Arrangement, it is expected that Palamina shareholders will hold between <percent>60.8%</percent> - <percent>65.7%</percent>, Palamina will hold <percent>10%</percent>, and the shareholders resulting from the Financings will hold approximately <percent>39.2%</percent> of the issued and outstanding shares of the Resulting Issuer  </p></li></ul><p>Palamina will call an annual and special meeting of shareholders to be held at the end of the second quarter (the \"<b>Shareholders Meeting</b>\") to approve its annual meeting matters, the Arrangement, the board of directors of Colt Silver, an option plan for Colt Silver and certain option grants to directors and officers of Colt Silver. The Arrangement is subject to the approval of not less than two-thirds of the votes cast by Palamina shareholders. The Arrangement is also subject to, among other conditions, the interim and ﬁnal approval of the Ontario Superior Court of Justice (Commercial List), the acceptance of the TSXV, listing of the common shares of Colt Silver on the TSXV, completion of the Financings, and satisfaction of certain other closing conditions that are customary for a transaction of this nature. Listing of the common shares of Colt Silver remains subject to TSXV acceptance. The Spin Out Transaction is anticipated to close in July 2026.</p><p>A management information circular providing details regarding the Spin Out Transaction, Colt Silver and the Assets, and the other matters to be considered at the Shareholders Meeting, will be mailed to the Palamina shareholders in accordance with regulatory requirements.  </p><p><b>Description of the Assets Part of the Spin Out Transaction </b></p><p>Colt Silver Corp. (an Ontario corporation) holds <percent>100%</percent> of the shares of Vicus Exploraciones S.A.C., its Peruvian subsidiary, which holds a <percent>100%</percent> interest in seven property groupings located in northeastern, central, and southeastern Peru.</p><p>Four of these projects are located in southeastern Peru in the Santa Lucia mining district, within a two hour drive of the Company's field office in the city of Juliaca: Galena, Esperanza, Volcano, and Sora silver-copper projects. As part of the spin out transaction, an NI 43-101 report on the Galena silver-copper-manganese project is underway. Once the spin out transaction is approved an inaugural drilling program is planned to test for Ag Cu Mn mineralization within the limestone contact horizon to determine whether it may host a deposit similar to Aftermath Silver Ltd.'s (TSXV: AMM) Berenguela silver-copper-manganese project. Berenguela is located northeast of Galena within the same Carbonate Replacement Deposit ('CRD') trend. Colt's Esperanza silver-copper-manganese project is being investigated as a possible extension of the Berenguela deposit. Colt's Volcano and Sora projects were recently increased in size through staking by over 4,500 hectares to cover ground relinquished by Fresnillo Plc. (LON: FRES) between the operating Tacaza mine and historical Santa Barbara mine. The Sora Project is contiguous to Ivanhoe Electric Inc's (TSE:IE) Pinaya copper-gold porphyry-skarn project. All four of these projects have year-round access and excellent access. </p><p>The Cristel copper project is located in in southeastern Peru, and was acquired to investigate a color anomaly caused by the oxidation of massive and semi-massive that locally contains copper. Minsur S.A.'s San Rafael copper-tin deposit located approximately 40 km to the south began as a high-grade copper deposit and high-grade tin mineralization was discovered at depth beneath the copper deposit.</p><p>The Ica copper-gold project is located in west-central Peru and is being investigated for a the iron oxide-copper-gold (IOCG) target. The Pluma sediment hosted copper project is in an emerging red-bed hosted copper district in northeastern Peru. Palamina's strategy is to maintain the Pluma project while Hannan   Metals Ltd's (TSXV: HAN) carries out a drilling program on their adjacent San Martin project.</p><p>Currently, Colt Silver has no other assets.</p><p><b>Debenture Offering and Subscription Receipt Offering</b></p><p><i>Debenture Offering</i></p><p>Colt Silver intends to complete a non-brokered private placement of up to <money>$500,000</money> in secured convertible debentures (the \"<b>Debentures</b>\").  The Debentures will mature on and become payable on December 31, 2026 (the \"<b>Maturity Date</b>\") and bear interest at a fixed rate of <percent>5%</percent> per annum, payable in arrears on the Maturity Date or the day immediately prior to the effective date of the Arrangement (the \"<b>Conversion Date</b>\").  The Debentures are secured by the assets of the Company through a general security agreement and rank equally with all other Debentures. On the Conversion Date, the total amount outstanding of the Debentures, including accrued interest, shall automatically convert into shares of Colt Silver at a conversion price of <money>$0.10</money> per share.  All securities issued pursuant to the Debenture Offering are subject to a statutory hold period and is subject to TSXV approval.</p><p><i>Subscription Receipt Offering</i></p><p>In connection with the proposed Spin Out Transaction, Palamina's management will incorporate Finco in order to complete a concurrent financing of subscription receipts (\"<b>Subscription Receipts</b>\") for gross proceeds of up to CDN<money>$2,250</money>0,000. On closing of the Spin Out Transaction, the Subscription Receipts will automatically convert into common shares of the Resulting Issuer. Pending the closing of the Spin Out Transaction the proceeds of the Subscription Receipts will be held in escrow by a trust company and released to the Resulting Issuer on closing of the Spin Out Transaction. In connection with the Subscription Receipt Offering, Palamina may pay a cash fee of <percent>6%</percent> of the gross proceeds and compensation Subscription Receipts equal to <percent>6%</percent> of the number of Subscription Receipts issued pursuant to the Subscription Receipt Offering. Completion of the Subscription Receipt Offering is a condition of the completion of the Spin Out Transaction. The Resulting Issuer intends to use the net proceeds of the Financings for exploration and advancement of the Assets, including additional drilling, core drilling for metallurgical studies, community relations, advance engineering studies and general corporate and working capital purposes.</p><p>The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the \"<b>U.S. Securities Act</b>\"), or the securities laws of any state of the \"United States\" (as such term is defined in Regulation S under the U.S. Securities Act), and may not be offered or sold in the United States unless registered under the U.S. Securities Act and the securities laws of any applicable state of the United States or an exemption from such registration requirements is available. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.</p><p>A National Instruction 43-101 compliant technical report is being prepared in respect of the Galena silver copper project and carve out financial statements being prepared and reviewed by the auditors. The Company expects to announce a management team and board of directors for Colt Silver shortly, along with a schedule for completion and a record date for the shareholders' meeting to approve the Spin Out Transaction. Further details of the capital structure, and financial information in respect of Colt Silver will also be included in a subsequent news release and the Information Circular to be mailed to the shareholders of Palamina.</p><p>The technical information herein has been reviewed and approved by Steve Preismeyer, C.P.G., a Qualified Person as defined by National Instrument 43-101.  Mr. Preismeyer acts as Palamian's lead geological consultant.</p><p><b>About Palamina</b></p><p>Palamina is a mineral exploration company with gold projects in the Puno Orogenic Gold Belt in southeastern Peru and copper-silver assets across southeastern, northeastern, and central Peru through its Canadian subsidiary, Colt Silver Corp. Colt Silver is being spun out to unlock additional shareholder value. Palamina trades on the TSX Venture Exchange (PA) and the OTCQB (<a class=\"symbol-link\" href=\"/overview/PLMNF/\" title=\"View PLMNF stock overview\">PLMNF</a>).</p><div id=\"contactInfo\"><p><b>On Behalf of the Board of Directors</b> </p><p>Andrew Thomson, President Phone: (416) 204-7536 or visit <a href=\"https://api.newsfilecorp.com/redirect/zAJX5IjoK5\" rel=\"nofollow noopener\">www.palamina.com</a> </p></div><p><i>Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. </i></p><p>This news release contains certain \"forward-looking statements\" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as \"plan\", \"continue\", \"expect\", \"project\", \"intend\", \"believe\", \"anticipate\", \"estimate\", \"may\", \"will\", \"potential\", \"proposed\" and other similar words, or statements that certain events or conditions \"may\" or \"will\" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements include, but are not limited to, the use of proceeds of the Offering and the Company's future business plans. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. A more complete discussion of the risks and uncertainties facing the Company appears in the Company's continuous disclosure filings, which are available at <a href=\"https://api.newsfilecorp.com/redirect/4YBbKHQPap\" rel=\"nofollow noopener\">www.sedarplus.ca</a>.</p><p style=\"text-align: center;\"><b>Not for distribution to U.S. news wire services or dissemination in the United States</b></p><p id=\"corporateLinkBack\">To view the source version of this press release, please visit <a href=\"https://api.newsfilecorp.com/redirect/jNYnMtOLaN\" rel=\"nofollow noopener\">https://www.newsfilecorp.com/release/285646</a></p><p><img alt=\"\" loading=\"lazy\" src=\"https://api.newsfilecorp.com/newsinfo/285646/375\"/></p></article>",
            "link": "https://www.stocktitan.net/news/PLMNF/palamina-announces-colt-silver-corp-spin-out-hktsva1e61e5.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 15:23:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer | PFE Stock News",
            "description": "<article class=\"article\"><ul class=\"bwlistdisc\"><li><i>In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease at surgery</i></li><li><i>The results, combined with the recent unprecedented data from the EV-303 trial, highlight the potential for this regimen to become a new standard of care for muscle-invasive bladder cancer patients, regardless of cisplatin eligibility</i></li><li><i>First and only platinum-free regimen to significantly improve event-free and overall survival when used before and after surgery</i></li></ul><p> <location idsrc=\"xmltag.org\" value=\"LU/us.ny.nyc\">NEW YORK</location> &amp; <location idsrc=\"xmltag.org\" value=\"LU/jp..tokyo\">TOKYO</location>--(BUSINESS WIRE)--Pfizer Inc. (NYSE: <a class=\"symbol-link\" href=\"/overview/PFE/\" title=\"View PFE stock overview\">PFE</a>) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEV<sup>TM</sup> (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda<sup>®</sup> (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative (before and after surgery) enfortumab vedotin plus pembrolizumab demonstrated a <percent>47%</percent> reduction in the risk of tumor recurrence, progression or death compared to patients treated with standard of care neoadjuvant (before surgery) gemcitabine and cisplatin (Hazard Ratio (HR) of 0.53; <percent>95%</percent> Confidence Interval (CI), 0.41–0.70; 1-sided p&lt;.0001).<sup>i</sup> An estimated <percent>79.4%</percent> of patients were event-free at two years, relative to <percent>66.2%</percent> treated with standard of care neoadjuvant chemotherapy.<sup>i</sup> These data will be presented today in an oral session (Abstract #LBA630) and were featured in the press program at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in <location idsrc=\"xmltag.org\" value=\"LU/us.ca.sanfrn\">San Francisco, CA.</location> They will also be discussed with global health authorities for potential regulatory filings.</p><p><b>Christopher Hoimes, DO, Director of the Bladder Cancer Program and Center for Cancer Immunotherapy at Duke Cancer Institute, and an EV-304 Principal Investigator</b></p><p>“Approximately half of patients with muscle-invasive bladder cancer experience disease recurrence even after having their bladder removed. The EV-304 results, combined with the EV-303 study, provide compelling evidence that perioperative enfortumab vedotin plus pembrolizumab may offer survival benefits in the curative setting for patients with muscle-invasive bladder cancer, highlighting a potential departure from platinum-based chemotherapy as a cornerstone of care.\"</p><p>Overall survival was a key secondary endpoint in EV-304 and showed a <percent>35%</percent> reduced risk of death in patients treated with perioperative enfortumab vedotin plus pembrolizumab versus neoadjuvant chemotherapy (HR of 0.65; <percent>95%</percent> CI, 0.48-0.89; 1-sided p=.0029).<sup>i</sup> The combination also demonstrated a pathological complete response (pCR) rate of <percent>55.8%</percent> compared with <percent>32.5%</percent> pCR rate at the time of surgery (estimated difference <percent>23.4%</percent>; <percent>95%</percent> CI, 16.7-29.8; 1-sided p&lt;.0001), indicating that more than half of patients treated with the combination had no detectable disease at the time of surgery.<sup>i </sup>EFS, OS and pCR benefits were generally consistent across all pre-defined subgroups, including age, gender, PD-L1 status, clinical stage and geographic region.<sup>i</sup></p><p>The safety profile for perioperative enfortumab vedotin plus pembrolizumab observed in EV-304 was consistent with prior experience with the combination and there were no new safety signals. Grade ≥3 adverse events (AEs) due to any cause occurred in <percent>75.7%</percent> of patients treated with perioperative enfortumab vedotin plus pembrolizumab compared to <percent>67.2%</percent> of patients treated with neoadjuvant chemotherapy.<sup>i</sup></p><p><b>Jeff Legos, PhD, MBA, Chief Oncology Officer, Pfizer</b></p><p>“For people with muscle‑invasive bladder cancer, a perioperative approach that avoids the need for platinum‑based chemotherapy has demonstrated significant survival benefits. These compelling data, reinforced by the unprecedented EV‑303 results, suggest a transformative opportunity to establish PADCEV plus pembrolizumab as the next standard of care if approved, and provide a meaningful step forward for patients and their families.”</p><p><b>Moitreyee Chatterjee-Kishore, PhD, MBA, Head of Oncology Development, Astellas</b></p><p>“The EV-304 study data further substantiate the role of enfortumab vedotin plus pembrolizumab in bladder cancer and demonstrate its potential to offer patients with muscle-invasive bladder cancer more time with their loved ones. We are delighted with these new data and remain committed to investigating therapies for challenging and hard-to-treat cancers, with a goal of bringing renewed hope to patients.”</p><p>Bladder cancer is the ninth most common cancer worldwide, diagnosed in more than 614,000 patients each year globally, including an estimated 85,000 people in the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location><sup>ii</sup>,<sup>iii</sup> MIBC represents approximately <percent>30%</percent> of all bladder cancer cases.<sup>iv</sup> Even after undergoing curative intent surgery, half of patients with MIBC experience disease recurrence.<sup>v</sup></p><p>PADCEV plus pembrolizumab is not currently approved for use as perioperative treatment in cisplatin-eligible patients with MIBC. PADCEV plus pembrolizumab was approved in November 2025 by the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location> FDA for use as perioperative treatment in cisplatin-ineligible patients with MIBC, based on results from the EV-303 Phase 3 clinical trial (also known as KEYNOTE-905), which were recently published in the <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2511674&amp;esheet=54434858&amp;newsitemid=20260227998629&amp;lan=en-US&amp;anchor=New+England+Journal+of+Medicine.&amp;index=1&amp;md5=35ee5f21dbedfb304b695d3f1db86734\" rel=\"nofollow noopener\" shape=\"rect\"><i>New England Journal of Medicine</i>.</a></p><p><b>About the EV-304/KEYNOTE-B15 Trial</b></p><p>The EV-304 trial is an ongoing, open-label, randomized, controlled, Phase 3 study evaluating neoadjuvant and adjuvant enfortumab vedotin in combination with pembrolizumab versus neoadjuvant chemotherapy (gemcitabine and cisplatin) in patients with MIBC who are eligible for cisplatin-based chemotherapy. Patients were randomized to receive either neoadjuvant and adjuvant PADCEV in combination with pembrolizumab (arm A) or neoadjuvant chemotherapy (arm B). Curative-intent surgery (cystectomy) was performed in both arms. Enfortumab vedotin in combination with pembrolizumab was administered as a planned total of 9 cycles of enfortumab vedotin and 17 cycles of pembrolizumab split before and after surgery.<sup>vi</sup></p><p>The primary endpoint of this trial is EFS, defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes radical cystectomy (RC) or failure to undergo RC in participants with residual disease, gross residual disease left behind at the time of surgery, local or distant recurrence based on blinded independent central review (BICR) or death due to any cause. Key secondary endpoints include OS and pCR rate.<sup>vi</sup></p><p>For more information on the global EV-304 trial, go to <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT04700124&amp;esheet=54434858&amp;newsitemid=20260227998629&amp;lan=en-US&amp;anchor=clinicaltrials.gov&amp;index=2&amp;md5=7241bab604f144869121620b9105a295\" rel=\"nofollow noopener\" shape=\"rect\">clinicaltrials.gov</a>.</p><p><b>About PADCEV<sup>TM </sup>(enfortumab vedotin)</b></p><p>PADCEV<sup>TM </sup>(enfortumab vedotin) is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.<sup>vi</sup> Nonclinical data suggest the anticancer activity of PADCEV is due to its binding to Nectin-4-expressing cells, followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis).<sup>vii</sup></p><p>PADCEV plus pembrolizumab is approved for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) in <location idsrc=\"xmltag.org\" value=\"LC/us\">the United States</location>, the European Union, <location idsrc=\"xmltag.org\" value=\"LC/jp\">Japan</location> and a number of other countries around the world. PADCEV is also approved globally as a single agent for the treatment of adult patients with la/mUC who have previously received a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.<sup>viii</sup></p><p><b>PADCEV<sup>®</sup> (enfortumab vedotin-ejfv) <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location> Indication &amp; Important Safety Information</b></p><p><b>BOXED WARNING: SERIOUS SKIN REACTIONS</b></p><ul class=\"bwlistdisc\"><li>PADCEV (enfortumab vedotin-ejfv) can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which occurred predominantly during the first cycle of treatment, but may occur later.</li><li>Closely monitor patients for skin reactions.</li><li>Immediately withhold PADCEV and consider referral for specialized care for suspected SJS or TEN or severe skin reactions.</li><li>Permanently discontinue PADCEV in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions.</li></ul><p><b>Indications</b></p><p>PADCEV, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy.</p><p>PADCEV, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC).</p><p>PADCEV, as a single agent, is indicated for the treatment of adult patients with locally advanced or mUC who:</p><ul class=\"bwlistdisc\"><li>have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or</li><li>are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.</li></ul><p><b>IMPORTANT SAFETY INFORMATION</b></p><p><b>WARNINGS AND PRECAUTIONS</b></p><p><b>Skin reactions </b>Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV. SJS and TEN occurred predominantly during the first cycle of treatment but may occur later.</p><p>Skin reactions occurred in <percent>61%</percent> (all grades) of the 167 patients treated with PADCEV in combination with intravenous pembrolizumab for the treatment of MIBC in clinical trials. The majority of skin reactions that occurred included rash and maculo-papular rash. Grade 3-4 skin reactions occurred in <percent>10%</percent> of patients (Grade 3: <percent>9%</percent>, Grade 4: <percent>1.2%</percent>), including rash, maculo-papular rash, toxic skin eruption, dermatitis exfoliative generalized, erythema, exfoliative rash, skin toxicity, toxic epidermal necrolysis, and toxic erythema of chemotherapy. A fatal reaction of toxic epidermal necrolysis occurred in one patient (<percent>0.6%</percent>). The median time to onset of severe skin reactions was 0.6 months (range: 0.2 to 8.8 months). Skin reactions led to discontinuation of PADCEV in <percent>10%</percent> of patients. Of the patients who experienced a skin reaction and had data regarding resolution (n=102), <percent>83%</percent> had complete resolution and <percent>17%</percent> had residual skin reactions at their last evaluation. Of the patients with residual skin reactions at last evaluation, <percent>29%</percent> (5/17) had Grade ≥2 skin reactions.</p><p>Skin reactions occurred in <percent>70%</percent> (all grades) of the 564 patients treated with PADCEV in combination with intravenous pembrolizumab for the treatment of locally advanced or mUC in clinical trials. The majority of skin reactions that occurred included maculo-papular rash, macular rash, and papular rash. Grade 3-4 skin reactions occurred in <percent>17%</percent> of patients (Grade 3: <percent>16%</percent>, Grade 4: <percent>1%</percent>), including maculo-papular rash, bullous dermatitis, dermatitis, exfoliative dermatitis, pemphigoid, rash, erythematous rash, macular rash, and papular rash. A fatal reaction of bullous dermatitis occurred in one patient (<percent>0.2%</percent>). The median time to onset of severe skin reactions was 1.7 months (range: 0.1 to 17.2 months). Skin reactions led to discontinuation of PADCEV in <percent>6%</percent> of patients. Of the patients who experienced a skin reaction and had data regarding resolution (n= 391), <percent>59%</percent> had complete resolution and <percent>41%</percent> had residual skin reactions at their last evaluation. Of the patients with residual skin reactions at last evaluation, <percent>27%</percent> (43/159) had Grade ≥2 skin reactions.</p><p>Skin reactions occurred in <percent>58%</percent> (all grades) of the 720 patients treated with PADCEV as a single agent in clinical trials. Twenty-three percent (<percent>23%</percent>) of patients had maculo-papular rash and <percent>34%</percent> had pruritus. Grade 3-4 skin reactions occurred in <percent>14%</percent> of patients, including maculo-papular rash, erythematous rash, rash or drug eruption, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), bullous dermatitis, exfoliative dermatitis, and palmar-plantar erythrodysesthesia. The median time to onset of severe skin reactions was 0.6 months (range: 0.1 to 8 months). Among patients experiencing a skin reaction leading to dose interruption who then restarted PADCEV (n=75), <percent>24%</percent> of patients restarting at the same dose and <percent>24%</percent> of patients restarting at a reduced dose experienced recurrent severe skin reactions. Skin reactions led to discontinuation of PADCEV in <percent>3.1%</percent> of patients. Of the patients who experienced a skin reaction and had data regarding resolution (n=328), <percent>58%</percent> had complete resolution and <percent>42%</percent> had residual skin reactions at their last evaluation. Of the patients with residual skin reactions at last evaluation, <percent>39%</percent> (53/137) had Grade ≥2 skin reactions.</p><p>Monitor patients closely throughout treatment for skin reactions. Consider topical corticosteroids and antihistamines, as clinically indicated. For persistent or recurrent Grade 2 skin reactions, consider withholding PADCEV until Grade ≤1. Withhold PADCEV and refer for specialized care for suspected SJS, TEN or for Grade 3 skin reactions. Permanently discontinue PADCEV in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions.</p><p><b>Hyperglycemia and diabetic ketoacidosis (DKA), </b>including fatal events, occurred in patients with and without preexisting diabetes mellitus, treated with PADCEV. Patients with baseline hemoglobin A1C ≥<percent>8%</percent> were excluded from clinical trials. In clinical trials of PADCEV as a single agent, <percent>17%</percent> of the 720 patients treated with PADCEV developed hyperglycemia of any grade; <percent>7%</percent> of patients developed Grade 3-4 hyperglycemia (Grade 3: <percent>6.5%</percent>, Grade 4: <percent>0.6%</percent>). Fatal events of hyperglycemia and diabetic ketoacidosis occurred in one patient each (<percent>0.1%</percent>). The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C. The median time to onset of hyperglycemia was 0.5 months (range: 0 to 20 months). Hyperglycemia led to discontinuation of PADCEV in <percent>0.7%</percent> of patients. Five percent (<percent>5%</percent>) of patients required initiation of insulin therapy for treatment of hyperglycemia. Of the patients who initiated insulin therapy for treatment of hyperglycemia, <percent>66%</percent> (23/35) discontinued insulin by the time of last evaluation. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (&gt;250 mg/dL), withhold PADCEV.</p><p><b>Pneumonitis/Interstitial Lung Disease (ILD) </b>Severe, life-threatening or fatal pneumonitis/ILD occurred in patients treated with PADCEV.</p><p>When PADCEV was given in combination with intravenous pembrolizumab for the treatment of MIBC, <percent>4.2%</percent> of the 167 patients had pneumonitis/ILD of any grade. All events were Grade 1-2. The median time to onset of any grade pneumonitis/ILD was 2.5 months (range: 1.9 to 9.7 months).</p><p>When PADCEV was given in combination with intravenous pembrolizumab for the treatment of locally advanced or mUC, <percent>10%</percent> of the 564 patients had pneumonitis/ILD of any grade and <percent>4%</percent> had Grade 3-4. A fatal event of pneumonitis/ILD occurred in two patients (<percent>0.4%</percent>). The median time to onset of any grade pneumonitis/ILD was 4 months (range: 0.3 to 26 months).</p><p>In clinical trials of PADCEV as a single agent, <percent>3%</percent> of the 720 patients treated with PADCEV had pneumonitis/ILD of any grade and <percent>0.8%</percent> had Grade 3-4. The median time to onset of any grade pneumonitis/ILD was 2.9 months (range: 0.6 to 6 months).</p><p>Monitor patients for signs and symptoms indicative of pneumonitis/ILD such as hypoxia, cough, dyspnea or interstitial infiltrates on radiologic exams. Evaluate and exclude infectious, neoplastic and other causes for such signs and symptoms through appropriate investigations. Withhold PADCEV for patients who develop Grade 2 pneumonitis/ILD and consider dose reduction. Permanently discontinue PADCEV in all patients with Grade 3 or 4 pneumonitis/ILD.</p><p><b>Peripheral neuropathy (PN) </b>When PADCEV was given in combination with intravenous pembrolizumab for the treatment of MIBC, <percent>39%</percent> of the 167 patients had PN of any grade, <percent>12%</percent> had Grade 2 neuropathy, and <percent>3%</percent> had Grade 3 neuropathy. The median time to onset of Grade ≥2 PN was 4.7 months (range: 0.2 to 11 months). Of the patients who experienced neuropathy and had data regarding resolution (n=65), <percent>32%</percent> had complete resolution, and <percent>68%</percent> of patients had residual neuropathy at last evaluation. Of the patients with residual neuropathy at last evaluation, <percent>27%</percent> (12/44) had Grade ≥2 neuropathy.</p><p>When PADCEV was given in combination with intravenous pembrolizumab for the treatment of locally advanced or mUC, <percent>67%</percent> of the 564 patients had PN of any grade, <percent>36%</percent> had Grade 2 neuropathy, and <percent>7%</percent> had Grade 3 neuropathy. The median time to onset of Grade ≥2 PN was 6 months (range: 0.3 to 25 months). Of the patients who experienced neuropathy and had data regarding resolution (n= 373), <percent>13%</percent> had complete resolution, and <percent>87%</percent> of patients had residual neuropathy at last evaluation. Of the patients with residual neuropathy at last evaluation, <percent>45%</percent> (146/326) had Grade ≥2 neuropathy.</p><p>PN occurred in <percent>53%</percent> of the 720 patients treated with PADCEV as a single agent in clinical trials including <percent>38%</percent> with sensory neuropathy, <percent>8%</percent> with muscular weakness, and <percent>7%</percent> with motor neuropathy. Thirty percent of patients experienced Grade 2 reactions and <percent>5%</percent> experienced Grade 3-4 reactions. PN occurred in patients treated with PADCEV with or without preexisting PN. The median time to onset of Grade ≥2 PN was 4.9 months (range: 0.1 to 20 months). Neuropathy led to treatment discontinuation in <percent>6%</percent> of patients. Of the patients who experienced neuropathy who had data regarding resolution (n= 296), <percent>11%</percent> had complete resolution, and <percent>89%</percent> had residual neuropathy at the time of their last evaluation. Of the patients with residual neuropathy at last evaluation, <percent>50%</percent> (132/262) had Grade ≥2 neuropathy.</p><p>Monitor patients for symptoms of new or worsening PN and consider dose interruption or dose reduction of PADCEV when PN occurs. Permanently discontinue PADCEV in patients who develop Grade <span class=\"bwuline\">&gt;</span>3 PN.</p><p><b>Ocular disorders </b>were reported in <percent>40%</percent> of the 384 patients treated with PADCEV as a single agent in clinical trials in which ophthalmologic exams were scheduled. The majority of these events involved the cornea and included events associated with dry eye such as keratitis, blurred vision, increased lacrimation, conjunctivitis, limbal stem cell deficiency, and keratopathy. Dry eye symptoms occurred in <percent>30%</percent> of patients, and blurred vision occurred in <percent>10%</percent> of patients, during treatment with PADCEV. The median time to onset to symptomatic ocular disorder was 1.7 months (range: 0 to 30.6 months). Monitor patients for ocular disorders. Consider artificial tears for prophylaxis of dry eyes and ophthalmologic evaluation if ocular symptoms occur or do not resolve. Consider treatment with ophthalmic topical steroids, if indicated after an ophthalmic exam. Consider dose interruption or dose reduction of PADCEV for symptomatic ocular disorders.</p><p><b>Infusion site extravasation </b>Skin and soft tissue reactions secondary to extravasation have been observed after administration of PADCEV. Of the 720 patients treated with PADCEV as a single agent in clinical trials, <percent>1%</percent> of patients experienced skin and soft tissue reactions, including <percent>0.3%</percent> who experienced Grade 3-4 reactions. Reactions may be delayed. Erythema, swelling, increased temperature, and pain worsened until 2-7 days after extravasation and resolved within 1-4 weeks of peak. Two patients (<percent>0.3%</percent>) developed extravasation reactions with secondary cellulitis, bullae, or exfoliation. Ensure adequate venous access prior to starting PADCEV and monitor for possible extravasation during administration. If extravasation occurs, stop the infusion and monitor for adverse reactions.</p><p><b>Embryo-fetal toxicity </b>PADCEV can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during PADCEV treatment and for 2 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with PADCEV and for 4 months after the last dose.</p><p><b>ADVERSE REACTIONS</b></p><p><b>Most common adverse reactions, including laboratory abnormalities (≥<percent>20%</percent>):</b></p><ul class=\"bwlistdisc\"><li><b>PADCEV in combination with intravenous pembrolizumab for the treatment of MIBC:</b> increased glucose, decreased hemoglobin, increased aspartate aminotransferase (AST), rash, increased alanine aminotransferase (ALT), fatigue, pruritus, increased creatinine, decreased sodium, decreased lymphocytes, peripheral neuropathy, increased potassium, alopecia, dysgeusia, diarrhea, decreased appetite, constipation, nausea, decreased phosphate, urinary tract infection, dry eye, and decreased weight.</li><li><b>PADCEV in combination with intravenous pembrolizumab for the treatment of locally advanced or mUC:</b> increased AST, increased creatinine, rash, increased glucose, peripheral neuropathy, increased lipase, decreased lymphocytes, increased ALT, decreased hemoglobin, fatigue, decreased sodium, decreased phosphate, decreased albumin, pruritus, diarrhea, alopecia, decreased weight, decreased appetite, increased urate, decreased neutrophils, decreased potassium, dry eye, nausea, constipation, increased potassium, dysgeusia, urinary tract infection, and decreased platelets.</li><li><b>PADCEV as a single agent:</b> increased glucose, increased AST, decreased lymphocytes, increased creatinine, rash, fatigue, peripheral neuropathy, decreased albumin, decreased hemoglobin, alopecia, decreased appetite, decreased neutrophils, decreased sodium, increased ALT, decreased phosphate, diarrhea, nausea, pruritus, increased urate, dry eye, dysgeusia, constipation, increased lipase, decreased weight, decreased platelets, abdominal pain, and dry skin.</li></ul><p><b>EV-303 Study: Patients with cisplatin-ineligible MIBC (PADCEV in combination with intravenous pembrolizumab)</b></p><ul class=\"bwlistdisc\"><li><b>Neoadjuvant phase</b>: Of a total of 167 patients, <b>serious adverse reactions</b> occurred in <percent>27%</percent> of patients receiving PADCEV in combination with intravenous pembrolizumab. The most frequent (≥<percent>2%</percent>) serious adverse reactions were urinary tract infection (<percent>3.6%</percent>) and hematuria (<percent>2.4%</percent>). <b>Fatal adverse reactions</b> occurred in <percent>1.2%</percent> of patients including myasthenia gravis and toxic epidermal necrolysis (<percent>0.6%</percent> each). Additional fatal adverse reactions were reported in <percent>2.7%</percent> of patients in the post-surgery phase before adjuvant treatment started, including sepsis and intestinal obstruction (<percent>1.4%</percent> each). <b>Adverse reactions leading to discontinuation</b> of PADCEV occurred in <percent>22%</percent> of patients. The most common adverse reactions (≥<percent>1%</percent>) leading to discontinuation of PADCEV were rash (<percent>4.8%</percent>), peripheral neuropathy (<percent>2.4%</percent>), and diarrhea, dysgeusia, fatigue, pruritus, and toxic epidermal necrolysis (<percent>1.2%</percent> each). <b>Adverse reactions leading to dose interruption</b> of PADCEV occurred in <percent>29%</percent> of patients. The most common adverse reactions (≥<percent>2%</percent>) leading to dose interruption of PADCEV were rash (<percent>8%</percent>), neutropenia (<percent>3.6%</percent>), and hyperglycemia (<percent>3%</percent>), and fatigue and peripheral neuropathy (<percent>2.4%</percent> each). <b>Adverse reactions leading to dose reduction</b> of PADCEV occurred in <percent>13%</percent> of patients. The most common adverse reactions (≥<percent>1%</percent>) leading to dose reduction of PADCEV were rash (<percent>4.8%</percent>), pruritus (<percent>1.8%</percent>), and peripheral neuropathy, increased alanine aminotransferase, increased aspartate aminotransferase, decreased appetite, fatigue, neutropenia, and decreased weight (<percent>1.2%</percent> each). Seven (<percent>4.2%</percent>) patients did not receive surgery due to adverse reactions. The <b>adverse reactions that led to cancellation of surgery</b> were acute myocardial infarction, bile duct cancer, colon cancer, respiratory distress, urinary tract infection and deaths due to myasthenia gravis and toxic epidermal necrolysis (<percent>0.6%</percent> each). Of the 146 patients who received neoadjuvant treatment with PADCEV in combination with intravenous pembrolizumab and underwent RC, 6 (<percent>4.1%</percent>) patients experienced delay of surgery due to adverse reactions.</li><li><b>Adjuvant phase</b>: Of the 149 patients who underwent surgery, 100 patients received adjuvant treatment with PADCEV in combination with intravenous pembrolizumab. Of the 49 patients who did not receive adjuvant treatment, discontinuation of treatment with PADCEV in combination with intravenous pembrolizumab prior to the adjuvant phase was due to an adverse event in 21 patients. <b>Serious adverse reactions</b> occurred in <percent>43%</percent> of patients receiving PADCEV in combination with pembrolizumab. The most frequent (≥<percent>2%</percent>) serious adverse reactions were urinary tract infection (<percent>8%</percent>), acute kidney injury and pyelonephritis (<percent>5%</percent> each), urosepsis (<percent>4%</percent>), and hypokalemia, intestinal obstruction, and sepsis (<percent>2%</percent> each). <b>Fatal adverse reactions</b> occurred in <percent>7%</percent> of patients, including urosepsis, hemorrhage intracranial, death, myocardial infarction, multiple organ dysfunction syndrome, and pneumonia pseudomonal (<percent>1%</percent> each).<b> Adverse reactions leading to discontinuation</b> of PADCEV occurred in <percent>26%</percent> of patients. The most common adverse reactions (≥<percent>2%</percent>) leading to discontinuation of PADCEV were peripheral neuropathy (<percent>5%</percent>) and rash (<percent>4%</percent>). <b>Adverse reactions leading to dose interruption</b> of PADCEV occurred in <percent>36%</percent> of patients. The most common adverse reactions (≥<percent>2%</percent>) leading to dose interruption of PADCEV were rash (<percent>6%</percent>), diarrhea and urinary tract infection (<percent>5%</percent> each), fatigue (<percent>4%</percent>), pruritus (<percent>3%</percent>), and peripheral neuropathy and pyelonephritis (<percent>2%</percent> each). <b>Adverse reactions leading to dose reduction</b> of PADCEV occurred in <percent>7%</percent> of patients. The most common adverse reactions (≥<percent>2%</percent>) leading to dose reduction of PADCEV was weight decreased (<percent>2%</percent>).</li></ul><p><b>EV-302 Study: 440 patients with previously untreated la/mUC (PADCEV in combination with intravenous pembrolizumab)</b></p><p><b>Serious adverse reactions</b> occurred in <percent>50%</percent> of patients treated with PADCEV in combination with intravenous pembrolizumab. The most common serious adverse reactions (≥<percent>2%</percent>) were rash (<percent>6%</percent>), acute kidney injury (<percent>5%</percent>), pneumonitis/ILD (<percent>4.5%</percent>), urinary tract infection (<percent>3.6%</percent>), diarrhea (<percent>3.2%</percent>), pneumonia (<percent>2.3%</percent>), pyrexia (<percent>2%</percent>), and hyperglycemia (<percent>2%</percent>). <b>Fatal adverse reactions </b>occurred in <percent>3.9%</percent> of patients treated with PADCEV in combination with intravenous pembrolizumab including acute respiratory failure (<percent>0.7%</percent>), pneumonia (<percent>0.5%</percent>), and pneumonitis/ILD (<percent>0.2%</percent>).</p><p>Adverse reactions leading to discontinuation of PADCEV occurred in <percent>35%</percent> of patients. The <b>most common adverse reactions (≥<percent>2%</percent>) leading to discontinuation</b> of PADCEV were PN (<percent>15%</percent>), rash (<percent>4.1%</percent>) and pneumonitis/ILD (<percent>2.3%</percent>). Adverse reactions leading to dose interruption of PADCEV occurred in <percent>73%</percent> of patients. The <b>most common adverse reactions (≥<percent>2%</percent>) leading to dose interruption </b>of PADCEV were PN (<percent>22%</percent>), rash (<percent>16%</percent>), COVID-19 (<percent>10%</percent>), diarrhea (<percent>5%</percent>), pneumonitis/ILD (<percent>4.8%</percent>), fatigue (<percent>3.9%</percent>), hyperglycemia (<percent>3.6%</percent>), increased ALT (<percent>3%</percent>) and pruritus (<percent>2.5%</percent>). Adverse reactions leading to dose reduction of PADCEV occurred in <percent>42%</percent> of patients. The <b>most common adverse reactions (≥<percent>2%</percent>) leading to dose reduction</b> of PADCEV were rash (<percent>16%</percent>), PN (<percent>13%</percent>) and fatigue (<percent>2.7%</percent>).</p><p><b>EV-301 Study: 296 patients previously treated with a PD-1/L1 inhibitor and platinum-based chemotherapy (PADCEV monotherapy)</b></p><p><b>Serious adverse reactions</b> occurred in <percent>47%</percent> of patients treated with PADCEV; the most common (≥<percent>2%</percent>) were urinary tract infection, acute kidney injury (<percent>7%</percent> each), and pneumonia (<percent>5%</percent>). <b>Fatal adverse reactions</b> occurred in <percent>3%</percent> of patients, including multiorgan dysfunction (<percent>1%</percent>), hepatic dysfunction, septic shock, hyperglycemia, pneumonitis/ILD, and pelvic abscess (<percent>0.3%</percent> each). <b>Adverse reactions leading to discontinuation</b> occurred in <percent>17%</percent> of patients; the most common (≥<percent>2%</percent>) were PN (<percent>5%</percent>) and rash (<percent>4%</percent>). <b>Adverse reactions leading to dose interruption</b> occurred in <percent>61%</percent> of patients; the most common (≥<percent>4%</percent>) were PN (<percent>23%</percent>), rash (<percent>11%</percent>), and fatigue (<percent>9%</percent>). <b>Adverse reactions leading to dose reduction</b> occurred in <percent>34%</percent> of patients; the most common (≥<percent>2%</percent>) were PN (<percent>10%</percent>), rash (<percent>8%</percent>), decreased appetite, and fatigue (<percent>3%</percent> each).</p><p><b>EV-201, Cohort 2 Study: 89 patients previously treated with a PD-1/L1 inhibitor and not eligible for cisplatin-based chemotherapy (PADCEV monotherapy)</b></p><p><b>Serious adverse reactions</b> occurred in <percent>39%</percent> of patients treated with PADCEV; the most common (≥<percent>3%</percent>) were pneumonia, sepsis, and diarrhea (<percent>5%</percent> each). <b>Fatal adverse reactions</b> occurred in <percent>8%</percent> of patients, including acute kidney injury (<percent>2.2%</percent>), metabolic acidosis, sepsis, multiorgan dysfunction, pneumonia, and pneumonitis/ILD (<percent>1.1%</percent> each). <b>Adverse reactions leading to discontinuation</b> occurred in <percent>20%</percent> of patients; the most common (≥<percent>2%</percent>) was PN (<percent>7%</percent>). <b>Adverse reactions leading to dose interruption</b> occurred in <percent>60%</percent> of patients; the most common (≥<percent>3%</percent>) were PN (<percent>19%</percent>), rash (<percent>9%</percent>), fatigue (<percent>8%</percent>), diarrhea (<percent>5%</percent>), increased AST, and hyperglycemia (<percent>3%</percent> each). <b>Adverse reactions leading to dose reduction</b> occurred in <percent>49%</percent> of patients; the most common (≥<percent>3%</percent>) were PN (<percent>19%</percent>), rash (<percent>11%</percent>), and fatigue (<percent>7%</percent>).</p><p><b>DRUG INTERACTIONS</b></p><p><b>Effects of other drugs on PADCEV </b>(<i>Dual P-gp and Strong CYP3A4 Inhibitors</i>)</p><p>Concomitant use with dual P-gp and strong CYP3A4 inhibitors may increase unconjugated monomethyl auristatin E exposure, which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.</p><p><b>SPECIFIC POPULATIONS</b></p><p><b>Lactation </b>Advise lactating women not to breastfeed during treatment with PADCEV and for 3 weeks after the last dose.</p><p><b>Hepatic impairment </b>Avoid the use of PADCEV in patients with moderate or severe hepatic impairment.</p><p><b>For more information, please see the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location> full Prescribing Information including BOXED WARNING for PADCEV </b><a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fastellas.us%2Fdocs%2FPADCEV_label.pdf&amp;esheet=54434858&amp;newsitemid=20260227998629&amp;lan=en-US&amp;anchor=here&amp;index=3&amp;md5=f133d1214638cd04f677cf869f7d3ce1\" rel=\"nofollow noopener\" shape=\"rect\"><b>here</b></a><b>.</b></p><p><b>About Pfizer Oncology</b></p><p>At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.</p><p><b>About Astellas</b></p><p>Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.com%2Fv3%2F__http%3A%2Fwww.astellas.com__%3B%21%21JboVxjCXSME%21J98d4NrloRSswMT9VsEBmjlwr1gOspAn8yvYzskgO3K2l1O8w3UDJ2aEwQUOuoH5SoZa3aTd-mOK_-nNcXr13oGUiytwWhiovw%24&amp;esheet=54434858&amp;newsitemid=20260227998629&amp;lan=en-US&amp;anchor=www.astellas.com&amp;index=4&amp;md5=2ed30bebdd2eb266459ee4d3a5531355\" rel=\"nofollow noopener\" shape=\"rect\">www.astellas.com</a>.</p><p><b>About the Pfizer, Astellas and Merck Collaboration</b></p><p>Seagen and Astellas previously entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen’s and Astellas’ PADCEV<sup>TM </sup>(enfortumab vedotin) and Merck’s Keytruda<sup>® </sup>(pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. Pfizer Inc. successfully completed its acquisition of Seagen on December 14, 2023. Keytruda is a registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., <location idsrc=\"xmltag.org\" value=\"LU/us.nj.rahway\">Rahway, NJ</location>, USA (known as MSD outside of <location idsrc=\"xmltag.org\" value=\"LC/us\">the United States</location> and <location idsrc=\"xmltag.org\" value=\"LC/ca\">Canada</location>).</p><p><b>Pfizer Disclosure Notice</b></p><p><i>The information contained in this release is as of February 27, 2026. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</i></p><p><i>This release contains forward-looking information about Pfizer Oncology and a potential indication for PADCEV<sup>TM</sup> (enfortumab vedotin) in combination with pembrolizumab in cisplatin-eligible patients with muscle-invasive bladder cancer, including their potential benefits, and plans to discuss the Phase 3 EV-304 clinical trial results with health authorities for potential regulatory filings that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risk and uncertainties include, among other things, uncertainties regarding the commercial success of PADCEV; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed with regulatory authorities in particular jurisdictions for any potential indication for PADCEV with pembrolizumab or as a single agent; whether and when any applications that may be pending or filed for PADCEV with pembrolizumab or as a single agent may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether PADCEV with pembrolizumab or as a single agent will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of PADCEV with pembrolizumab or as a single agent; whether the collaboration between Pfizer, Astellas and Merck will be successful; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</i></p><p><i>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location> Securities and Exchange Commission and available at </i><a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54434858&amp;newsitemid=20260227998629&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=09839e697ae452cfcbf40ed3657bef2b\" rel=\"nofollow noopener\" shape=\"rect\"><i>www.sec.gov</i></a><i> and </i><a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pfizer.com%2F&amp;esheet=54434858&amp;newsitemid=20260227998629&amp;lan=en-US&amp;anchor=www.pfizer.com&amp;index=6&amp;md5=d213cb2afda5c1ddfa8fb84511784073\" rel=\"nofollow noopener\" shape=\"rect\"><i>www.pfizer.com</i></a><i>.</i></p><p><b>Astellas Cautionary Notes</b></p><p><i>In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.</i></p><p><sup>i</sup> Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study. Abstract #LBA630. 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Congress.<br/><sup>ii</sup> World Bladder Cancer Patient Coalition. GLOBOCAN 2022: Bladder cancer 9th most common worldwide. Accessed January 29, 2026. Available at: <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fworldbladdercancer.org%2Fnews_events%2Fglobocan-2022-bladder-cancer-is-the-9th-most-commonly-diagnosed-worldwide%2F&amp;esheet=54434858&amp;newsitemid=20260227998629&amp;lan=en-US&amp;anchor=https%3A%2F%2Fworldbladdercancer.org%2Fnews_events%2Fglobocan-2022-bladder-cancer-is-the-9th-most-commonly-diagnosed-worldwide%2F&amp;index=7&amp;md5=2ab0d4de0c224fa2bad1339259c52c36\" rel=\"nofollow noopener\" shape=\"rect\">https://worldbladdercancer.org/news_events/globocan-2022-bladder-cancer-is-the-9th-most-commonly-diagnosed-worldwide/</a><br/><sup>iii</sup> American Cancer Society. Cancer Facts &amp; Figures 2025. Accessed January 29, 2026. Available at: <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cancer.org%2Fresearch%2Fcancer-facts-statistics%2Fall-cancer-facts-figures%2F2025-cancer-facts-figures.html&amp;esheet=54434858&amp;newsitemid=20260227998629&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.cancer.org%2Fresearch%2Fcancer-facts-statistics%2Fall-cancer-facts-figures%2F2025-cancer-facts-figures.html&amp;index=8&amp;md5=1b1ef48f9badf989f241ef45de8b63b0\" rel=\"nofollow noopener\" shape=\"rect\">https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2025-cancer-facts-figures.html</a><br/><sup>iv</sup> Bladder Cancer Awareness Network. What is Muscle Invasive Bladder Cancer? Accessed January 29, 2026. Available at: <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbcan.org%2Fwhat-is-muscle-invasive-bladder-cancer%2F%23%3A%7E%3Atext%3DWhen%2520tumors%2520grow%2520into%2520or%2CVirginia%2520Health%2520System%2520explain%2520MIBC&amp;esheet=54434858&amp;newsitemid=20260227998629&amp;lan=en-US&amp;anchor=https%3A%2F%2Fbcan.org%2Fwhat-is-muscle-invasive-bladder-cancer%2F%23%3A%7E%3Atext%3DWhen%2520tumors%2520grow%2520into%2520or%2CVirginia%2520Health%2520System%2520explain%2520MIBC&amp;index=9&amp;md5=caac3a73e8e45367bf38894582668137\" rel=\"nofollow noopener\" shape=\"rect\">https://bcan.org/what-is-muscle-invasive-bladder-cancer/#:~:text=When%20tumors%20grow%20into%20or,Virginia%20Health%20System%20explain%20MIBC</a>.<br/><sup>v</sup> Squires P, Cook EE, Song Y, Wang C, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R. Treatment Patterns, Disease Recurrence, and Overall Survival in Patients with Muscle-Invasive Bladder Cancer after Radical Cystectomy: A Population-Level Claims-Based Analysis. <i>Clinical Genitourinary Cancer. </i>2025 Nov;102466. <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.1016%2Fj.clgc.2025.102466&amp;esheet=54434858&amp;newsitemid=20260227998629&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdoi.org%2F10.1016%2Fj.clgc.2025.102466&amp;index=10&amp;md5=7ef60ac04de3e086c866a1dc7b972cc0\" rel=\"nofollow noopener\" shape=\"rect\">https://doi.org/10.1016/j.clgc.2025.102466</a>.<br/><sup>vi</sup> Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. <i>Cancer Res</i> 2016;76(10):3003-13.<br/><sup>vii</sup> PADCEV [package insert]. <location idsrc=\"xmltag.org\" value=\"LU/us.il.norook\">Northbrook, IL</location>: Astellas Pharma US, Inc.</p><p><img alt=\"\" loading=\"lazy\" src=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260227998629r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"/><span class=\"bwct31415\"></span></p><p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: </span><span id=\"mmgallerylink-link\"><a href=\"https://www.businesswire.com/news/home/20260227998629/en/\" rel=\"nofollow noopener\">https://www.businesswire.com/news/home/20260227998629/en/</a></span></p><p><b>Pfizer Contacts:<br/></b><a href=\"mailto:PfizerMediaRelations@Pfizer.com\" rel=\"nofollow noopener\" shape=\"rect\">PfizerMediaRelations@Pfizer.com</a><br/><br/><i>For Investors<br/></i><a href=\"mailto:IR@pfizer.com\" rel=\"nofollow noopener\" shape=\"rect\">IR@pfizer.com</a><br/><br/><b>Astellas Contacts:<br/></b>Garrett Karaaziz<br/><a href=\"mailto:Garrett.Karaaziz@Astellas.com\" rel=\"nofollow noopener\" shape=\"rect\">Garrett.Karaaziz@Astellas.com</a><br/><br/><i>Corporate Communications<br/></i>+81-3-3244-3201</p><p>Source: Pfizer Inc.</p></article>",
            "link": "https://www.stocktitan.net/news/PFE/padcevtm-keytruda-cuts-risk-of-recurrence-or-death-by-nearly-50-in-5dfuenku8yfe.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 15:00:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery | MRK Stock News",
            "description": "<article class=\"article\"><p class=\"bwalignc\"><b>First and only immunotherapy plus antibody-drug conjugate regimen, used perioperatively, to significantly extend survival for these patients</b></p><p class=\"bwalignc\"><b>KEYNOTE-B15 is the sixth study demonstrating overall survival with a KEYTRUDA-based regimen in an earlier-stage cancer</b></p><p class=\"bwalignc\"><b>Late-breaking results from the Phase 3 KEYNOTE-B15 trial were selected for the official Press Program and will be presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium</b></p><p> <location idsrc=\"xmltag.org\" value=\"LU/us.nj.rahway\">RAHWAY, N.J.</location>--(BUSINESS WIRE)--Merck (NYSE: <a class=\"symbol-link\" href=\"/overview/MRK/\" title=\"View MRK stock overview\">MRK</a>), known as MSD outside of <location idsrc=\"xmltag.org\" value=\"LC/us\">the United States</location> and <location idsrc=\"xmltag.org\" value=\"LC/ca\">Canada</location>, today announced KEYTRUDA<sup>®</sup> (pembrolizumab) plus Padcev<b><sup> </sup></b><sup>®</sup> (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by <percent>47%</percent> and reduced the risk of death by <percent>35%</percent> when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. These late-breaking data will be presented for the first time today during an oral abstract session at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (abstract #LBA630) and are included in the official ASCO GU Press Program.</p><p>After a median follow-up of 33.6 months, KEYTRUDA plus Padcev, as perioperative treatment, demonstrated a statistically significant and clinically meaningful improvement in EFS, the trial’s primary endpoint, reducing the risk of EFS events by <percent>47%</percent> (HR=0.53 [<percent>95%</percent> CI, 0.41-0.70]; p&lt;0.0001) versus neoadjuvant chemotherapy and surgery in patients with MIBC who are eligible for cisplatin-based chemotherapy. Median EFS was not reached (NR) (<percent>95%</percent> CI, NR-NR) for the KEYTRUDA plus Padcev regimen versus 48.5 months (<percent>95%</percent> CI, 43.3-NR) for neoadjuvant chemotherapy and surgery. Approximately <percent>79.4%</percent> of patients treated with KEYTRUDA plus Padcev were alive without disease progression or recurrence versus approximately <percent>66.2%</percent> for patients treated with neoadjuvant chemotherapy and surgery at two years.</p><p>“These findings demonstrate the strength and consistency of KEYTRUDA plus Padcev in treating muscle-invasive bladder cancer,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “Showing a survival benefit in cisplatin-eligible patients in the perioperative setting reinforces the potential of this combination to play a foundational role in bladder cancer care.”</p><p>KEYTRUDA plus Padcev also demonstrated a statistically significant and clinically meaningful improvement in key secondary endpoints of overall survival (OS) and pathologic complete response (pCR) rate. KEYTRUDA plus Padcev reduced the risk of death by <percent>35%</percent> (HR=0.65 [<percent>95%</percent> CI, 0.48-0.89]; p=0.0029) versus neoadjuvant chemotherapy and surgery. Median OS was NR (<percent>95%</percent> CI, NR-NR) for either regimen. Approximately <percent>86.9%</percent> of patients treated with KEYTRUDA plus Padcev were alive versus approximately <percent>81.3%</percent> of patients treated with neoadjuvant chemotherapy and surgery at two years. The pCR rate increased from <percent>32.5%</percent> in patients treated with neoadjuvant chemotherapy and surgery to <percent>55.8%</percent> in patients treated with perioperative KEYTRUDA plus Padcev, an estimated increase of <percent>23.4%</percent> (<percent>95%</percent> CI, 16.7-29.8; p&lt;0.0001).</p><p>\"For almost 25 years, cisplatin-based neoadjuvant chemotherapy was the standard of care for approximately half of patients with muscle-invasive bladder cancer who were eligible to receive platinum-based treatment,” said Dr. Matthew Galsky, Lillian and Howard Stratton Professor of Medicine, director of genitourinary medical oncology, Mount Sinai Tisch Cancer Center. “Results from KEYNOTE-B15 further support that a perioperative approach with pembrolizumab plus enfortumab vedotin can significantly improve survival compared to neoadjuvant chemotherapy in cis-eligible patients with muscle-invasive bladder cancer – setting the stage for a new treatment standard in this disease setting.”</p><p>KEYNOTE-B15<b> </b>evaluated Merck’s KEYTRUDA, an anti-PD-1 therapy, plus Padcev, an antibody-drug conjugate (ADC), and was conducted in collaboration with Pfizer and Astellas. The companies plan to share these results with regulatory authorities worldwide for potential regulatory filings. KEYTRUDA plus Padcev is currently approved for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) in the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location>, the European Union (EU), <location idsrc=\"xmltag.org\" value=\"LC/jp\">Japan</location> and several other countries around the world. KEYTRUDA plus Padcev is also approved in the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location> for the treatment of adult patients with MIBC who are ineligible for cisplatin-based chemotherapy. KEYTRUDA as a monotherapy is also approved in the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location>, EU, <location idsrc=\"xmltag.org\" value=\"LC/jp\">Japan</location> and other countries for the treatment of certain patients with la/mUC or a type of non-muscle-invasive bladder cancer (NMIBC).</p><p>KEYTRUDA plus Padcev has now demonstrated an OS benefit across three Phase 3 trials bladder cancer. In addition to KEYNOTE-B15, these trials include <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Fkeytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-reduced-risk-of-event-free-survival-events-by-60-and-risk-of-death-by-50-for-certain-patients-with-muscle-invasive-bladder-ca%2F&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=KEYNOTE-905&amp;index=1&amp;md5=e134bcb534915dee41a8683340294cdb\" rel=\"nofollow noopener\" shape=\"rect\">KEYNOTE-905</a> for the treatment of patients with MIBC who are not eligible for or declined cisplatin-based chemotherapy and <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Fkeytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-reduced-risk-of-death-by-more-than-half-versus-chemotherapy-in-patients-with-previously-untreated-locally-advanced-or-metasta%2F&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=KEYNOTE-A39&amp;index=2&amp;md5=4f5208468fbf3ec05948e298d63cd663\" rel=\"nofollow noopener\" shape=\"rect\">KEYNOTE-A39</a> for the treatment of adult patients with la/mUC. Three additional Phase 3 studies are currently evaluating KEYTRUDA across all stages of bladder cancer, including non-muscle-invasive, muscle-invasive and metastatic disease. Two of these studies are in MIBC including KEYNOTE-866 (<a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03924856&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=NCT03924856&amp;index=3&amp;md5=759e163cbcce74d9626a4ccac0584a5c\" rel=\"nofollow noopener\" shape=\"rect\">NCT03924856</a>) and KEYNOTE-992 (<a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04241185&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=NCT04241185&amp;index=4&amp;md5=d51dfe62bd1b74d035085086666b4e0c\" rel=\"nofollow noopener\" shape=\"rect\">NCT04241185</a>). KEYTRUDA is also being evaluated in combination with Bacillus Calmette-Guerin (BCG) in patients with NMIBC in KEYNOTE-676 (<a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03711032&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=NCT03711032&amp;index=5&amp;md5=3bb294d7c55977411d9d0847a9da4fd5\" rel=\"nofollow noopener\" shape=\"rect\">NCT03711032</a>).</p><p>KEYNOTE-B15 is one of six Phase 3 studies of a KEYTRUDA-based regimen in an earlier stage of cancer to demonstrate an OS benefit. It is also the 14<sup>th</sup> positive pivotal trial for a KEYTRUDA-based regimen in earlier-stage cancers.</p><p><b>Study design and additional data from KEYNOTE-B15/EV-304<br/></b>KEYNOTE-B15, also known as EV-304, is an open-label, randomized Phase 3 trial (ClinicalTrials.gov, <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT04700124&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=NCT04700124&amp;index=6&amp;md5=f5d23403c5722030ea33dbca6c8afeb2\" rel=\"nofollow noopener\" shape=\"rect\">NCT04700124</a>) evaluating perioperative KEYTRUDA in combination with Padcev and surgery (radical cystectomy and pelvic lymph node dissection) versus neoadjuvant chemotherapy (gemcitabine plus cisplatin) and surgery in patients with MIBC who are cisplatin-eligible. The trial enrolled 808 patients who were randomized to receive either:</p><ul class=\"bwlistdisc\"><li>Four cycles (each cycle length is 21 days) of neoadjuvant KEYTRUDA intravenous (IV) infusion plus enfortumab vedotin IV infusion, followed by surgery, followed by 13 cycles of adjuvant KEYTRUDA IV infusion plus five cycles of enfortumab vedotin IV infusion, or;</li><li>Four cycles (each cycle is 21 days) of standard of care neoadjuvant chemotherapy followed by surgery.</li></ul><p>The primary endpoint is EFS, defined as the time from randomization to the first occurrence of the following events: radiographic disease progression precluding radical cystectomy and pelvic lymph node dissection, failure to undergo surgery in participants with residual disease, gross residual disease left behind at time of surgery, local or distant recurrence based on blinded independent central review or death due to any cause. The key secondary endpoints are OS and pCR rate.</p><p>The safety profile of KEYTRUDA plus Padcev in this study was consistent with the known safety profiles of each agent. Grade ≥3 treatment-emergent adverse events occurred in <percent>75.7%</percent> of patients receiving KEYTRUDA plus Padcev versus <percent>67.2%</percent> of patients receiving neoadjuvant chemotherapy and surgery.</p><p><b>About bladder cancer<br/></b>In 2022, bladder cancer changed the lives of more than 600,000 people around the world. According to some clinical practice guidelines, about <percent>25%</percent> of newly diagnosed bladder cancer cases are MIBC. The standard of care for patients with MIBC has been neoadjuvant cisplatin-based chemotherapy followed by surgery, which is shown to prolong survival. However, nearly half of patients who undergo this standard treatment experience recurrence.</p><p><b>About Merck’s early-stage cancer clinical program<br/></b>Finding cancer at an earlier stage may give patients a greater chance of long-term survival. Many cancers are considered most treatable and potentially curable in their earliest stage of disease. Building on the strong understanding of the role of KEYTRUDA in later-stage cancers, Merck is evaluating our portfolio of medicines and pipeline candidates in earlier disease states, with more than 30 ongoing registrational studies across multiple types of cancer.</p><p><b>About Merck’s research in genitourinary cancers<br/></b>Merck is advancing research aimed at helping transform the treatment landscape and broaden options for people with genitourinary (GU) cancers, including bladder, kidney and prostate cancers. Globally, GU cancers account for an estimated 2.6 million new cancer diagnoses each year, equaling over 1 in 8 of all cancer incidences. Through a robust clinical development program with more than 50 clinical trials evaluating more than 22,000 patients around the world, Merck is investigating the potential of several portfolio medicines and pipeline assets, leveraging multiple novel combination strategies, across various stages of disease, to help address unmet needs in GU cancers.</p><p><b>About KEYTRUDA<sup>®</sup> (pembrolizumab) injection for intravenous use, 100 mg<br/></b>KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.</p><p>Merck has the industry’s largest immuno-oncology clinical research program. There are currently more than 1,600 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.</p><p><b>Selected KEYTRUDA<sup>®</sup> (pembrolizumab) Indications in the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location><br/></b><i>Urothelial Cancer<br/></i>KEYTRUDA, in combination with enfortumab vedotin, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer.</p><p>KEYTRUDA, as a single agent, is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma:</p><ul class=\"bwlistdisc\"><li>who are not eligible for any platinum-containing chemotherapy, or</li><li>who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.</li></ul><p>KEYTRUDA, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy.</p><p>KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.</p><p><i>See additional selected KEYTRUDA indications in the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location> after the Selected Important Safety Information.</i></p><p><b>Selected Important Safety Information for KEYTRUDA<br/></b><b>Severe and Fatal Immune-Mediated Adverse Reactions<br/></b>KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or the programmed death ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can affect more than one body system simultaneously, and can occur at any time after starting treatment or after discontinuation of treatment. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.</p><p>Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Early identification and management are essential to ensure safe use of anti–PD-1/PD-L1 treatments. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. For patients with TNBC treated with KEYTRUDA in the neoadjuvant setting, monitor blood cortisol at baseline, prior to surgery, and as clinically indicated. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.</p><p>Withhold or permanently discontinue KEYTRUDA depending on severity of the immune-mediated adverse reaction. In general, if KEYTRUDA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroid therapy.</p><p><span class=\"bwuline\">Immune-Mediated Pneumonitis<br/></span>KEYTRUDA can cause immune-mediated pneumonitis. The incidence is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in <percent>3.4%</percent> (94/2799) of patients receiving KEYTRUDA, including fatal (<percent>0.1%</percent>), Grade 4 (<percent>0.3%</percent>), Grade 3 (<percent>0.9%</percent>), and Grade 2 (<percent>1.3%</percent>) reactions. Systemic corticosteroids were required in <percent>67%</percent> (63/94) of patients. Pneumonitis led to permanent discontinuation of KEYTRUDA in <percent>1.3%</percent> (36) and withholding in <percent>0.9%</percent> (26) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, <percent>23%</percent> had recurrence. Pneumonitis resolved in <percent>59%</percent> of the 94 patients.</p><p>Pneumonitis occurred in <percent>8%</percent> (31/389) of adult patients with cHL receiving KEYTRUDA as a single agent, including Grades 3-4 in <percent>2.3%</percent> of patients. Patients received high-dose corticosteroids for a median duration of 10 days (range: 2 days to 53 months). Pneumonitis rates were similar in patients with and without prior thoracic radiation. Pneumonitis led to discontinuation of KEYTRUDA in <percent>5.4%</percent> (21) of patients. Of the patients who developed pneumonitis, <percent>42%</percent> interrupted KEYTRUDA, <percent>68%</percent> discontinued KEYTRUDA, and <percent>77%</percent> had resolution.</p><p>Pneumonitis occurred in <percent>7%</percent> (41/580) of adult patients with resected NSCLC who received KEYTRUDA as a single agent for adjuvant treatment of NSCLC, including fatal (<percent>0.2%</percent>), Grade 4 (<percent>0.3%</percent>), and Grade 3 (<percent>1%</percent>) adverse reactions. Patients received high-dose corticosteroids for a median duration of 10 days (range: 1 day to 2.3 months). Pneumonitis led to discontinuation of KEYTRUDA in 26 (<percent>4.5%</percent>) of patients. Of the patients who developed pneumonitis, <percent>54%</percent> interrupted KEYTRUDA, <percent>63%</percent> discontinued KEYTRUDA, and <percent>71%</percent> had resolution.</p><p><span class=\"bwuline\">Immune-Mediated Colitis<br/></span>KEYTRUDA can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Immune-mediated colitis occurred in <percent>1.7%</percent> (48/2799) of patients receiving KEYTRUDA, including Grade 4 (&lt;<percent>0.1%</percent>), Grade 3 (<percent>1.1%</percent>), and Grade 2 (<percent>0.4%</percent>) reactions. Systemic corticosteroids were required in <percent>69%</percent> (33/48); additional immunosuppressant therapy was required in <percent>4.2%</percent> of patients. Colitis led to permanent discontinuation of KEYTRUDA in <percent>0.5%</percent> (15) and withholding in <percent>0.5%</percent> (13) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, <percent>23%</percent> had recurrence. Colitis resolved in <percent>85%</percent> of the 48 patients.</p><p><span class=\"bwuline\">Hepatotoxicity and Immune-Mediated Hepatitis<br/></span><i>KEYTRUDA as a Single Agent<br/></i>KEYTRUDA can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in <percent>0.7%</percent> (19/2799) of patients receiving KEYTRUDA, including Grade 4 (&lt;<percent>0.1%</percent>), Grade 3 (<percent>0.4%</percent>), and Grade 2 (<percent>0.1%</percent>) reactions. Systemic corticosteroids were required in <percent>68%</percent> (13/19) of patients; additional immunosuppressant therapy was required in <percent>11%</percent> of patients. Hepatitis led to permanent discontinuation of KEYTRUDA in <percent>0.2%</percent> (6) and withholding in <percent>0.3%</percent> (9) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Hepatitis resolved in <percent>79%</percent> of the 19 patients.</p><p><i>KEYTRUDA With Axitinib<br/></i>KEYTRUDA in combination with axitinib can cause hepatic toxicity. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider monitoring more frequently as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased alanine aminotransferase (ALT) (<percent>20%</percent>) and increased aspartate aminotransferase (AST) (<percent>13%</percent>) were seen at a higher frequency compared to KEYTRUDA alone. Fifty-nine percent of the patients with increased ALT received systemic corticosteroids. In patients with ALT ≥3 times upper limit of normal (ULN) (Grades 2-4, n=116), ALT resolved to Grades 0-1 in <percent>94%</percent>. Among the 92 patients who were rechallenged with either KEYTRUDA (n=3) or axitinib (n=34) administered as a single agent or with both (n=55), recurrence of ALT ≥3 times ULN was observed in 1 patient receiving KEYTRUDA, 16 patients receiving axitinib, and 24 patients receiving both. All patients with a recurrence of ALT ≥3 ULN subsequently recovered from the event.</p><p><span class=\"bwuline\">Immune-Mediated Endocrinopathies<br/></span><i>Adrenal Insufficiency<br/></i>KEYTRUDA can cause primary or secondary adrenal insufficiency. For Grade 2 or higher, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold KEYTRUDA depending on severity. Adrenal insufficiency occurred in <percent>0.8%</percent> (22/2799) of patients receiving KEYTRUDA, including Grade 4 (&lt;<percent>0.1%</percent>), Grade 3 (<percent>0.3%</percent>), and Grade 2 (<percent>0.3%</percent>) reactions. Systemic corticosteroids were required in <percent>77%</percent> (17/22) of patients; of these, the majority remained on systemic corticosteroids. Adrenal insufficiency led to permanent discontinuation of KEYTRUDA in &lt;<percent>0.1%</percent> (1) and withholding in <percent>0.3%</percent> (8) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.</p><p><i>Hypophysitis<br/></i>KEYTRUDA can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Hypophysitis occurred in <percent>0.6%</percent> (17/2799) of patients receiving KEYTRUDA, including Grade 4 (&lt;<percent>0.1%</percent>), Grade 3 (<percent>0.3%</percent>), and Grade 2 (<percent>0.2%</percent>) reactions. Systemic corticosteroids were required in <percent>94%</percent> (16/17) of patients; of these, the majority remained on systemic corticosteroids. Hypophysitis led to permanent discontinuation of KEYTRUDA in <percent>0.1%</percent> (4) and withholding in <percent>0.3%</percent> (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.</p><p><i>Thyroid Disorders<br/></i>KEYTRUDA can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Thyroiditis occurred in <percent>0.6%</percent> (16/2799) of patients receiving KEYTRUDA, including Grade 2 (<percent>0.3%</percent>). None discontinued, but KEYTRUDA was withheld in &lt;<percent>0.1%</percent> (1) of patients.</p><p>Hyperthyroidism occurred in <percent>3.4%</percent> (96/2799) of patients receiving KEYTRUDA, including Grade 3 (<percent>0.1%</percent>) and Grade 2 (<percent>0.8%</percent>). It led to permanent discontinuation of KEYTRUDA in &lt;<percent>0.1%</percent> (2) and withholding in <percent>0.3%</percent> (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. Hypothyroidism occurred in <percent>8%</percent> (237/2799) of patients receiving KEYTRUDA, including Grade 3 (<percent>0.1%</percent>) and Grade 2 (<percent>6.2%</percent>). It led to permanent discontinuation of KEYTRUDA in &lt;<percent>0.1%</percent> (1) and withholding in <percent>0.5%</percent> (14) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. The majority of patients with hypothyroidism required long-term thyroid hormone replacement. The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC, occurring in <percent>16%</percent> of patients receiving KEYTRUDA as a single agent or in combination with platinum and FU, including Grade 3 (<percent>0.3%</percent>) hypothyroidism. The incidence of new or worsening hypothyroidism was higher in 389 adult patients with cHL (<percent>17%</percent>) receiving KEYTRUDA as a single agent, including Grade 1 (<percent>6.2%</percent>) and Grade 2 (<percent>10.8%</percent>) hypothyroidism. The incidence of new or worsening hyperthyroidism was higher in 580 patients with resected NSCLC, occurring in <percent>11%</percent> of patients receiving KEYTRUDA as a single agent as adjuvant treatment, including Grade 3 (<percent>0.2%</percent>) hyperthyroidism. The incidence of new or worsening hypothyroidism was higher in 580 patients with resected NSCLC, occurring in <percent>22%</percent> of patients receiving KEYTRUDA as a single agent as adjuvant treatment (KEYNOTE-091), including Grade 3 (<percent>0.3%</percent>) hypothyroidism.</p><p><i>Type 1 Diabetes Mellitus (DM), Which Can Present With Diabetic Ketoacidosis<br/></i>Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold KEYTRUDA depending on severity. Type 1 DM occurred in <percent>0.2%</percent> (6/2799) of patients receiving KEYTRUDA. It led to permanent discontinuation in &lt;<percent>0.1%</percent> (1) and withholding of KEYTRUDA in &lt;<percent>0.1%</percent> (1) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.</p><p><span class=\"bwuline\">Immune-Mediated Nephritis With Renal Dysfunction<br/></span>KEYTRUDA can cause immune-mediated nephritis. Immune-mediated nephritis occurred in <percent>0.3%</percent> (9/2799) of patients receiving KEYTRUDA, including Grade 4 (&lt;<percent>0.1%</percent>), Grade 3 (<percent>0.1%</percent>), and Grade 2 (<percent>0.1%</percent>) reactions. Systemic corticosteroids were required in <percent>89%</percent> (8/9) of patients. Nephritis led to permanent discontinuation of KEYTRUDA in <percent>0.1%</percent> (3) and withholding in <percent>0.1%</percent> (3) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Nephritis resolved in <percent>56%</percent> of the 9 patients.</p><p><span class=\"bwuline\">Immune-Mediated Dermatologic Adverse Reactions<br/></span>KEYTRUDA can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms, and toxic epidermal necrolysis, has occurred with anti– PD-1/PD-L1 treatments. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes. Withhold or permanently discontinue KEYTRUDA depending on severity. Immune-mediated dermatologic adverse reactions occurred in <percent>1.4%</percent> (38/2799) of patients receiving KEYTRUDA, including Grade 3 (<percent>1%</percent>) and Grade 2 (<percent>0.1%</percent>) reactions. Systemic corticosteroids were required in <percent>40%</percent> (15/38) of patients. These reactions led to permanent discontinuation in <percent>0.1%</percent> (2) and withholding of KEYTRUDA in <percent>0.6%</percent> (16) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, <percent>6%</percent> had recurrence. The reactions resolved in <percent>79%</percent> of the 38 patients.</p><p><span class=\"bwuline\">Other Immune-Mediated Adverse Reactions<br/></span>The following clinically significant immune-mediated adverse reactions occurred at an incidence of &lt;<percent>1%</percent> (unless otherwise noted) in patients who received KEYTRUDA or were reported with the use of other anti–PD-1/PD-L1 treatments. Severe or fatal cases have been reported for some of these adverse reactions. <i>Cardiac/Vascular: </i>Myocarditis, pericarditis, vasculitis; <i>Nervous System:</i> Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy; <i>Ocular: </i>Uveitis, iritis and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss; <i>Gastrointestinal:</i> Pancreatitis, to include increases in serum amylase and lipase levels, gastritis, duodenitis; <i>Musculoskeletal and Connective Tissue: </i>Myositis/polymyositis, rhabdomyolysis (and associated sequelae, including renal failure), arthritis (<percent>1.5%</percent>), polymyalgia rheumatica; <i>Endocrine: </i>Hypoparathyroidism;<i> Hematologic/Immune: </i>Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection.</p><p><b>Infusion-Related Reactions<br/></b>KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in <percent>0.2%</percent> of 2799 patients receiving KEYTRUDA. Monitor for signs and symptoms of infusion-related reactions. Interrupt or slow the rate of infusion for Grade 1 or Grade 2 reactions. For Grade 3 or Grade 4 reactions, stop infusion and permanently discontinue KEYTRUDA.</p><p><b>Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)<br/></b>Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after anti–PD-1/PD-L1 treatments. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute and chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between anti–PD-1/PD-L1 treatments and allogeneic HSCT. Follow patients closely for evidence of these complications and intervene promptly. Consider the benefit vs risks of using anti–PD-1/PD-L1 treatments prior to or after an allogeneic HSCT.</p><p><b>Increased Mortality in Patients With Multiple Myeloma<br/></b>In trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of these patients with an anti–PD-1/PD-L1 treatment in this combination is not recommended outside of controlled trials.</p><p><b>Embryofetal Toxicity<br/></b>Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA and advise them to use effective contraception during treatment and for 4 months after the last dose.</p><p><b>Adverse Reactions<br/></b>In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in <percent>9%</percent> of 555 patients with advanced melanoma; adverse reactions leading to permanent discontinuation in more than one patient were colitis (<percent>1.4%</percent>), autoimmune hepatitis (<percent>0.7%</percent>), allergic reaction (<percent>0.4%</percent>), polyneuropathy (<percent>0.4%</percent>), and cardiac failure (<percent>0.4%</percent>). The most common adverse reactions (≥<percent>20%</percent>) with KEYTRUDA were fatigue (<percent>28%</percent>), diarrhea (<percent>26%</percent>), rash (<percent>24%</percent>), and nausea (<percent>21%</percent>).</p><p>In KEYNOTE-054, when KEYTRUDA was administered as a single agent to patients with stage III melanoma, KEYTRUDA was permanently discontinued due to adverse reactions in <percent>14%</percent> of 509 patients; the most common (≥<percent>1%</percent>) were pneumonitis (<percent>1.4%</percent>), colitis (<percent>1.2%</percent>), and diarrhea (<percent>1%</percent>). Serious adverse reactions occurred in <percent>25%</percent> of patients receiving KEYTRUDA. The most common adverse reaction (≥<percent>20%</percent>) with KEYTRUDA was diarrhea (<percent>28%</percent>). In KEYNOTE-716, when KEYTRUDA was administered as a single agent to patients with stage IIB or IIC melanoma, adverse reactions occurring in patients with stage IIB or IIC melanoma were similar to those occurring in 1011 patients with stage III melanoma from KEYNOTE-054.</p><p>In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in <percent>20%</percent> of 405 patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonitis (<percent>3%</percent>) and acute kidney injury (<percent>2%</percent>). The most common adverse reactions (≥<percent>20%</percent>) with KEYTRUDA were nausea (<percent>56%</percent>), fatigue (<percent>56%</percent>), constipation (<percent>35%</percent>), diarrhea (<percent>31%</percent>), decreased appetite (<percent>28%</percent>), rash (<percent>25%</percent>), vomiting (<percent>24%</percent>), cough (<percent>21%</percent>), dyspnea (<percent>21%</percent>), and pyrexia (<percent>20%</percent>).</p><p>In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and either paclitaxel or paclitaxel protein-bound in metastatic squamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in <percent>15%</percent> of 101 patients. The most frequent serious adverse reactions reported in at least <percent>2%</percent> of patients were febrile neutropenia, pneumonia, and urinary tract infection. Adverse reactions observed in KEYNOTE-407 were similar to those observed in KEYNOTE-189 with the exception that increased incidences of alopecia (<percent>47%</percent> vs <percent>36%</percent>) and peripheral neuropathy (<percent>31%</percent> vs <percent>25%</percent>) were observed in the KEYTRUDA and chemotherapy arm compared to the placebo and chemotherapy arm in KEYNOTE-407.</p><p>In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in <percent>19%</percent> of 636 patients with advanced NSCLC; the most common were pneumonitis (<percent>3%</percent>), death due to unknown cause (<percent>1.6%</percent>), and pneumonia (<percent>1.4%</percent>). The most frequent serious adverse reactions reported in at least <percent>2%</percent> of patients were pneumonia (<percent>7%</percent>), pneumonitis (<percent>3.9%</percent>), pulmonary embolism (<percent>2.4%</percent>), and pleural effusion (<percent>2.2%</percent>). The most common adverse reaction (≥<percent>20%</percent>) was fatigue (<percent>25%</percent>).</p><p>In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse reactions in <percent>8%</percent> of 682 patients with metastatic NSCLC; the most common was pneumonitis (<percent>1.8%</percent>). The most common adverse reactions (≥<percent>20%</percent>) were decreased appetite (<percent>25%</percent>), fatigue (<percent>25%</percent>), dyspnea (<percent>23%</percent>), and nausea (<percent>20%</percent>).</p><p>In KEYNOTE-671, adverse reactions occurring in patients with resectable NSCLC receiving KEYTRUDA in combination with platinum-containing chemotherapy, given as neoadjuvant treatment and continued as single-agent adjuvant treatment, were generally similar to those occurring in patients in other clinical trials across tumor types receiving KEYTRUDA in combination with chemotherapy.</p><p>The most common adverse reactions (reported in ≥<percent>20%</percent>) in patients receiving KEYTRUDA in combination with chemotherapy or chemoradiotherapy were fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, stomatitis, headache, weight loss, abdominal pain, arthralgia, myalgia, insomnia, palmar-plantar erythrodysesthesia, urinary tract infection, hypothyroidism, radiation skin injury, dysphagia, dry mouth, and musculoskeletal pain.</p><p>In the neoadjuvant phase of KEYNOTE-671, when KEYTRUDA was administered in combination with platinum-containing chemotherapy as neoadjuvant treatment, serious adverse reactions occurred in <percent>34%</percent> of 396 patients. The most frequent (≥<percent>2%</percent>) serious adverse reactions were pneumonia (<percent>4.8%</percent>), venous thromboembolism (<percent>3.3%</percent>), and anemia (<percent>2%</percent>). Fatal adverse reactions occurred in <percent>1.3%</percent> of patients, including death due to unknown cause (<percent>0.8%</percent>), sepsis (<percent>0.3%</percent>), and immune-mediated lung disease (<percent>0.3%</percent>). Permanent discontinuation of any study drug due to an adverse reaction occurred in <percent>18%</percent> of patients who received KEYTRUDA in combination with platinum-containing chemotherapy; the most frequent adverse reactions (≥<percent>1%</percent>) that led to permanent discontinuation of any study drug were acute kidney injury (<percent>1.8%</percent>), interstitial lung disease (<percent>1.8%</percent>), anemia (<percent>1.5%</percent>), neutropenia (<percent>1.5%</percent>), and pneumonia (<percent>1.3%</percent>).</p><p>Of the KEYTRUDA-treated patients who received neoadjuvant treatment, <percent>6%</percent> of 396 patients did not receive surgery due to adverse reactions. The most frequent (≥<percent>1%</percent>) adverse reaction that led to cancellation of surgery in the KEYTRUDA arm was interstitial lung disease (<percent>1%</percent>).</p><p>In the adjuvant phase of KEYNOTE-671, when KEYTRUDA was administered as a single agent as adjuvant treatment, serious adverse reactions occurred in <percent>14%</percent> of 290 patients. The most frequent serious adverse reaction was pneumonia (<percent>3.4%</percent>). One fatal adverse reaction of pulmonary hemorrhage occurred. Permanent discontinuation of KEYTRUDA due to an adverse reaction occurred in <percent>12%</percent> of patients who received KEYTRUDA as a single agent, given as adjuvant treatment; the most frequent adverse reactions (≥<percent>1%</percent>) that led to permanent discontinuation of KEYTRUDA were diarrhea (<percent>1.7%</percent>), interstitial lung disease (<percent>1.4%</percent>), increased aspartate aminotransferase (<percent>1%</percent>), and musculoskeletal pain (<percent>1%</percent>).</p><p>Adverse reactions observed in KEYNOTE-091 were generally similar to those occurring in other patients with NSCLC receiving KEYTRUDA as a single agent, with the exception of hypothyroidism (<percent>22%</percent>), hyperthyroidism (<percent>11%</percent>), and pneumonitis (<percent>7%</percent>). Two fatal adverse reactions of myocarditis occurred.</p><p>Adverse reactions observed in KEYNOTE-483 were generally similar to those occurring in other patients receiving KEYTRUDA in combination with pemetrexed and platinum chemotherapy.</p><p>In KEYNOTE-689, the most common adverse reactions (≥<percent>20%</percent>) in patients receiving KEYTRUDA were stomatitis (<percent>48%</percent>), radiation skin injury (<percent>40%</percent>), weight loss (<percent>36%</percent>), fatigue (<percent>33%</percent>), dysphagia (<percent>29%</percent>), constipation (<percent>27%</percent>), hypothyroidism (<percent>26%</percent>), nausea (<percent>24%</percent>), rash (<percent>22%</percent>), dry mouth (<percent>22%</percent>), diarrhea (<percent>22%</percent>), and musculoskeletal pain (<percent>22%</percent>).</p><p>In the neoadjuvant phase of KEYNOTE-689, of the 361 patients who received at least one dose of single agent KEYTRUDA, <percent>11%</percent> experienced serious adverse reactions. Serious adverse reactions that occurred in more than one patient were pneumonia (<percent>1.4%</percent>), tumor hemorrhage (<percent>0.8%</percent>), dysphagia (<percent>0.6%</percent>), immune-mediated hepatitis (<percent>0.6%</percent>), cellulitis (<percent>0.6%</percent>), and dyspnea (<percent>0.6%</percent>). Fatal adverse reactions occurred in <percent>1.1%</percent> of patients, including respiratory failure, clostridium infection, septic shock, and myocardial infarction (one patient each). Permanent discontinuation of KEYTRUDA due to an adverse reaction occurred in <percent>2.8%</percent> of patients who received KEYTRUDA as neoadjuvant treatment. The most frequent adverse reaction which resulted in permanent discontinuation of neoadjuvant KEYTRUDA in more than one patient was arthralgia (<percent>0.6%</percent>).</p><p>Of the 361 patients who received KEYTRUDA as neoadjuvant treatment, <percent>11%</percent> did not receive surgery. Surgical cancellation on the KEYTRUDA arm was due to disease progression in <percent>4%</percent>, patient decision in <percent>3%</percent>, adverse reactions in <percent>1.4%</percent>, physician’s decision in <percent>1.1%</percent>, unresectable tumor in <percent>0.6%</percent>, loss of follow-up in <percent>0.3%</percent>, and use of non-study anti-cancer therapy in <percent>0.3%</percent>.</p><p>Of the 323 KEYTRUDA-treated patients who received surgery following the neoadjuvant phase, <percent>1.2%</percent> experienced delay of surgery (defined as on-study surgery occurring ≥9 weeks after initiation of neoadjuvant KEYTRUDA) due to adverse reactions, and <percent>2.8%</percent> did not receive adjuvant treatment due to adverse reactions.</p><p>In the adjuvant phase of KEYNOTE-689, of the 255 patients who received at least one dose of KEYTRUDA, <percent>38%</percent> experienced serious adverse reactions. The most frequent serious adverse reactions reported in ≥<percent>1%</percent> of KEYTRUDA- treated patients were pneumonia (<percent>2.7%</percent>), pyrexia (<percent>2.4%</percent>), stomatitis (<percent>2.4%</percent>), acute kidney injury (<percent>2.0%</percent>), pneumonitis (<percent>1.6%</percent>), COVID-19 (<percent>1.2%</percent>), death not otherwise specified (<percent>1.2%</percent>), diarrhea (<percent>1.2%</percent>), dysphagia (<percent>1.2%</percent>), gastrostomy tube site complication (<percent>1.2%</percent>), and immune-mediated hepatitis (<percent>1.2%</percent>). Fatal adverse reactions occurred in <percent>5%</percent> of patients, including death not otherwise specified (<percent>1.2%</percent>), acute renal failure (<percent>0.4%</percent>), hypercalcemia (<percent>0.4%</percent>), pulmonary hemorrhage (<percent>0.4%</percent>), dysphagia/malnutrition (<percent>0.4%</percent>), mesenteric thrombosis (<percent>0.4%</percent>), sepsis (<percent>0.4%</percent>), pneumonia (<percent>0.4%</percent>), COVID-19 (<percent>0.4%</percent>), respiratory failure (<percent>0.4%</percent>), cardiovascular disorder (<percent>0.4%</percent>), and gastrointestinal hemorrhage (<percent>0.4%</percent>). Permanent discontinuation of adjuvant KEYTRUDA due to an adverse reaction occurred in <percent>17%</percent> of patients. The most frequent (≥<percent>1%</percent>) adverse reactions that led to permanent discontinuation of adjuvant KEYTRUDA were pneumonitis, colitis, immune-mediated hepatitis, and death not otherwise specified.</p><p>In KEYNOTE-048, KEYTRUDA monotherapy was discontinued due to adverse events in <percent>12%</percent> of 300 patients with HNSCC; the most common adverse reactions leading to permanent discontinuation were sepsis (<percent>1.7%</percent>) and pneumonia (<percent>1.3%</percent>). The most common adverse reactions (≥<percent>20%</percent>) were fatigue (<percent>33%</percent>), constipation (<percent>20%</percent>), and rash (<percent>20%</percent>).</p><p>In KEYNOTE-048, when KEYTRUDA was administered in combination with platinum (cisplatin or carboplatin) and FU chemotherapy, KEYTRUDA was discontinued due to adverse reactions in <percent>16%</percent> of 276 patients with HNSCC. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonia (<percent>2.5%</percent>), pneumonitis (<percent>1.8%</percent>), and septic shock (<percent>1.4%</percent>). The most common adverse reactions (≥<percent>20%</percent>) were nausea (<percent>51%</percent>), fatigue (<percent>49%</percent>), constipation (<percent>37%</percent>), vomiting (<percent>32%</percent>), mucosal inflammation (<percent>31%</percent>), diarrhea (<percent>29%</percent>), decreased appetite (<percent>29%</percent>), stomatitis (<percent>26%</percent>), and cough (<percent>22%</percent>).</p><p>In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in <percent>17%</percent> of 192 patients with HNSCC. Serious adverse reactions occurred in <percent>45%</percent> of patients. The most frequent serious adverse reactions reported in at least <percent>2%</percent> of patients were pneumonia, dyspnea, confusional state, vomiting, pleural effusion, and respiratory failure. The most common adverse reactions (≥<percent>20%</percent>) were fatigue, decreased appetite, and dyspnea. Adverse reactions occurring in patients with HNSCC were generally similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy, with the exception of increased incidences of facial edema and new or worsening hypothyroidism.</p><p>In KEYNOTE-204, KEYTRUDA was discontinued due to adverse reactions in <percent>14%</percent> of 148 patients with cHL. Serious adverse reactions occurred in <percent>30%</percent> of patients receiving KEYTRUDA; those ≥<percent>1%</percent> were pneumonitis, pneumonia, pyrexia, myocarditis, acute kidney injury, febrile neutropenia, and sepsis. Three patients died from causes other than disease progression: 2 from complications after allogeneic HSCT and 1 from unknown cause. The most common adverse reactions (≥<percent>20%</percent>) were upper respiratory tract infection (<percent>41%</percent>), musculoskeletal pain (<percent>32%</percent>), diarrhea (<percent>22%</percent>), and pyrexia, fatigue, rash, and cough (<percent>20%</percent> each).</p><p>In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in <percent>5%</percent> of 210 patients with cHL. Serious adverse reactions occurred in <percent>16%</percent> of patients; those ≥<percent>1%</percent> were pneumonia, pneumonitis, pyrexia, dyspnea, GVHD, and herpes zoster. Two patients died from causes other than disease progression: 1 from GVHD after subsequent allogeneic HSCT and 1 from septic shock. The most common adverse reactions (≥<percent>20%</percent>) were fatigue (<percent>26%</percent>), pyrexia (<percent>24%</percent>), cough (<percent>24%</percent>), musculoskeletal pain (<percent>21%</percent>), diarrhea (<percent>20%</percent>), and rash (<percent>20%</percent>).</p><p>In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in <percent>8%</percent> of 53 patients with PMBCL. Serious adverse reactions occurred in <percent>26%</percent> of patients and included arrhythmia (<percent>4%</percent>), cardiac tamponade (<percent>2%</percent>), myocardial infarction (<percent>2%</percent>), pericardial effusion (<percent>2%</percent>), and pericarditis (<percent>2%</percent>). Six (<percent>11%</percent>) patients died within 30 days of start of treatment. The most common adverse reactions (≥<percent>20%</percent>) were musculoskeletal pain (<percent>30%</percent>), upper respiratory tract infection and pyrexia (<percent>28%</percent> each), cough (<percent>26%</percent>), fatigue (<percent>23%</percent>), and dyspnea (<percent>21%</percent>).</p><p>In KEYNOTE-A39, when KEYTRUDA was administered in combination with enfortumab vedotin to patients with locally advanced or metastatic urothelial cancer (n=440), fatal adverse reactions occurred in <percent>3.9%</percent> of patients, including acute respiratory failure (<percent>0.7%</percent>), pneumonia (<percent>0.5%</percent>), and pneumonitis/ILD (<percent>0.2%</percent>). Serious adverse reactions occurred in <percent>50%</percent> of patients receiving KEYTRUDA in combination with enfortumab vedotin; the serious adverse reactions in ≥<percent>2%</percent> of patients were rash (<percent>6%</percent>), acute kidney injury (<percent>5%</percent>), pneumonitis/ILD (<percent>4.5%</percent>), urinary tract infection (<percent>3.6%</percent>), diarrhea (<percent>3.2%</percent>), pneumonia (<percent>2.3%</percent>), pyrexia (<percent>2%</percent>), and hyperglycemia (<percent>2%</percent>). Permanent discontinuation of KEYTRUDA occurred in <percent>27%</percent> of patients. The most common adverse reactions (≥<percent>2%</percent>) resulting in permanent discontinuation of KEYTRUDA were pneumonitis/ILD (<percent>4.8%</percent>) and rash (<percent>3.4%</percent>). The most common adverse reactions (≥<percent>20%</percent>) occurring in patients treated with KEYTRUDA in combination with enfortumab vedotin were rash (<percent>68%</percent>), peripheral neuropathy (<percent>67%</percent>), fatigue (<percent>51%</percent>), pruritus (<percent>41%</percent>), diarrhea (<percent>38%</percent>), alopecia (<percent>35%</percent>), weight loss (<percent>33%</percent>), decreased appetite (<percent>33%</percent>), nausea (<percent>26%</percent>), constipation (<percent>26%</percent>), dry eye (<percent>24%</percent>), dysgeusia (<percent>21%</percent>), and urinary tract infection (<percent>21%</percent>).</p><p>In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in <percent>11%</percent> of 370 patients with locally advanced or metastatic urothelial carcinoma. Serious adverse reactions occurred in <percent>42%</percent> of patients; those ≥<percent>2%</percent> were urinary tract infection, hematuria, acute kidney injury, pneumonia, and urosepsis. The most common adverse reactions (≥<percent>20%</percent>) were fatigue (<percent>38%</percent>), musculoskeletal pain (<percent>24%</percent>), decreased appetite (<percent>22%</percent>), constipation (<percent>21%</percent>), rash (<percent>21%</percent>), and diarrhea (<percent>20%</percent>).</p><p>In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in <percent>8%</percent> of 266 patients with locally advanced or metastatic urothelial carcinoma. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA was pneumonitis (<percent>1.9%</percent>). Serious adverse reactions occurred in <percent>39%</percent> of KEYTRUDA-treated patients; those ≥<percent>2%</percent> were urinary tract infection, pneumonia, anemia, and pneumonitis. The most common adverse reactions (≥<percent>20%</percent>) in patients who received KEYTRUDA were fatigue (<percent>38%</percent>), musculoskeletal pain (<percent>32%</percent>), pruritus (<percent>23%</percent>), decreased appetite (<percent>21%</percent>), nausea (<percent>21%</percent>), and rash (<percent>20%</percent>).</p><p>In KEYNOTE-905, the most common adverse reactions (≥<percent>20%</percent>) occurring in cisplatin-ineligible patients with MIBC treated with KEYTRUDA in combination with enfortumab vedotin (n=167) were rash (<percent>54%</percent>), pruritus (<percent>47%</percent>), fatigue (<percent>47%</percent>), peripheral neuropathy (<percent>39%</percent>), alopecia (<percent>35%</percent>), dysgeusia (<percent>35%</percent>), diarrhea (<percent>34%</percent>), constipation (<percent>28%</percent>), decreased appetite (<percent>28%</percent>), nausea (<percent>26%</percent>), urinary tract infection (<percent>24%</percent>), dry eye (<percent>21%</percent>), and weight loss (<percent>20%</percent>).</p><p>In the neoadjuvant phase of KEYNOTE-905, serious adverse reactions occurred in <percent>27%</percent> (n=167) of patients; the most frequent (≥<percent>2%</percent>) were urinary tract infection (<percent>3.6%</percent>) and hematuria (<percent>2.4%</percent>). Fatal adverse reactions occurred in <percent>1.2%</percent> of patients, including myasthenia gravis and toxic epidermal necrolysis (<percent>0.6%</percent> each). Additional fatal adverse reactions were reported in <percent>2.7%</percent> of patients in the post-surgery phase before adjuvant treatment started, including sepsis and intestinal obstruction (<percent>1.4%</percent> each). Permanent discontinuation of KEYTRUDA due to an adverse reaction occurred in <percent>15%</percent> of patients; the most frequent (&gt;<percent>1%</percent>) were rash (<percent>2.4%</percent>, including generalized exfoliative dermatitis), increased alanine aminotransferase, increased aspartate aminotransferase, diarrhea, dysgeusia, and toxic epidermal necrolysis (<percent>1.2%</percent> each). Of the 167 patients in the KEYTRUDA in combination with enfortumab vedotin arm who received neoadjuvant treatment, 7 (<percent>4.2%</percent>) patients did not receive surgery due to adverse reactions. The adverse reactions that led to cancellation of surgery were acute myocardial infarction, bile duct cancer, colon cancer, respiratory distress, urinary tract infection, and the two deaths due to myasthenia gravis and toxic epidermal necrolysis (<percent>0.6%</percent> each).</p><p>Of the 146 patients who received neoadjuvant treatment with KEYTRUDA in combination with enfortumab vedotin and underwent radical cystectomy, 6 (<percent>4.1%</percent>) patients experienced delay of surgery (defined as time from last neoadjuvant treatment to surgery exceeding 8 weeks) due to adverse reactions.</p><p>In the adjuvant phase of KEYNOTE-905, serious adverse reactions occurred in <percent>43%</percent> (n=100) of patients; the most frequent (≥<percent>2%</percent>) were urinary tract infection (<percent>8%</percent>); acute kidney injury and pyelonephritis (<percent>5%</percent> each); urosepsis (<percent>4%</percent>); and hypokalemia, intestinal obstruction, and sepsis (<percent>2%</percent> each). Fatal adverse reactions occurred in <percent>7%</percent> of patients, including urosepsis, intracranial hemorrhage, death, myocardial infarction, multiple organ dysfunction syndrome, and pseudomonal pneumonia (<percent>1%</percent> each). Permanent discontinuation of KEYTRUDA due to an adverse reaction occurred in <percent>28%</percent> of patients; the most frequent (&gt;<percent>1%</percent>) were diarrhea (<percent>5%</percent>), peripheral neuropathy, acute kidney injury, and pneumonitis (<percent>2%</percent> each).</p><p>In KEYNOTE-057, KEYTRUDA was discontinued due to adverse reactions in <percent>11%</percent> of 148 patients with high-risk NMIBC. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA was pneumonitis (<percent>1.4%</percent>). Serious adverse reactions occurred in <percent>28%</percent> of patients; those ≥<percent>2%</percent> were pneumonia (<percent>3%</percent>), cardiac ischemia (<percent>2%</percent>), colitis (<percent>2%</percent>), pulmonary embolism (<percent>2%</percent>), sepsis (<percent>2%</percent>), and urinary tract infection (<percent>2%</percent>). The most common adverse reactions (≥<percent>20%</percent>) were fatigue (<percent>29%</percent>), diarrhea (<percent>24%</percent>), and rash (<percent>24%</percent>).</p><p>Adverse reactions occurring in patients with MSI-H or dMMR CRC were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.</p><p>In KEYNOTE-158 and KEYNOTE-164, adverse reactions occurring in patients with MSI-H or dMMR cancer were similar to those occurring in patients with other solid tumors who received KEYTRUDA as a single agent.</p><p>In KEYNOTE-811, fatal adverse reactions occurred in 3 patients who received KEYTRUDA in combination with trastuzumab and CAPOX (capecitabine plus oxaliplatin) or FP (5-FU plus cisplatin) and included pneumonitis in 2 patients and hepatitis in 1 patient. KEYTRUDA was discontinued due to adverse reactions in <percent>13%</percent> of 350 patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma. Adverse reactions resulting in permanent discontinuation of KEYTRUDA in ≥<percent>1%</percent> of patients were pneumonitis (<percent>2.0%</percent>) and pneumonia (<percent>1.1%</percent>). In the KEYTRUDA arm vs placebo, there was a difference of ≥<percent>5%</percent> incidence between patients treated with KEYTRUDA vs standard of care for diarrhea (<percent>53%</percent> vs <percent>47%</percent>), rash (<percent>35%</percent> vs <percent>28%</percent>), hypothyroidism (<percent>11%</percent> vs <percent>5%</percent>), and pneumonia (<percent>11%</percent> vs <percent>5%</percent>).</p><p>In KEYNOTE-859, when KEYTRUDA was administered in combination with fluoropyrimidine- and platinum-containing chemotherapy, serious adverse reactions occurred in <percent>45%</percent> of 785 patients. Serious adverse reactions in &gt;<percent>2%</percent> of patients included pneumonia (<percent>4.1%</percent>), diarrhea (<percent>3.9%</percent>), hemorrhage (<percent>3.9%</percent>), and vomiting (<percent>2.4%</percent>). Fatal adverse reactions occurred in <percent>8%</percent> of patients who received KEYTRUDA, including infection (<percent>2.3%</percent>) and thromboembolism (<percent>1.3%</percent>). KEYTRUDA was permanently discontinued due to adverse reactions in <percent>15%</percent> of patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA (≥<percent>1%</percent>) were infections (<percent>1.8%</percent>) and diarrhea (<percent>1.0%</percent>). The most common adverse reactions (reported in ≥<percent>20%</percent>) in patients receiving KEYTRUDA in combination with chemotherapy were peripheral neuropathy (<percent>47%</percent>), nausea (<percent>46%</percent>), fatigue (<percent>40%</percent>), diarrhea (<percent>36%</percent>), vomiting (<percent>34%</percent>), decreased appetite (<percent>29%</percent>), abdominal pain (<percent>26%</percent>), palmar-plantar erythrodysesthesia syndrome (<percent>25%</percent>), constipation (<percent>22%</percent>), and weight loss (<percent>20%</percent>).</p><p>In KEYNOTE-590, when KEYTRUDA was administered with cisplatin and fluorouracil to patients with metastatic or locally advanced esophageal or GEJ (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma who were not candidates for surgical resection or definitive chemoradiation, KEYTRUDA was discontinued due to adverse reactions in <percent>15%</percent> of 370 patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA (≥<percent>1%</percent>) were pneumonitis (<percent>1.6%</percent>), acute kidney injury (<percent>1.1%</percent>), and pneumonia (<percent>1.1%</percent>). The most common adverse reactions (≥<percent>20%</percent>) with KEYTRUDA in combination with chemotherapy were nausea (<percent>67%</percent>), fatigue (<percent>57%</percent>), decreased appetite (<percent>44%</percent>), constipation (<percent>40%</percent>), diarrhea (<percent>36%</percent>), vomiting (<percent>34%</percent>), stomatitis (<percent>27%</percent>), and weight loss (<percent>24%</percent>).</p><p>Adverse reactions occurring in patients with esophageal cancer who received KEYTRUDA as a monotherapy were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.</p><p>In KEYNOTE-A18, when KEYTRUDA was administered with CRT (cisplatin plus external beam radiation therapy [EBRT] followed by brachytherapy [BT]) to patients with FIGO 2014 Stage III-IVA cervical cancer, fatal adverse reactions occurred in <percent>1.4%</percent> of 294 patients, including 1 case each (<percent>0.3%</percent>) of large intestinal perforation, urosepsis, sepsis, and vaginal hemorrhage. Serious adverse reactions occurred in <percent>34%</percent> of patients; those ≥<percent>1%</percent> included urinary tract infection (<percent>3.1%</percent>), urosepsis (<percent>1.4%</percent>), and sepsis (<percent>1%</percent>). KEYTRUDA was discontinued for adverse reactions in <percent>9%</percent> of patients. The most common adverse reaction (≥<percent>1%</percent>) resulting in permanent discontinuation was diarrhea (<percent>1%</percent>). For patients treated with KEYTRUDA in combination with CRT, the most common adverse reactions (≥<percent>10%</percent>) were nausea (<percent>56%</percent>), diarrhea (<percent>51%</percent>), urinary tract infection (<percent>35%</percent>), vomiting (<percent>34%</percent>), fatigue (<percent>28%</percent>), hypothyroidism (<percent>23%</percent>), constipation (<percent>20%</percent>), weight loss (<percent>19%</percent>), decreased appetite (<percent>18%</percent>), pyrexia (<percent>14%</percent>), abdominal pain and hyperthyroidism (<percent>13%</percent> each), dysuria and rash (<percent>12%</percent> each), back and pelvic pain (<percent>11%</percent> each), and COVID-19 (<percent>10%</percent>).</p><p>In KEYNOTE-826, when KEYTRUDA was administered in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab (n=307), to patients with persistent, recurrent, or first-line metastatic cervical cancer regardless of tumor PD-L1 expression who had not been treated with chemotherapy except when used concurrently as a radio-sensitizing agent, fatal adverse reactions occurred in <percent>4.6%</percent> of patients, including 3 cases of hemorrhage, 2 cases each of sepsis and due to unknown causes, and 1 case each of acute myocardial infarction, autoimmune encephalitis, cardiac arrest, cerebrovascular accident, femur fracture with perioperative pulmonary embolus, intestinal perforation, and pelvic infection. Serious adverse reactions occurred in <percent>50%</percent> of patients receiving KEYTRUDA in combination with chemotherapy with or without bevacizumab; those ≥<percent>3%</percent> were febrile neutropenia (<percent>6.8%</percent>), urinary tract infection (<percent>5.2%</percent>), anemia (<percent>4.6%</percent>), and acute kidney injury and sepsis (<percent>3.3%</percent> each).</p><p>KEYTRUDA was discontinued in <percent>15%</percent> of patients due to adverse reactions. The most common adverse reaction resulting in permanent discontinuation (≥<percent>1%</percent>) was colitis (<percent>1%</percent>).</p><p>For patients treated with KEYTRUDA, chemotherapy, and bevacizumab (n=196), the most common adverse reactions (≥<percent>20%</percent>) were peripheral neuropathy (<percent>62%</percent>), alopecia (<percent>58%</percent>), anemia (<percent>55%</percent>), fatigue/asthenia (<percent>53%</percent>), nausea and neutropenia (<percent>41%</percent> each), diarrhea (<percent>39%</percent>), hypertension and thrombocytopenia (<percent>35%</percent> each), constipation and arthralgia (<percent>31%</percent> each), vomiting (<percent>30%</percent>), urinary tract infection (<percent>27%</percent>), rash (<percent>26%</percent>), leukopenia (<percent>24%</percent>), hypothyroidism (<percent>22%</percent>), and decreased appetite (<percent>21%</percent>).</p><p>For patients treated with KEYTRUDA in combination with chemotherapy with or without bevacizumab, the most common adverse reactions (≥<percent>20%</percent>) were peripheral neuropathy (<percent>58%</percent>), alopecia (<percent>56%</percent>), fatigue (<percent>47%</percent>), nausea (<percent>40%</percent>), diarrhea (<percent>36%</percent>), constipation (<percent>28%</percent>), arthralgia (<percent>27%</percent>), vomiting (<percent>26%</percent>), hypertension and urinary tract infection (<percent>24%</percent> each), and rash (<percent>22%</percent>).</p><p>In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in <percent>8%</percent> of 98 patients with previously treated recurrent or metastatic cervical cancer. Serious adverse reactions occurred in <percent>39%</percent> of patients receiving KEYTRUDA; the most frequent included anemia (<percent>7%</percent>), fistula, hemorrhage, and infections [except urinary tract infections] (<percent>4.1%</percent> each). The most common adverse reactions (≥<percent>20%</percent>) were fatigue (<percent>43%</percent>), musculoskeletal pain (<percent>27%</percent>), diarrhea (<percent>23%</percent>), pain and abdominal pain (<percent>22%</percent> each), and decreased appetite (<percent>21%</percent>).</p><p>In KEYNOTE-394, KEYTRUDA was discontinued due to adverse reactions in <percent>13%</percent> of 299 patients with previously treated hepatocellular carcinoma. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA was ascites (<percent>2.3%</percent>). The most common adverse reactions in patients receiving KEYTRUDA (≥<percent>10%</percent>) were pyrexia (<percent>18%</percent>), rash (<percent>18%</percent>), diarrhea (<percent>16%</percent>), decreased appetite (<percent>15%</percent>), pruritus (<percent>12%</percent>), upper respiratory tract infection (<percent>11%</percent>), cough (<percent>11%</percent>), and hypothyroidism (<percent>10%</percent>).</p><p>In KEYNOTE-966, when KEYTRUDA was administered in combination with gemcitabine and cisplatin, KEYTRUDA was discontinued for adverse reactions in <percent>15%</percent> of 529 patients with locally advanced unresectable or metastatic biliary tract cancer. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA (≥<percent>1%</percent>) was pneumonitis (<percent>1.3%</percent>). Adverse reactions leading to the interruption of KEYTRUDA occurred in <percent>55%</percent> of patients. The most common adverse reactions or laboratory abnormalities leading to interruption of KEYTRUDA (≥<percent>2%</percent>) were decreased neutrophil count (<percent>18%</percent>), decreased platelet count (<percent>10%</percent>), anemia (<percent>6%</percent>), decreased white blood cell count (<percent>4%</percent>), pyrexia (<percent>3.8%</percent>), fatigue (<percent>3.0%</percent>), cholangitis (<percent>2.8%</percent>), increased ALT (<percent>2.6%</percent>), increased AST (<percent>2.5%</percent>), and biliary obstruction (<percent>2.3%</percent>).</p><p>In KEYNOTE-017 and KEYNOTE-913, adverse reactions occurring in patients with MCC (n=105) were generally similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a single agent.</p><p>In KEYNOTE-426, when KEYTRUDA was administered in combination with axitinib, fatal adverse reactions occurred in <percent>3.3%</percent> of 429 patients. Serious adverse reactions occurred in <percent>40%</percent> of patients, the most frequent (≥<percent>1%</percent>) were hepatotoxicity (<percent>7%</percent>), diarrhea (<percent>4.2%</percent>), acute kidney injury (<percent>2.3%</percent>), dehydration (<percent>1%</percent>), and pneumonitis (<percent>1%</percent>). Permanent discontinuation due to an adverse reaction occurred in <percent>31%</percent> of patients; KEYTRUDA only (<percent>13%</percent>), axitinib only (<percent>13%</percent>), and the combination (<percent>8%</percent>); the most common were hepatotoxicity (<percent>13%</percent>), diarrhea/colitis (<percent>1.9%</percent>), acute kidney injury (<percent>1.6%</percent>), and cerebrovascular accident (<percent>1.2%</percent>). The most common adverse reactions (≥<percent>20%</percent>) were diarrhea (<percent>56%</percent>), fatigue/asthenia (<percent>52%</percent>), hypertension (<percent>48%</percent>), hepatotoxicity (<percent>39%</percent>), hypothyroidism (<percent>35%</percent>), decreased appetite (<percent>30%</percent>), palmar-plantar erythrodysesthesia (<percent>28%</percent>), nausea (<percent>28%</percent>), stomatitis/mucosal inflammation (<percent>27%</percent>), dysphonia (<percent>25%</percent>), rash (<percent>25%</percent>), cough (<percent>21%</percent>), and constipation (<percent>21%</percent>).</p><p>In KEYNOTE-564, when KEYTRUDA was administered as a single agent for the adjuvant treatment of renal cell carcinoma, serious adverse reactions occurred in <percent>20%</percent> of patients receiving KEYTRUDA; the serious adverse reactions (≥<percent>1%</percent>) were acute kidney injury, adrenal insufficiency, pneumonia, colitis, and diabetic ketoacidosis (<percent>1%</percent> each). Fatal adverse reactions occurred in <percent>0.2%</percent> including 1 case of pneumonia. Discontinuation of KEYTRUDA due to adverse reactions occurred in <percent>21%</percent> of 488 patients; the most common (≥<percent>1%</percent>) were increased ALT (<percent>1.6%</percent>), colitis (<percent>1%</percent>), and adrenal insufficiency (<percent>1%</percent>). The most common adverse reactions (≥<percent>20%</percent>) were musculoskeletal pain (<percent>41%</percent>), fatigue (<percent>40%</percent>), rash (<percent>30%</percent>), diarrhea (<percent>27%</percent>), pruritus (<percent>23%</percent>), and hypothyroidism (<percent>21%</percent>).</p><p>In KEYNOTE-868, when KEYTRUDA was administered in combination with chemotherapy (paclitaxel and carboplatin) to patients with advanced or recurrent endometrial carcinoma (n=382), serious adverse reactions occurred in <percent>35%</percent> of patients receiving KEYTRUDA in combination with chemotherapy, compared to <percent>19%</percent> of patients receiving placebo in combination with chemotherapy (n=377). Fatal adverse reactions occurred in <percent>1.6%</percent> of patients receiving KEYTRUDA in combination with chemotherapy, including COVID-19 (<percent>0.5%</percent>) and cardiac arrest (<percent>0.3%</percent>). KEYTRUDA was discontinued for an adverse reaction in <percent>14%</percent> of patients. Adverse reactions occurring in patients treated with KEYTRUDA and chemotherapy were generally similar to those observed with KEYTRUDA alone or chemotherapy alone, with the exception of rash (<percent>33%</percent> all Grades; <percent>2.9%</percent> Grades 3-4).</p><p>Adverse reactions occurring in patients with MSI-H or dMMR endometrial carcinoma who received KEYTRUDA as a single agent were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a single agent.</p><p>Adverse reactions occurring in patients with TMB-H cancer were similar to those occurring in patients with other solid tumors who received KEYTRUDA as a single agent.</p><p>Adverse reactions occurring in patients with recurrent or metastatic cSCC or locally advanced cSCC were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.</p><p>In KEYNOTE-522, when KEYTRUDA was administered with neoadjuvant chemotherapy (carboplatin and paclitaxel followed by doxorubicin or epirubicin and cyclophosphamide) followed by surgery and continued adjuvant treatment with KEYTRUDA as a single agent (n=778) to patients with newly diagnosed, previously untreated, high-risk early-stage TNBC, fatal adverse reactions occurred in <percent>0.9%</percent> of patients, including 1 each of adrenal crisis, autoimmune encephalitis, hepatitis, pneumonia, pneumonitis, pulmonary embolism, and sepsis in association with multiple organ dysfunction syndrome and myocardial infarction. Serious adverse reactions occurred in <percent>44%</percent> of patients receiving KEYTRUDA; those ≥<percent>2%</percent> were febrile neutropenia (<percent>15%</percent>), pyrexia (<percent>3.7%</percent>), anemia (<percent>2.6%</percent>), and neutropenia (<percent>2.2%</percent>). KEYTRUDA was discontinued in <percent>20%</percent> of patients due to adverse reactions. The most common reactions (≥<percent>1%</percent>) resulting in permanent discontinuation were increased ALT (<percent>2.7%</percent>), increased AST (<percent>1.5%</percent>), and rash (<percent>1%</percent>). The most common adverse reactions (≥<percent>20%</percent>) in patients receiving KEYTRUDA were fatigue (<percent>70%</percent>), nausea (<percent>67%</percent>), alopecia (<percent>61%</percent>), rash (<percent>52%</percent>), constipation (<percent>42%</percent>), diarrhea and peripheral neuropathy (<percent>41%</percent> each), stomatitis (<percent>34%</percent>), vomiting (<percent>31%</percent>), headache (<percent>30%</percent>), arthralgia (<percent>29%</percent>), pyrexia (<percent>28%</percent>), cough (<percent>26%</percent>), abdominal pain (<percent>24%</percent>), decreased appetite (<percent>23%</percent>), insomnia (<percent>21%</percent>), and myalgia (<percent>20%</percent>).</p><p>In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who had not been previously treated with chemotherapy in the metastatic setting (n=596), fatal adverse reactions occurred in <percent>2.5%</percent> of patients, including cardio-respiratory arrest (<percent>0.7%</percent>) and septic shock (<percent>0.3%</percent>). Serious adverse reactions occurred in <percent>30%</percent> of patients receiving KEYTRUDA in combination with chemotherapy; the serious reactions in ≥<percent>2%</percent> were pneumonia (<percent>2.9%</percent>), anemia (<percent>2.2%</percent>), and thrombocytopenia (<percent>2%</percent>). KEYTRUDA was discontinued in <percent>11%</percent> of patients due to adverse reactions. The most common reactions resulting in permanent discontinuation (≥<percent>1%</percent>) were increased ALT (<percent>2.2%</percent>), increased AST (<percent>1.5%</percent>), and pneumonitis (<percent>1.2%</percent>). The most common adverse reactions (≥<percent>20%</percent>) in patients receiving KEYTRUDA in combination with chemotherapy were fatigue (<percent>48%</percent>), nausea (<percent>44%</percent>), alopecia (<percent>34%</percent>), diarrhea and constipation (<percent>28%</percent> each), vomiting and rash (<percent>26%</percent> each), cough (<percent>23%</percent>), decreased appetite (<percent>21%</percent>), and headache (<percent>20%</percent>).</p><p>In KEYNOTE-B96, when KEYTRUDA was administered in combination with paclitaxel, with or without bevacizumab, serious adverse reactions occurred in <percent>54%</percent> of patients. Serious adverse reactions in ≥<percent>2%</percent> of patients were pneumonia (<percent>4.3%</percent>), urinary tract infection (<percent>3.9%</percent>), adrenal insufficiency (<percent>3%</percent>), hyponatremia (<percent>3%</percent>), COVID-19, decreased neutrophil count, pulmonary embolism (<percent>2.6%</percent> each), abdominal pain, anemia, colitis, diarrhea, febrile neutropenia, pyrexia, and vomiting (<percent>2.1%</percent> each).</p><p>Fatal adverse reactions occurred in <percent>3.9%</percent> of patients receiving KEYTRUDA and paclitaxel, with or without bevacizumab, including assisted suicide (<percent>0.9%</percent>), death, intestinal perforation, sepsis, COVID-19, cardio-respiratory arrest, colitis, and embolic stroke (<percent>0.4%</percent> each).</p><p>KEYTRUDA was permanently discontinued for adverse reactions in <percent>16%</percent> of patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA (≥<percent>1%</percent>) were colitis and increased alanine aminotransferase (<percent>1.3%</percent> each). Adverse reactions leading to the interruption of KEYTRUDA occurred in <percent>44%</percent> of patients. The most common adverse reactions leading to interruption of KEYTRUDA in ≥<percent>2%</percent> were urinary tract infection (<percent>3.9%</percent>), adrenal insufficiency, pyrexia, pneumonitis, upper respiratory tract infection (<percent>2.6%</percent> each), neutropenia, diarrhea, and COVID-19 (<percent>2.1%</percent> each).</p><p>The most common adverse reactions (≥<percent>20%</percent>) for patients treated with KEYTRUDA in combination with paclitaxel, with or without bevacizumab, were diarrhea (<percent>45%</percent>), fatigue (<percent>43%</percent>), nausea (<percent>41%</percent>), alopecia, peripheral neuropathy (<percent>38%</percent> each), epistaxis (<percent>31%</percent>), urinary tract infection (<percent>27%</percent>), constipation (<percent>25%</percent>), abdominal pain, decreased appetite, vomiting (<percent>24%</percent> each), hypothyroidism (<percent>21%</percent>), cough, hypertension, and rash (<percent>20%</percent> each).</p><p>For patients treated with KEYTRUDA in combination with paclitaxel and bevacizumab (N=169), decreased white blood cell count (<percent>27%</percent>), stomatitis (<percent>22%</percent>), and pyrexia (<percent>21%</percent>) were also reported as adverse reactions.</p><p><b>Lactation<br/></b>Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the last dose.</p><p><b>Pediatric Use<br/></b>In KEYNOTE-051, 173 pediatric patients (65 pediatric patients aged 6 months to younger than 12 years and 108 pediatric patients aged 12 years to 17 years) were administered KEYTRUDA 2 mg/kg every 3 weeks. The median duration of exposure was 2.1 months (range: 1 day to 25 months).</p><p>Adverse reactions that occurred at a ≥<percent>10%</percent> higher rate in pediatric patients when compared to adults were pyrexia (<percent>33%</percent>), leukopenia (<percent>30%</percent>), vomiting (<percent>29%</percent>), neutropenia (<percent>28%</percent>), headache (<percent>25%</percent>), abdominal pain (<percent>23%</percent>), thrombocytopenia (<percent>22%</percent>), Grade 3 anemia (<percent>17%</percent>), decreased lymphocyte count (<percent>13%</percent>), and decreased white blood cell count (<percent>11%</percent>).</p><p><b>Geriatric Use<br/></b>Of the 564 patients with locally advanced or metastatic urothelial cancer treated with KEYTRUDA in combination with enfortumab vedotin, <percent>44%</percent> (n=247) were 65-74 years and <percent>26%</percent> (n=144) were 75 years or older. No overall differences in effectiveness were observed between patients 65 years of age or older and younger patients. Patients 75 years of age or older treated with KEYTRUDA in combination with enfortumab vedotin experienced a higher incidence of fatal adverse reactions than younger patients. The incidence of fatal adverse reactions was <percent>4%</percent> in patients younger than 75 and <percent>7%</percent> in patients 75 years or older.</p><p>Of the 167 patients with MIBC treated with KEYTRUDA in combination with enfortumab vedotin, <percent>37%</percent> (n=61) were 65-74 years and <percent>46%</percent> (n=77) were 75 years or older. Patients 75 years of age or older treated with KEYTRUDA in combination with enfortumab vedotin experienced a higher incidence of fatal adverse reactions than younger patients. The incidence of fatal adverse reactions was <percent>4%</percent> in patients younger than 75 and <percent>12%</percent> in patients 75 years or older.</p><p><b>Additional Selected KEYTRUDA Indications in the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location><br/></b><i>Melanoma<br/></i>KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.</p><p>KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection.</p><p><i>Non-Small Cell Lung Cancer<br/></i>KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.</p><p>KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.</p><p>KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥<percent>1%</percent>] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, and is:</p><ul class=\"bwlistdisc\"><li>Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or</li><li>metastatic.</li></ul><p>KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥<percent>1%</percent>) as determined by an FDA- authorized test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.</p><p>KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.</p><p>KEYTRUDA, as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.</p><p><i>Malignant Pleural Mesothelioma<br/></i>KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).</p><p><i>Head and Neck Squamous Cell Cancer<br/></i>KEYTRUDA is indicated for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA- authorized test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.</p><p>KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.</p><p>KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.</p><p>KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.</p><p><i>Classical Hodgkin Lymphoma<br/></i>KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).</p><p>KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.</p><p><i>Primary Mediastinal Large B-Cell Lymphoma<br/></i>KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.</p><p><i>Microsatellite Instability-High or Mismatch Repair Deficient Cancer<br/></i>KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.</p><p><i>Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer<br/></i>KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test.</p><p><i>Gastric Cancer<br/></i>KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.</p><p>KEYTRUDA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA approved test.</p><p><i>Esophageal Cancer<br/></i>KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:</p><ul class=\"bwlistdisc\"><li>in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that express PD-L1 (CPS ≥1), or</li><li>as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.</li></ul><p><i>Cervical Cancer<br/></i>KEYTRUDA, in combination with chemoradiotherapy (CRT), is indicated for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA).</p><p>KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.</p><p>KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.</p><p><i>Hepatocellular Carcinoma<br/></i>KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.</p><p><i>Biliary Tract Cancer<br/></i>KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).</p><p><i>Merkel Cell Carcinoma<br/></i>KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).</p><p><i>Renal Cell Carcinoma<br/></i>KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).</p><p>KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.</p><p><i>Endometrial Carcinoma<br/></i>KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.</p><p>KEYTRUDA, as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.</p><p><i>Tumor Mutational Burden-High Cancer<br/></i>KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.</p><p>This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.</p><p><i>Cutaneous Squamous Cell Carcinoma<br/></i>KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation.</p><p><i>Triple-Negative Breast Cancer<br/></i>KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.</p><p>KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.</p><p><i>Ovarian Cancer<br/></i>KEYTRUDA, in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.</p><p><b>Merck’s focus on cancer<br/></b>Every day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 25 novel mechanisms. With one of the largest clinical development programs across more than 30 tumor types, we strive to advance breakthrough science that will shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fresearch%2Foncology%2F&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=www.merck.com%2Fresearch%2Foncology&amp;index=7&amp;md5=dbf155bce882cf32adfad7ef9c5ff609\" rel=\"nofollow noopener\" shape=\"rect\">www.merck.com/research/oncology</a>.</p><p><b>About Merck<br/></b>At Merck, known as MSD outside of <location idsrc=\"xmltag.org\" value=\"LC/us\">the United States</location> and <location idsrc=\"xmltag.org\" value=\"LC/ca\">Canada</location>, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=8&amp;md5=f621fcdea78f2ff869a7bd02cd03eaa9\" rel=\"nofollow noopener\" shape=\"rect\">www.merck.com</a> and connect with us on <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FMerck&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=X+%28formerly+Twitter%29&amp;index=9&amp;md5=15fcf1e9e3642b9b906f59827b4e3015\" rel=\"nofollow noopener\" shape=\"rect\">X (formerly Twitter)</a>, <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=Facebook&amp;index=10&amp;md5=a38cfcbcf4edff41d4f78ccb56428e81\" rel=\"nofollow noopener\" shape=\"rect\">Facebook</a>, <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=Instagram&amp;index=11&amp;md5=6444ddfeeaf08214f4a3268f6fdb1021\" rel=\"nofollow noopener\" shape=\"rect\">Instagram</a>, <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=YouTube&amp;index=12&amp;md5=b9b586c94e5274bd198e9447f2c14039\" rel=\"nofollow noopener\" shape=\"rect\">YouTube</a> and <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=13&amp;md5=8ad036c7755d249ff2f1594ef28b45b9\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn</a>.</p><p><b>Forward-Looking Statement of Merck &amp; Co., Inc., <location idsrc=\"xmltag.org\" value=\"LU/us.nj.rahway\">Rahway, N.J.</location>, USA<br/></b>This news release of Merck &amp; Co., Inc., <location idsrc=\"xmltag.org\" value=\"LU/us.nj.rahway\">Rahway, N.J.</location>, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location> Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.</p><p>Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in <location idsrc=\"xmltag.org\" value=\"LC/us\">the United States</location> and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.</p><p>The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward- looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (<a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=14&amp;md5=4d8cce5702a051672dc10de461f9c3f8\" rel=\"nofollow noopener\" shape=\"rect\">www.sec.gov</a>).</p><p><b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at </b><a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=15&amp;md5=4ebd130fb75e31e676c854ef897c0be3\" rel=\"nofollow noopener\" shape=\"rect\"><b>http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf</b></a><b> and Medication Guide for KEYTRUDA at </b><a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=54434988&amp;newsitemid=20260226100375&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf.&amp;index=16&amp;md5=35ddae8154e41e4a691602af7ca0c72c\" rel=\"nofollow noopener\" shape=\"rect\"><b>http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_mg.pdf.</b></a></p><p><img alt=\"\" loading=\"lazy\" src=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260226100375r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"/><span class=\"bwct31415\"></span></p><p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: </span><span id=\"mmgallerylink-link\"><a href=\"https://www.businesswire.com/news/home/20260226100375/en/\" rel=\"nofollow noopener\">https://www.businesswire.com/news/home/20260226100375/en/</a></span></p><p>Media Contacts:<br/>Julie Cunningham<br/>(617) 519-6264<br/><br/>Marian Cutler<br/>(973) 517-0519<br/><br/>Investor Contacts:<br/>Peter Dannenbaum<br/>(732) 594-1579<br/><br/>Steven Graziano<br/>(732) 594-1583</p><p>Source: Merck &amp; Co., Inc.</p></article>",
            "link": "https://www.stocktitan.net/news/MRK/keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-reduced-5zl10fjzcwfw.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 15:00:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer | MRK Stock News",
            "description": "<article class=\"article\"><p class=\"bwalignc\"><b>KEYTRUDA plus paclitaxel with or without bevacizumab is the first PD-1 inhibitor-based regimen to show a statistically significant improvement in OS regardless of PD-L1 status</b></p><p class=\"bwalignc\"><b>Results from the final analysis of the Phase 3 KEYNOTE-B96 trial to be presented during a Best Oral Session at the European Society of Gynaecological Oncology 2026 Congress</b></p><p class=\"bwalignc\"><b>Positive EU CHMP opinion granted for KEYTRUDA plus paclitaxel with or without bevacizumab in certain adults with PD-L1 (CPS ≥1) platinum-resistant ovarian carcinoma who have received one or two prior systemic treatment regimens</b></p><p> <location idsrc=\"xmltag.org\" value=\"LU/us.nj.rahway\">RAHWAY, N.J.</location>--(BUSINESS WIRE)--Merck (NYSE: <a class=\"symbol-link\" href=\"/overview/MRK/\" title=\"View MRK stock overview\">MRK</a>), known as MSD outside of <location idsrc=\"xmltag.org\" value=\"LC/us\">the United States</location> and <location idsrc=\"xmltag.org\" value=\"LC/ca\">Canada</location>, today announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA<sup>® </sup>(pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab significantly improved overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer regardless of PD-L1 status versus paclitaxel with or without bevacizumab alone, the most active standard of care control arm for patients who are bevacizumab-eligible. These data will be presented for the first time today during a Best Oral Session at the European Society of Gynaecological Oncology (ESGO) 2026 Congress (abstract #526).</p><p>As <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Fkeytruda-pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-reduced-risk-of-disease-progression-or-death-versus-chemotherapy-with-or-without-bevacizumab-in-certain-patients-with-plati%2F&amp;esheet=54435066&amp;newsitemid=20260227462624&amp;lan=en-US&amp;anchor=previously+reported&amp;index=1&amp;md5=d19adc0f1fb2f29d4a66f38582801ff1\" rel=\"nofollow noopener\" shape=\"rect\">previously reported</a> at the European Society for Medical Oncology (ESMO) Congress 2025, KEYTRUDA plus paclitaxel with or without bevacizumab met its primary endpoint of progression-free survival (PFS) in the all comers population of patients with platinum-resistant recurrent ovarian cancer, as well as in patients whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1). The KEYTRUDA regimen also met its key secondary endpoint of OS in patients with platinum-resistant recurrent ovarian cancer whose tumors express PD-L1 (CPS ≥1).</p><p>At the final analysis, after a median follow-up of 32.7 months (range, 26.1-44.1), KEYTRUDA plus paclitaxel with or without bevacizumab demonstrated a statistically significant and clinically meaningful improvement in OS in all comers, reducing the risk of death by <percent>18%</percent> (HR=0.82 [<percent>95%</percent> CI, 0.69-0.97]; p=0.0115) compared to paclitaxel with or without bevacizumab alone. For patients who received the KEYTRUDA regimen, median OS was 17.7 months versus 14.0 months for patients receiving the placebo regimen. The observed OS is among the longest reported in any clinical trial for platinum-resistant recurrent ovarian cancer, showing a clinically meaningful benefit of this regimen relative to the most active standard of care control arm, weekly paclitaxel with bevacizumab in bevacizumab-eligible patients.</p><p>“Patients with platinum-resistant ovarian cancer show reduced responses to traditional treatment regimens and may experience poor overall survival,” said Dr. Nicoletta Colombo, director of the Gynecologic Oncology Program at the European Institute of Oncology in <location idsrc=\"xmltag.org\" value=\"LU/it..milan\">Milan, Italy</location>. “These results build on prior data from the KEYNOTE-B96 trial and further define the clinical impact of this pembrolizumab-based regimen in appropriate patients with platinum-resistant recurrent ovarian cancer.”</p><p>Additionally, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA in combination with paclitaxel with or without bevacizumab for the treatment of platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma in adults whose tumors express PD-L1 (CPS ≥1), and who have received one or two prior systemic treatment regimens.</p><p>In February, KEYTRUDA plus paclitaxel with or without bevacizumab was <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fnews%2Fkeytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyaluronidase-alfa-pmph-plus-paclitaxel-%25c2%25b1-bevacizumab-approved-for-certain-adults-with-pd-l1-cps-%25e2%2589%25a51%2F&amp;esheet=54435066&amp;newsitemid=20260227462624&amp;lan=en-US&amp;anchor=approved&amp;index=2&amp;md5=8928d6374d9fc9ad0a0325d817f44ce3\" rel=\"nofollow noopener\" shape=\"rect\">approved</a> by the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location> Food and Drug Administration (FDA) to treat adult patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens based on previous data from the KEYNOTE-B96 trial.</p><p>“Results from the final analysis of KEYNOTE-B96, including overall survival data in the all comers population, demonstrate the continued clinical benefit of KEYTRUDA plus paclitaxel with or without bevacizumab for certain patients with platinum-resistant recurrent ovarian cancer,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories. “Taken together, the recent FDA approval and CHMP positive opinion underscore our commitment to the ovarian cancer community and our ongoing focus on delivering therapies that can help patients with unmet needs across women’s cancers.”</p><p><b>Study design and additional data from KEYNOTE-B96/ENGOT-ov65<br/></b>KEYNOTE-B96, also known as ENGOT-ov65, is a multicenter, randomized, double-blind placebo-controlled Phase 3 trial (ClinicalTrials.gov, <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT05116189&amp;esheet=54435066&amp;newsitemid=20260227462624&amp;lan=en-US&amp;anchor=NCT05116189&amp;index=3&amp;md5=331bbb1862c743fa5cae552cf47a3be6\" rel=\"nofollow noopener\" shape=\"rect\">NCT05116189</a>) sponsored by Merck and conducted in collaboration with the European Network for Gynecologic Oncology Trial (ENGOT) groups investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab compared to placebo plus paclitaxel with or without bevacizumab for the treatment of platinum-resistant recurrent ovarian cancer. The primary endpoint is PFS, as assessed by investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), and OS is a key secondary endpoint. The trial enrolled 643 patients with epithelial ovarian, fallopian tube or primary peritoneal carcinoma, regardless of PD-L1 tumor expression status, who received one or two prior lines of systemic therapy for ovarian carcinoma, including at least one line of platinum-based chemotherapy. Of the 643 enrolled patients, <percent>72%</percent> of patients had tumors expressing PD-L1 (CPS ≥1). Patients were enrolled in KEYNOTE-B96 regardless of PD-L1 tumor expression status. Patients were randomized (1:1) to receive either KEYTRUDA plus paclitaxel with or without bevacizumab, or placebo plus paclitaxel with or without bevacizumab. KEYTRUDA (400 mg) or placebo were administered on Day 1 of each six-week treatment cycle and paclitaxel (80 mg/m<sup>2</sup>) was administered on Days 1, 8 and 15 of each three-week treatment cycle. The option to use bevacizumab was by investigator choice prior to randomization. Bevacizumab (10 mg/kg) was administered on Day 1 of a two-week treatment cycle.</p><p>At the final analysis, in the all comers population, KEYTRUDA plus paclitaxel with or without bevacizumab reduced the risk of disease progression or death by <percent>27%</percent> (HR=0.73 [<percent>95%</percent> CI, 0.62-0.87]) compared to paclitaxel with or without bevacizumab alone. In patients with platinum-resistant recurrent ovarian cancer whose tumors express PD-L1 (CPS ≥1), the KEYTRUDA regimen reduced the risk of disease progression or death by <percent>24%</percent> (HR=0.76 [<percent>95%</percent> CI, 0.62-0.93]) versus paclitaxel with or without bevacizumab alone. The KEYTRUDA regimen also continued to demonstrate a clinically meaningful improvement in OS, a key secondary endpoint of the study, in patients with platinum-resistant recurrent ovarian cancer whose tumors express PD-L1 (CPS ≥1), reducing the risk of death by <percent>24%</percent> (HR=0.76 [<percent>95%</percent> CI, 0.62-0.93]) compared to paclitaxel with or without bevacizumab.</p><p>The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety concerns were identified. Grade ≥3 treatment-related adverse events (TRAEs) occurred in <percent>67.8%</percent> of patients receiving the KEYTRUDA regimen (n=320) versus <percent>55.3%</percent> of patients receiving the placebo regimen (n=318). TRAEs led to death in <percent>1.3%</percent> of patients receiving the KEYTRUDA regimen and <percent>1.6%</percent> of patients receiving the placebo regimen.</p><p>Immune-mediated adverse events (AEs) and infusion reactions of any grade occurred in <percent>39.4%</percent> of patients receiving the KEYTRUDA regimen and <percent>18.9%</percent> of patients receiving the placebo regimen. The most common of these events (occurring in ≥<percent>10%</percent> of patients) was hypothyroidism (<percent>18.1%</percent>) in patients receiving the KEYTRUDA regimen. Immune-mediated AEs led to death in <percent>0.6%</percent> of patients in the KEYTRUDA arm and in no patients in the placebo arm.</p><p><b>About platinum-resistant ovarian cancer<br/></b>Ovarian cancer often begins in the fallopian tubes or the ovaries. As of 2022, it is the eighth most commonly diagnosed cancer and the eighth leading cause of cancer death among women worldwide. Globally, there were more than 324,000 patients diagnosed with ovarian cancer and almost 207,000 deaths from the disease in 2022. In many regions, its incidence has been increasing, with estimates projecting a <percent>42%</percent> increase in new cases worldwide by 2040. Over <percent>80%</percent> of patients diagnosed with ovarian cancer will experience disease progression following standard treatment with platinum-based chemotherapy regimens. Of these patients, approximately <percent>25%</percent> will experience disease progression within six months of completing first-line platinum-based chemotherapy – defined as primary platinum-resistant ovarian cancer. Prognosis is particularly poor for these patients and approved treatment options are limited.</p><p><b>About Merck’s research in women’s cancers<br/></b>Merck is advancing research aimed at expanding treatment options for certain breast and gynecologic (ovarian, cervical and endometrial) cancers, with a goal of improving outcomes for more patients affected by these diseases. Breast cancer and gynecologic cancers are the first and second most commonly occurring cancer types among women worldwide, respectively, and Merck aims to give patients facing these devastating diseases options. With more than 20 clinical trials in nearly 20,000 patients around the world, Merck is driving innovative research to purposefully advance standards of care in women’s cancers. Merck’s research efforts include trials focused on evaluating its medicines in earlier stages, as well as identifying novel mechanisms and new combinations with these treatments. Merck is working to develop a portfolio and pipeline to address the impact of women’s cancers on patients, their families and communities globally.</p><p><b>About KEYTRUDA<sup>®</sup> (pembrolizumab) injection for intravenous use, 100 mg<br/></b>KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.</p><p>Merck has the industry’s largest immuno-oncology clinical research program. There are currently more than 1,600 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.</p><p><b>Selected KEYTRUDA<sup>®</sup> (pembrolizumab) Indications in the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location><br/></b><i>Ovarian Cancer<br/></i>KEYTRUDA, in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.</p><p><i>See additional selected KEYTRUDA indications in the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location> after the Selected Important Safety Information.</i></p><p><b>Selected Important Safety Information for KEYTRUDA<br/></b><b>Severe and Fatal Immune-Mediated Adverse Reactions<br/></b>KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or the programmed death ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can affect more than one body system simultaneously, and can occur at any time after starting treatment or after discontinuation of treatment. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.</p><p>Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Early identification and management are essential to ensure safe use of anti–PD-1/PD-L1 treatments. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. For patients with TNBC treated with KEYTRUDA in the neoadjuvant setting, monitor blood cortisol at baseline, prior to surgery, and as clinically indicated. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.</p><p>Withhold or permanently discontinue KEYTRUDA depending on severity of the immune-mediated adverse reaction. In general, if KEYTRUDA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroid therapy.</p><p><span class=\"bwuline\">Immune-Mediated Pneumonitis<br/></span>KEYTRUDA can cause immune-mediated pneumonitis. The incidence is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in <percent>3.4%</percent> (94/2799) of patients receiving KEYTRUDA, including fatal (<percent>0.1%</percent>), Grade 4 (<percent>0.3%</percent>), Grade 3 (<percent>0.9%</percent>), and Grade 2 (<percent>1.3%</percent>) reactions. Systemic corticosteroids were required in <percent>67%</percent> (63/94) of patients. Pneumonitis led to permanent discontinuation of KEYTRUDA in <percent>1.3%</percent> (36) and withholding in <percent>0.9%</percent> (26) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, <percent>23%</percent> had recurrence. Pneumonitis resolved in <percent>59%</percent> of the 94 patients.</p><p>Pneumonitis occurred in <percent>8%</percent> (31/389) of adult patients with cHL receiving KEYTRUDA as a single agent, including Grades 3-4 in <percent>2.3%</percent> of patients. Patients received high-dose corticosteroids for a median duration of 10 days (range: 2 days to 53 months). Pneumonitis rates were similar in patients with and without prior thoracic radiation. Pneumonitis led to discontinuation of KEYTRUDA in <percent>5.4%</percent> (21) of patients. Of the patients who developed pneumonitis, <percent>42%</percent> interrupted KEYTRUDA, <percent>68%</percent> discontinued KEYTRUDA, and <percent>77%</percent> had resolution.</p><p>Pneumonitis occurred in <percent>7%</percent> (41/580) of adult patients with resected NSCLC who received KEYTRUDA as a single agent for adjuvant treatment of NSCLC, including fatal (<percent>0.2%</percent>), Grade 4 (<percent>0.3%</percent>), and Grade 3 (<percent>1%</percent>) adverse reactions. Patients received high-dose corticosteroids for a median duration of 10 days (range: 1 day to 2.3 months). Pneumonitis led to discontinuation of KEYTRUDA in 26 (<percent>4.5%</percent>) of patients. Of the patients who developed pneumonitis, <percent>54%</percent> interrupted KEYTRUDA, <percent>63%</percent> discontinued KEYTRUDA, and <percent>71%</percent> had resolution.</p><p><span class=\"bwuline\">Immune-Mediated Colitis<br/></span>KEYTRUDA can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Immune-mediated colitis occurred in <percent>1.7%</percent> (48/2799) of patients receiving KEYTRUDA, including Grade 4 (&lt;<percent>0.1%</percent>), Grade 3 (<percent>1.1%</percent>), and Grade 2 (<percent>0.4%</percent>) reactions. Systemic corticosteroids were required in <percent>69%</percent> (33/48); additional immunosuppressant therapy was required in <percent>4.2%</percent> of patients. Colitis led to permanent discontinuation of KEYTRUDA in <percent>0.5%</percent> (15) and withholding in <percent>0.5%</percent> (13) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, <percent>23%</percent> had recurrence. Colitis resolved in <percent>85%</percent> of the 48 patients.</p><p><span class=\"bwuline\">Hepatotoxicity and Immune-Mediated Hepatitis<br/></span><i>KEYTRUDA as a Single Agent<br/></i>KEYTRUDA can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in <percent>0.7%</percent> (19/2799) of patients receiving KEYTRUDA, including Grade 4 (&lt;<percent>0.1%</percent>), Grade 3 (<percent>0.4%</percent>), and Grade 2 (<percent>0.1%</percent>) reactions. Systemic corticosteroids were required in <percent>68%</percent> (13/19) of patients; additional immunosuppressant therapy was required in <percent>11%</percent> of patients. Hepatitis led to permanent discontinuation of KEYTRUDA in <percent>0.2%</percent> (6) and withholding in <percent>0.3%</percent> (9) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Hepatitis resolved in <percent>79%</percent> of the 19 patients.</p><p><i>KEYTRUDA With Axitinib<br/></i>KEYTRUDA in combination with axitinib can cause hepatic toxicity. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider monitoring more frequently as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased alanine aminotransferase (ALT) (<percent>20%</percent>) and increased aspartate aminotransferase (AST) (<percent>13%</percent>) were seen at a higher frequency compared to KEYTRUDA alone. Fifty-nine percent of the patients with increased ALT received systemic corticosteroids. In patients with ALT ≥3 times upper limit of normal (ULN) (Grades 2-4, n=116), ALT resolved to Grades 0-1 in <percent>94%</percent>. Among the 92 patients who were rechallenged with either KEYTRUDA (n=3) or axitinib (n=34) administered as a single agent or with both (n=55), recurrence of ALT ≥3 times ULN was observed in 1 patient receiving KEYTRUDA, 16 patients receiving axitinib, and 24 patients receiving both. All patients with a recurrence of ALT ≥3 ULN subsequently recovered from the event.</p><p><span class=\"bwuline\">Immune-Mediated Endocrinopathies<br/></span><i>Adrenal Insufficiency<br/></i>KEYTRUDA can cause primary or secondary adrenal insufficiency. For Grade 2 or higher, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold KEYTRUDA depending on severity. Adrenal insufficiency occurred in <percent>0.8%</percent> (22/2799) of patients receiving KEYTRUDA, including Grade 4 (&lt;<percent>0.1%</percent>), Grade 3 (<percent>0.3%</percent>), and Grade 2 (<percent>0.3%</percent>) reactions. Systemic corticosteroids were required in <percent>77%</percent> (17/22) of patients; of these, the majority remained on systemic corticosteroids. Adrenal insufficiency led to permanent discontinuation of KEYTRUDA in &lt;<percent>0.1%</percent> (1) and withholding in <percent>0.3%</percent> (8) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.</p><p><i>Hypophysitis<br/></i>KEYTRUDA can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Hypophysitis occurred in <percent>0.6%</percent> (17/2799) of patients receiving KEYTRUDA, including Grade 4 (&lt;<percent>0.1%</percent>), Grade 3 (<percent>0.3%</percent>), and Grade 2 (<percent>0.2%</percent>) reactions. Systemic corticosteroids were required in <percent>94%</percent> (16/17) of patients; of these, the majority remained on systemic corticosteroids. Hypophysitis led to permanent discontinuation of KEYTRUDA in <percent>0.1%</percent> (4) and withholding in <percent>0.3%</percent> (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.</p><p><i>Thyroid Disorders<br/></i>KEYTRUDA can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Thyroiditis occurred in <percent>0.6%</percent> (16/2799) of patients receiving KEYTRUDA, including Grade 2 (<percent>0.3%</percent>). None discontinued, but KEYTRUDA was withheld in &lt;<percent>0.1%</percent> (1) of patients.</p><p>Hyperthyroidism occurred in <percent>3.4%</percent> (96/2799) of patients receiving KEYTRUDA, including Grade 3 (<percent>0.1%</percent>) and Grade 2 (<percent>0.8%</percent>). It led to permanent discontinuation of KEYTRUDA in &lt;<percent>0.1%</percent> (2) and withholding in <percent>0.3%</percent> (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. Hypothyroidism occurred in <percent>8%</percent> (237/2799) of patients receiving KEYTRUDA, including Grade 3 (<percent>0.1%</percent>) and Grade 2 (<percent>6.2%</percent>). It led to permanent discontinuation of KEYTRUDA in &lt;<percent>0.1%</percent> (1) and withholding in <percent>0.5%</percent> (14) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. The majority of patients with hypothyroidism required long-term thyroid hormone replacement. The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC, occurring in <percent>16%</percent> of patients receiving KEYTRUDA as a single agent or in combination with platinum and FU, including Grade 3 (<percent>0.3%</percent>) hypothyroidism. The incidence of new or worsening hypothyroidism was higher in 389 adult patients with cHL (<percent>17%</percent>) receiving KEYTRUDA as a single agent, including Grade 1 (<percent>6.2%</percent>) and Grade 2 (<percent>10.8%</percent>) hypothyroidism. The incidence of new or worsening hyperthyroidism was higher in 580 patients with resected NSCLC, occurring in <percent>11%</percent> of patients receiving KEYTRUDA as a single agent as adjuvant treatment, including Grade 3 (<percent>0.2%</percent>) hyperthyroidism. The incidence of new or worsening hypothyroidism was higher in 580 patients with resected NSCLC, occurring in <percent>22%</percent> of patients receiving KEYTRUDA as a single agent as adjuvant treatment (KEYNOTE-091), including Grade 3 (<percent>0.3%</percent>) hypothyroidism.</p><p><i>Type 1 Diabetes Mellitus (DM), Which Can Present With Diabetic Ketoacidosis<br/></i>Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold KEYTRUDA depending on severity. Type 1 DM occurred in <percent>0.2%</percent> (6/2799) of patients receiving KEYTRUDA. It led to permanent discontinuation in &lt;<percent>0.1%</percent> (1) and withholding of KEYTRUDA in &lt;<percent>0.1%</percent> (1) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.</p><p><span class=\"bwuline\">Immune-Mediated Nephritis With Renal Dysfunction<br/></span>KEYTRUDA can cause immune-mediated nephritis. Immune-mediated nephritis occurred in <percent>0.3%</percent> (9/2799) of patients receiving KEYTRUDA, including Grade 4 (&lt;<percent>0.1%</percent>), Grade 3 (<percent>0.1%</percent>), and Grade 2 (<percent>0.1%</percent>) reactions. Systemic corticosteroids were required in <percent>89%</percent> (8/9) of patients. Nephritis led to permanent discontinuation of KEYTRUDA in <percent>0.1%</percent> (3) and withholding in <percent>0.1%</percent> (3) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Nephritis resolved in <percent>56%</percent> of the 9 patients.</p><p><span class=\"bwuline\">Immune-Mediated Dermatologic Adverse Reactions<br/></span>KEYTRUDA can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms, and toxic epidermal necrolysis, has occurred with anti–PD-1/PD-L1 treatments. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes. Withhold or permanently discontinue KEYTRUDA depending on severity. Immune-mediated dermatologic adverse reactions occurred in <percent>1.4%</percent> (38/2799) of patients receiving KEYTRUDA, including Grade 3 (<percent>1%</percent>) and Grade 2 (<percent>0.1%</percent>) reactions. Systemic corticosteroids were required in <percent>40%</percent> (15/38) of patients. These reactions led to permanent discontinuation in <percent>0.1%</percent> (2) and withholding of KEYTRUDA in <percent>0.6%</percent> (16) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, <percent>6%</percent> had recurrence. The reactions resolved in <percent>79%</percent> of the 38 patients.</p><p><span class=\"bwuline\">Other Immune-Mediated Adverse Reactions<br/></span>The following clinically significant immune-mediated adverse reactions occurred at an incidence of &lt;<percent>1%</percent> (unless otherwise noted) in patients who received KEYTRUDA or were reported with the use of other anti–PD-1/PD-L1 treatments. Severe or fatal cases have been reported for some of these adverse reactions. <i>Cardiac/Vascular:</i> Myocarditis, pericarditis, vasculitis; <i>Nervous System:</i> Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy; <i>Ocular:</i> Uveitis, iritis and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss; <i>Gastrointestinal:</i> Pancreatitis, to include increases in serum amylase and lipase levels, gastritis, duodenitis; <i>Musculoskeletal and Connective Tissue:</i> Myositis/polymyositis, rhabdomyolysis (and associated sequelae, including renal failure), arthritis (<percent>1.5%</percent>), polymyalgia rheumatica; <i>Endocrine: </i>Hypoparathyroidism; <i>Hematologic/Immune:</i> Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection.</p><p><b>Infusion-Related Reactions<br/></b>KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in <percent>0.2%</percent> of 2799 patients receiving KEYTRUDA. Monitor for signs and symptoms of infusion-related reactions. Interrupt or slow the rate of infusion for Grade 1 or Grade 2 reactions. For Grade 3 or Grade 4 reactions, stop infusion and permanently discontinue KEYTRUDA.</p><p><b>Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)<br/></b>Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after anti–PD-1/PD-L1 treatments. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute and chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between anti–PD-1/PD-L1 treatments and allogeneic HSCT. Follow patients closely for evidence of these complications and intervene promptly. Consider the benefit vs risks of using anti–PD-1/PD-L1 treatments prior to or after an allogeneic HSCT.</p><p><b>Increased Mortality in Patients With Multiple Myeloma<br/></b>In trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of these patients with an anti–PD-1/PD-L1 treatment in this combination is not recommended outside of controlled trials.</p><p><b>Embryofetal Toxicity<br/></b>Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA and advise them to use effective contraception during treatment and for 4 months after the last dose.</p><p><b>Adverse Reactions<br/></b>In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in <percent>9%</percent> of 555 patients with advanced melanoma; adverse reactions leading to permanent discontinuation in more than one patient were colitis (<percent>1.4%</percent>), autoimmune hepatitis (<percent>0.7%</percent>), allergic reaction (<percent>0.4%</percent>), polyneuropathy (<percent>0.4%</percent>), and cardiac failure (<percent>0.4%</percent>). The most common adverse reactions (≥<percent>20%</percent>) with KEYTRUDA were fatigue (<percent>28%</percent>), diarrhea (<percent>26%</percent>), rash (<percent>24%</percent>), and nausea (<percent>21%</percent>).</p><p>In KEYNOTE-054, when KEYTRUDA was administered as a single agent to patients with stage III melanoma, KEYTRUDA was permanently discontinued due to adverse reactions in <percent>14%</percent> of 509 patients; the most common (≥<percent>1%</percent>) were pneumonitis (<percent>1.4%</percent>), colitis (<percent>1.2%</percent>), and diarrhea (<percent>1%</percent>). Serious adverse reactions occurred in <percent>25%</percent> of patients receiving KEYTRUDA. The most common adverse reaction (≥<percent>20%</percent>) with KEYTRUDA was diarrhea (<percent>28%</percent>). In KEYNOTE-716, when KEYTRUDA was administered as a single agent to patients with stage IIB or IIC melanoma, adverse reactions occurring in patients with stage IIB or IIC melanoma were similar to those occurring in 1011 patients with stage III melanoma from KEYNOTE-054.</p><p>In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in <percent>20%</percent> of 405 patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonitis (<percent>3%</percent>) and acute kidney injury (<percent>2%</percent>). The most common adverse reactions (≥<percent>20%</percent>) with KEYTRUDA were nausea (<percent>56%</percent>), fatigue (<percent>56%</percent>), constipation (<percent>35%</percent>), diarrhea (<percent>31%</percent>), decreased appetite (<percent>28%</percent>), rash (<percent>25%</percent>), vomiting (<percent>24%</percent>), cough (<percent>21%</percent>), dyspnea (<percent>21%</percent>), and pyrexia (<percent>20%</percent>).</p><p>In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and either paclitaxel or paclitaxel protein-bound in metastatic squamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in <percent>15%</percent> of 101 patients. The most frequent serious adverse reactions reported in at least <percent>2%</percent> of patients were febrile neutropenia, pneumonia, and urinary tract infection. Adverse reactions observed in KEYNOTE-407 were similar to those observed in KEYNOTE-189 with the exception that increased incidences of alopecia (<percent>47%</percent> vs <percent>36%</percent>) and peripheral neuropathy (<percent>31%</percent> vs <percent>25%</percent>) were observed in the KEYTRUDA and chemotherapy arm compared to the placebo and chemotherapy arm in KEYNOTE-407.</p><p>In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in <percent>19%</percent> of 636 patients with advanced NSCLC; the most common were pneumonitis (<percent>3%</percent>), death due to unknown cause (<percent>1.6%</percent>), and pneumonia (<percent>1.4%</percent>). The most frequent serious adverse reactions reported in at least <percent>2%</percent> of patients were pneumonia (<percent>7%</percent>), pneumonitis (<percent>3.9%</percent>), pulmonary embolism (<percent>2.4%</percent>), and pleural effusion (<percent>2.2%</percent>). The most common adverse reaction (≥<percent>20%</percent>) was fatigue (<percent>25%</percent>).</p><p>In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse reactions in <percent>8%</percent> of 682 patients with metastatic NSCLC; the most common was pneumonitis (<percent>1.8%</percent>). The most common adverse reactions (≥<percent>20%</percent>) were decreased appetite (<percent>25%</percent>), fatigue (<percent>25%</percent>), dyspnea (<percent>23%</percent>), and nausea (<percent>20%</percent>).</p><p>In KEYNOTE-671, adverse reactions occurring in patients with resectable NSCLC receiving KEYTRUDA in combination with platinum-containing chemotherapy, given as neoadjuvant treatment and continued as single-agent adjuvant treatment, were generally similar to those occurring in patients in other clinical trials across tumor types receiving KEYTRUDA in combination with chemotherapy.</p><p>The most common adverse reactions (reported in ≥<percent>20%</percent>) in patients receiving KEYTRUDA in combination with chemotherapy or chemoradiotherapy were fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, stomatitis, headache, weight loss, abdominal pain, arthralgia, myalgia, insomnia, palmar-plantar erythrodysesthesia, urinary tract infection, hypothyroidism, radiation skin injury, dysphagia, dry mouth, and musculoskeletal pain.</p><p>In the neoadjuvant phase of KEYNOTE-671, when KEYTRUDA was administered in combination with platinum-containing chemotherapy as neoadjuvant treatment, serious adverse reactions occurred in <percent>34%</percent> of 396 patients. The most frequent (≥<percent>2%</percent>) serious adverse reactions were pneumonia (<percent>4.8%</percent>), venous thromboembolism (<percent>3.3%</percent>), and anemia (<percent>2%</percent>). Fatal adverse reactions occurred in <percent>1.3%</percent> of patients, including death due to unknown cause (<percent>0.8%</percent>), sepsis (<percent>0.3%</percent>), and immune-mediated lung disease (<percent>0.3%</percent>). Permanent discontinuation of any study drug due to an adverse reaction occurred in <percent>18%</percent> of patients who received KEYTRUDA in combination with platinum-containing chemotherapy; the most frequent adverse reactions (≥<percent>1%</percent>) that led to permanent discontinuation of any study drug were acute kidney injury (<percent>1.8%</percent>), interstitial lung disease (<percent>1.8%</percent>), anemia (<percent>1.5%</percent>), neutropenia (<percent>1.5%</percent>), and pneumonia (<percent>1.3%</percent>).</p><p>Of the KEYTRUDA-treated patients who received neoadjuvant treatment, <percent>6%</percent> of 396 patients did not receive surgery due to adverse reactions. The most frequent (≥<percent>1%</percent>) adverse reaction that led to cancellation of surgery in the KEYTRUDA arm was interstitial lung disease (<percent>1%</percent>).</p><p>In the adjuvant phase of KEYNOTE-671, when KEYTRUDA was administered as a single agent as adjuvant treatment, serious adverse reactions occurred in <percent>14%</percent> of 290 patients. The most frequent serious adverse reaction was pneumonia (<percent>3.4%</percent>). One fatal adverse reaction of pulmonary hemorrhage occurred. Permanent discontinuation of KEYTRUDA due to an adverse reaction occurred in <percent>12%</percent> of patients who received KEYTRUDA as a single agent, given as adjuvant treatment; the most frequent adverse reactions (≥<percent>1%</percent>) that led to permanent discontinuation of KEYTRUDA were diarrhea (<percent>1.7%</percent>), interstitial lung disease (<percent>1.4%</percent>), increased aspartate aminotransferase (<percent>1%</percent>), and musculoskeletal pain (<percent>1%</percent>).</p><p>Adverse reactions observed in KEYNOTE-091 were generally similar to those occurring in other patients with NSCLC receiving KEYTRUDA as a single agent, with the exception of hypothyroidism (<percent>22%</percent>), hyperthyroidism (<percent>11%</percent>), and pneumonitis (<percent>7%</percent>). Two fatal adverse reactions of myocarditis occurred.</p><p>Adverse reactions observed in KEYNOTE-483 were generally similar to those occurring in other patients receiving KEYTRUDA in combination with pemetrexed and platinum chemotherapy.</p><p>In KEYNOTE-689, the most common adverse reactions (≥<percent>20%</percent>) in patients receiving KEYTRUDA were stomatitis (<percent>48%</percent>), radiation skin injury (<percent>40%</percent>), weight loss (<percent>36%</percent>), fatigue (<percent>33%</percent>), dysphagia (<percent>29%</percent>), constipation (<percent>27%</percent>), hypothyroidism (<percent>26%</percent>), nausea (<percent>24%</percent>), rash (<percent>22%</percent>), dry mouth (<percent>22%</percent>), diarrhea (<percent>22%</percent>), and musculoskeletal pain (<percent>22%</percent>).</p><p>In the neoadjuvant phase of KEYNOTE-689, of the 361 patients who received at least one dose of single agent KEYTRUDA, <percent>11%</percent> experienced serious adverse reactions. Serious adverse reactions that occurred in more than one patient were pneumonia (<percent>1.4%</percent>), tumor hemorrhage (<percent>0.8%</percent>), dysphagia (<percent>0.6%</percent>), immune-mediated hepatitis (<percent>0.6%</percent>), cellulitis (<percent>0.6%</percent>), and dyspnea (<percent>0.6%</percent>). Fatal adverse reactions occurred in <percent>1.1%</percent> of patients, including respiratory failure, clostridium infection, septic shock, and myocardial infarction (one patient each). Permanent discontinuation of KEYTRUDA due to an adverse reaction occurred in <percent>2.8%</percent> of patients who received KEYTRUDA as neoadjuvant treatment. The most frequent adverse reaction which resulted in permanent discontinuation of neoadjuvant KEYTRUDA in more than one patient was arthralgia (<percent>0.6%</percent>).</p><p>Of the 361 patients who received KEYTRUDA as neoadjuvant treatment, <percent>11%</percent> did not receive surgery. Surgical cancellation on the KEYTRUDA arm was due to disease progression in <percent>4%</percent>, patient decision in <percent>3%</percent>, adverse reactions in <percent>1.4%</percent>, physician’s decision in <percent>1.1%</percent>, unresectable tumor in <percent>0.6%</percent>, loss of follow-up in <percent>0.3%</percent>, and use of non-study anti-cancer therapy in <percent>0.3%</percent>.</p><p>Of the 323 KEYTRUDA-treated patients who received surgery following the neoadjuvant phase, <percent>1.2%</percent> experienced delay of surgery (defined as on-study surgery occurring ≥9 weeks after initiation of neoadjuvant KEYTRUDA) due to adverse reactions, and <percent>2.8%</percent> did not receive adjuvant treatment due to adverse reactions.</p><p>In the adjuvant phase of KEYNOTE-689, of the 255 patients who received at least one dose of KEYTRUDA, <percent>38%</percent> experienced serious adverse reactions. The most frequent serious adverse reactions reported in ≥<percent>1%</percent> of KEYTRUDA- treated patients were pneumonia (<percent>2.7%</percent>), pyrexia (<percent>2.4%</percent>), stomatitis (<percent>2.4%</percent>), acute kidney injury (<percent>2.0%</percent>), pneumonitis (<percent>1.6%</percent>), COVID-19 (<percent>1.2%</percent>), death not otherwise specified (<percent>1.2%</percent>), diarrhea (<percent>1.2%</percent>), dysphagia (<percent>1.2%</percent>), gastrostomy tube site complication (<percent>1.2%</percent>), and immune-mediated hepatitis (<percent>1.2%</percent>). Fatal adverse reactions occurred in <percent>5%</percent> of patients, including death not otherwise specified (<percent>1.2%</percent>), acute renal failure (<percent>0.4%</percent>), hypercalcemia (<percent>0.4%</percent>), pulmonary hemorrhage (<percent>0.4%</percent>), dysphagia/malnutrition (<percent>0.4%</percent>), mesenteric thrombosis (<percent>0.4%</percent>), sepsis (<percent>0.4%</percent>), pneumonia (<percent>0.4%</percent>), COVID-19 (<percent>0.4%</percent>), respiratory failure (<percent>0.4%</percent>), cardiovascular disorder (<percent>0.4%</percent>), and gastrointestinal hemorrhage (<percent>0.4%</percent>). Permanent discontinuation of adjuvant KEYTRUDA due to an adverse reaction occurred in <percent>17%</percent> of patients. The most frequent (≥<percent>1%</percent>) adverse reactions that led to permanent discontinuation of adjuvant KEYTRUDA were pneumonitis, colitis, immune-mediated hepatitis, and death not otherwise specified.</p><p>In KEYNOTE-048, KEYTRUDA monotherapy was discontinued due to adverse events in <percent>12%</percent> of 300 patients with HNSCC; the most common adverse reactions leading to permanent discontinuation were sepsis (<percent>1.7%</percent>) and pneumonia (<percent>1.3%</percent>). The most common adverse reactions (≥<percent>20%</percent>) were fatigue (<percent>33%</percent>), constipation (<percent>20%</percent>), and rash (<percent>20%</percent>).</p><p>In KEYNOTE-048, when KEYTRUDA was administered in combination with platinum (cisplatin or carboplatin) and FU chemotherapy, KEYTRUDA was discontinued due to adverse reactions in <percent>16%</percent> of 276 patients with HNSCC. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonia (<percent>2.5%</percent>), pneumonitis (<percent>1.8%</percent>), and septic shock (<percent>1.4%</percent>). The most common adverse reactions (≥<percent>20%</percent>) were nausea (<percent>51%</percent>), fatigue (<percent>49%</percent>), constipation (<percent>37%</percent>), vomiting (<percent>32%</percent>), mucosal inflammation (<percent>31%</percent>), diarrhea (<percent>29%</percent>), decreased appetite (<percent>29%</percent>), stomatitis (<percent>26%</percent>), and cough (<percent>22%</percent>).</p><p>In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in <percent>17%</percent> of 192 patients with HNSCC. Serious adverse reactions occurred in <percent>45%</percent> of patients. The most frequent serious adverse reactions reported in at least <percent>2%</percent> of patients were pneumonia, dyspnea, confusional state, vomiting, pleural effusion, and respiratory failure. The most common adverse reactions (≥<percent>20%</percent>) were fatigue, decreased appetite, and dyspnea. Adverse reactions occurring in patients with HNSCC were generally similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy, with the exception of increased incidences of facial edema and new or worsening hypothyroidism.</p><p>In KEYNOTE-204, KEYTRUDA was discontinued due to adverse reactions in <percent>14%</percent> of 148 patients with cHL. Serious adverse reactions occurred in <percent>30%</percent> of patients receiving KEYTRUDA; those ≥<percent>1%</percent> were pneumonitis, pneumonia, pyrexia, myocarditis, acute kidney injury, febrile neutropenia, and sepsis. Three patients died from causes other than disease progression: 2 from complications after allogeneic HSCT and 1 from unknown cause. The most common adverse reactions (≥<percent>20%</percent>) were upper respiratory tract infection (<percent>41%</percent>), musculoskeletal pain (<percent>32%</percent>), diarrhea (<percent>22%</percent>), and pyrexia, fatigue, rash, and cough (<percent>20%</percent> each).</p><p>In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in <percent>5%</percent> of 210 patients with cHL. Serious adverse reactions occurred in <percent>16%</percent> of patients; those ≥<percent>1%</percent> were pneumonia, pneumonitis, pyrexia, dyspnea, GVHD, and herpes zoster. Two patients died from causes other than disease progression: 1 from GVHD after subsequent allogeneic HSCT and 1 from septic shock. The most common adverse reactions (≥<percent>20%</percent>) were fatigue (<percent>26%</percent>), pyrexia (<percent>24%</percent>), cough (<percent>24%</percent>), musculoskeletal pain (<percent>21%</percent>), diarrhea (<percent>20%</percent>), and rash (<percent>20%</percent>).</p><p>In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in <percent>8%</percent> of 53 patients with PMBCL. Serious adverse reactions occurred in <percent>26%</percent> of patients and included arrhythmia (<percent>4%</percent>), cardiac tamponade (<percent>2%</percent>), myocardial infarction (<percent>2%</percent>), pericardial effusion (<percent>2%</percent>), and pericarditis (<percent>2%</percent>). Six (<percent>11%</percent>) patients died within 30 days of start of treatment. The most common adverse reactions (≥<percent>20%</percent>) were musculoskeletal pain (<percent>30%</percent>), upper respiratory tract infection and pyrexia (<percent>28%</percent> each), cough (<percent>26%</percent>), fatigue (<percent>23%</percent>), and dyspnea (<percent>21%</percent>).</p><p>In KEYNOTE-A39, when KEYTRUDA was administered in combination with enfortumab vedotin to patients with locally advanced or metastatic urothelial cancer (n=440), fatal adverse reactions occurred in <percent>3.9%</percent> of patients, including acute respiratory failure (<percent>0.7%</percent>), pneumonia (<percent>0.5%</percent>), and pneumonitis/ILD (<percent>0.2%</percent>). Serious adverse reactions occurred in <percent>50%</percent> of patients receiving KEYTRUDA in combination with enfortumab vedotin; the serious adverse reactions in ≥<percent>2%</percent> of patients were rash (<percent>6%</percent>), acute kidney injury (<percent>5%</percent>), pneumonitis/ILD (<percent>4.5%</percent>), urinary tract infection (<percent>3.6%</percent>), diarrhea (<percent>3.2%</percent>), pneumonia (<percent>2.3%</percent>), pyrexia (<percent>2%</percent>), and hyperglycemia (<percent>2%</percent>). Permanent discontinuation of KEYTRUDA occurred in <percent>27%</percent> of patients. The most common adverse reactions (≥<percent>2%</percent>) resulting in permanent discontinuation of KEYTRUDA were pneumonitis/ILD (<percent>4.8%</percent>) and rash (<percent>3.4%</percent>). The most common adverse reactions (≥<percent>20%</percent>) occurring in patients treated with KEYTRUDA in combination with enfortumab vedotin were rash (<percent>68%</percent>), peripheral neuropathy (<percent>67%</percent>), fatigue (<percent>51%</percent>), pruritus (<percent>41%</percent>), diarrhea (<percent>38%</percent>), alopecia (<percent>35%</percent>), weight loss (<percent>33%</percent>), decreased appetite (<percent>33%</percent>), nausea (<percent>26%</percent>), constipation (<percent>26%</percent>), dry eye (<percent>24%</percent>), dysgeusia (<percent>21%</percent>), and urinary tract infection (<percent>21%</percent>).</p><p>In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in <percent>11%</percent> of 370 patients with locally advanced or metastatic urothelial carcinoma. Serious adverse reactions occurred in <percent>42%</percent> of patients; those ≥<percent>2%</percent> were urinary tract infection, hematuria, acute kidney injury, pneumonia, and urosepsis. The most common adverse reactions (≥<percent>20%</percent>) were fatigue (<percent>38%</percent>), musculoskeletal pain (<percent>24%</percent>), decreased appetite (<percent>22%</percent>), constipation (<percent>21%</percent>), rash (<percent>21%</percent>), and diarrhea (<percent>20%</percent>).</p><p>In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in <percent>8%</percent> of 266 patients with locally advanced or metastatic urothelial carcinoma. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA was pneumonitis (<percent>1.9%</percent>). Serious adverse reactions occurred in <percent>39%</percent> of KEYTRUDA-treated patients; those ≥<percent>2%</percent> were urinary tract infection, pneumonia, anemia, and pneumonitis. The most common adverse reactions (≥<percent>20%</percent>) in patients who received KEYTRUDA were fatigue (<percent>38%</percent>), musculoskeletal pain (<percent>32%</percent>), pruritus (<percent>23%</percent>), decreased appetite (<percent>21%</percent>), nausea (<percent>21%</percent>), and rash (<percent>20%</percent>).</p><p>In KEYNOTE-905, the most common adverse reactions (≥<percent>20%</percent>) occurring in cisplatin-ineligible patients with MIBC treated with KEYTRUDA in combination with enfortumab vedotin (n=167) were rash (<percent>54%</percent>), pruritus (<percent>47%</percent>), fatigue (<percent>47%</percent>), peripheral neuropathy (<percent>39%</percent>), alopecia (<percent>35%</percent>), dysgeusia (<percent>35%</percent>), diarrhea (<percent>34%</percent>), constipation (<percent>28%</percent>), decreased appetite (<percent>28%</percent>), nausea (<percent>26%</percent>), urinary tract infection (<percent>24%</percent>), dry eye (<percent>21%</percent>), and weight loss (<percent>20%</percent>).</p><p>In the neoadjuvant phase of KEYNOTE-905, serious adverse reactions occurred in <percent>27%</percent> (n=167) of patients; the most frequent (≥<percent>2%</percent>) were urinary tract infection (<percent>3.6%</percent>) and hematuria (<percent>2.4%</percent>). Fatal adverse reactions occurred in <percent>1.2%</percent> of patients, including myasthenia gravis and toxic epidermal necrolysis (<percent>0.6%</percent> each). Additional fatal adverse reactions were reported in <percent>2.7%</percent> of patients in the post-surgery phase before adjuvant treatment started, including sepsis and intestinal obstruction (<percent>1.4%</percent> each). Permanent discontinuation of KEYTRUDA due to an adverse reaction occurred in <percent>15%</percent> of patients; the most frequent (&gt;<percent>1%</percent>) were rash (<percent>2.4%</percent>, including generalized exfoliative dermatitis), increased alanine aminotransferase, increased aspartate aminotransferase, diarrhea, dysgeusia, and toxic epidermal necrolysis (<percent>1.2%</percent> each). Of the 167 patients in the KEYTRUDA in combination with enfortumab vedotin arm who received neoadjuvant treatment, 7 (<percent>4.2%</percent>) patients did not receive surgery due to adverse reactions. The adverse reactions that led to cancellation of surgery were acute myocardial infarction, bile duct cancer, colon cancer, respiratory distress, urinary tract infection, and the two deaths due to myasthenia gravis and toxic epidermal necrolysis (<percent>0.6%</percent> each).</p><p>Of the 146 patients who received neoadjuvant treatment with KEYTRUDA in combination with enfortumab vedotin and underwent radical cystectomy, 6 (<percent>4.1%</percent>) patients experienced delay of surgery (defined as time from last neoadjuvant treatment to surgery exceeding 8 weeks) due to adverse reactions.</p><p>In the adjuvant phase of KEYNOTE-905, serious adverse reactions occurred in <percent>43%</percent> (n=100) of patients; the most frequent (≥<percent>2%</percent>) were urinary tract infection (<percent>8%</percent>); acute kidney injury and pyelonephritis (<percent>5%</percent> each); urosepsis (<percent>4%</percent>); and hypokalemia, intestinal obstruction, and sepsis (<percent>2%</percent> each). Fatal adverse reactions occurred in <percent>7%</percent> of patients, including urosepsis, intracranial hemorrhage, death, myocardial infarction, multiple organ dysfunction syndrome, and pseudomonal pneumonia (<percent>1%</percent> each). Permanent discontinuation of KEYTRUDA due to an adverse reaction occurred in <percent>28%</percent> of patients; the most frequent (&gt;<percent>1%</percent>) were diarrhea (<percent>5%</percent>), peripheral neuropathy, acute kidney injury, and pneumonitis (<percent>2%</percent> each).</p><p>In KEYNOTE-057, KEYTRUDA was discontinued due to adverse reactions in <percent>11%</percent> of 148 patients with high-risk NMIBC. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA was pneumonitis (<percent>1.4%</percent>). Serious adverse reactions occurred in <percent>28%</percent> of patients; those ≥<percent>2%</percent> were pneumonia (<percent>3%</percent>), cardiac ischemia (<percent>2%</percent>), colitis (<percent>2%</percent>), pulmonary embolism (<percent>2%</percent>), sepsis (<percent>2%</percent>), and urinary tract infection (<percent>2%</percent>). The most common adverse reactions (≥<percent>20%</percent>) were fatigue (<percent>29%</percent>), diarrhea (<percent>24%</percent>), and rash (<percent>24%</percent>).</p><p>Adverse reactions occurring in patients with MSI-H or dMMR CRC were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.</p><p>In KEYNOTE-158 and KEYNOTE-164, adverse reactions occurring in patients with MSI-H or dMMR cancer were similar to those occurring in patients with other solid tumors who received KEYTRUDA as a single agent.</p><p>In KEYNOTE-811, fatal adverse reactions occurred in 3 patients who received KEYTRUDA in combination with trastuzumab and CAPOX (capecitabine plus oxaliplatin) or FP (5-FU plus cisplatin) and included pneumonitis in 2 patients and hepatitis in 1 patient. KEYTRUDA was discontinued due to adverse reactions in <percent>13%</percent> of 350 patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma. Adverse reactions resulting in permanent discontinuation of KEYTRUDA in ≥<percent>1%</percent> of patients were pneumonitis (<percent>2.0%</percent>) and pneumonia (<percent>1.1%</percent>). In the KEYTRUDA arm vs placebo, there was a difference of ≥<percent>5%</percent> incidence between patients treated with KEYTRUDA vs standard of care for diarrhea (<percent>53%</percent> vs <percent>47%</percent>), rash (<percent>35%</percent> vs <percent>28%</percent>), hypothyroidism (<percent>11%</percent> vs <percent>5%</percent>), and pneumonia (<percent>11%</percent> vs <percent>5%</percent>).</p><p>In KEYNOTE-859, when KEYTRUDA was administered in combination with fluoropyrimidine- and platinum-containing chemotherapy, serious adverse reactions occurred in <percent>45%</percent> of 785 patients. Serious adverse reactions in &gt;<percent>2%</percent> of patients included pneumonia (<percent>4.1%</percent>), diarrhea (<percent>3.9%</percent>), hemorrhage (<percent>3.9%</percent>), and vomiting (<percent>2.4%</percent>). Fatal adverse reactions occurred in <percent>8%</percent> of patients who received KEYTRUDA, including infection (<percent>2.3%</percent>) and thromboembolism (<percent>1.3%</percent>). KEYTRUDA was permanently discontinued due to adverse reactions in <percent>15%</percent> of patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA (≥<percent>1%</percent>) were infections (<percent>1.8%</percent>) and diarrhea (<percent>1.0%</percent>). The most common adverse reactions (reported in ≥<percent>20%</percent>) in patients receiving KEYTRUDA in combination with chemotherapy were peripheral neuropathy (<percent>47%</percent>), nausea (<percent>46%</percent>), fatigue (<percent>40%</percent>), diarrhea (<percent>36%</percent>), vomiting (<percent>34%</percent>), decreased appetite (<percent>29%</percent>), abdominal pain (<percent>26%</percent>), palmar-plantar erythrodysesthesia syndrome (<percent>25%</percent>), constipation (<percent>22%</percent>), and weight loss (<percent>20%</percent>).</p><p>In KEYNOTE-590, when KEYTRUDA was administered with cisplatin and fluorouracil to patients with metastatic or locally advanced esophageal or GEJ (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma who were not candidates for surgical resection or definitive chemoradiation, KEYTRUDA was discontinued due to adverse reactions in <percent>15%</percent> of 370 patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA (≥<percent>1%</percent>) were pneumonitis (<percent>1.6%</percent>), acute kidney injury (<percent>1.1%</percent>), and pneumonia (<percent>1.1%</percent>). The most common adverse reactions (≥<percent>20%</percent>) with KEYTRUDA in combination with chemotherapy were nausea (<percent>67%</percent>), fatigue (<percent>57%</percent>), decreased appetite (<percent>44%</percent>), constipation (<percent>40%</percent>), diarrhea (<percent>36%</percent>), vomiting (<percent>34%</percent>), stomatitis (<percent>27%</percent>), and weight loss (<percent>24%</percent>).</p><p>Adverse reactions occurring in patients with esophageal cancer who received KEYTRUDA as a monotherapy were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.</p><p>In KEYNOTE-A18, when KEYTRUDA was administered with CRT (cisplatin plus external beam radiation therapy [EBRT] followed by brachytherapy [BT]) to patients with FIGO 2014 Stage III-IVA cervical cancer, fatal adverse reactions occurred in <percent>1.4%</percent> of 294 patients, including 1 case each (<percent>0.3%</percent>) of large intestinal perforation, urosepsis, sepsis, and vaginal hemorrhage. Serious adverse reactions occurred in <percent>34%</percent> of patients; those ≥<percent>1%</percent> included urinary tract infection (<percent>3.1%</percent>), urosepsis (<percent>1.4%</percent>), and sepsis (<percent>1%</percent>). KEYTRUDA was discontinued for adverse reactions in <percent>9%</percent> of patients. The most common adverse reaction (≥<percent>1%</percent>) resulting in permanent discontinuation was diarrhea (<percent>1%</percent>). For patients treated with KEYTRUDA in combination with CRT, the most common adverse reactions (≥<percent>10%</percent>) were nausea (<percent>56%</percent>), diarrhea (<percent>51%</percent>), urinary tract infection (<percent>35%</percent>), vomiting (<percent>34%</percent>), fatigue (<percent>28%</percent>), hypothyroidism (<percent>23%</percent>), constipation (<percent>20%</percent>), weight loss (<percent>19%</percent>), decreased appetite (<percent>18%</percent>), pyrexia (<percent>14%</percent>), abdominal pain and hyperthyroidism (<percent>13%</percent> each), dysuria and rash (<percent>12%</percent> each), back and pelvic pain (<percent>11%</percent> each), and COVID-19 (<percent>10%</percent>).</p><p>In KEYNOTE-826, when KEYTRUDA was administered in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab (n=307), to patients with persistent, recurrent, or first-line metastatic cervical cancer regardless of tumor PD-L1 expression who had not been treated with chemotherapy except when used concurrently as a radio-sensitizing agent, fatal adverse reactions occurred in <percent>4.6%</percent> of patients, including 3 cases of hemorrhage, 2 cases each of sepsis and due to unknown causes, and 1 case each of acute myocardial infarction, autoimmune encephalitis, cardiac arrest, cerebrovascular accident, femur fracture with perioperative pulmonary embolus, intestinal perforation, and pelvic infection. Serious adverse reactions occurred in <percent>50%</percent> of patients receiving KEYTRUDA in combination with chemotherapy with or without bevacizumab; those ≥<percent>3%</percent> were febrile neutropenia (<percent>6.8%</percent>), urinary tract infection (<percent>5.2%</percent>), anemia (<percent>4.6%</percent>), and acute kidney injury and sepsis (<percent>3.3%</percent> each).</p><p>KEYTRUDA was discontinued in <percent>15%</percent> of patients due to adverse reactions. The most common adverse reaction resulting in permanent discontinuation (≥<percent>1%</percent>) was colitis (<percent>1%</percent>).</p><p>For patients treated with KEYTRUDA, chemotherapy, and bevacizumab (n=196), the most common adverse reactions (≥<percent>20%</percent>) were peripheral neuropathy (<percent>62%</percent>), alopecia (<percent>58%</percent>), anemia (<percent>55%</percent>), fatigue/asthenia (<percent>53%</percent>), nausea and neutropenia (<percent>41%</percent> each), diarrhea (<percent>39%</percent>), hypertension and thrombocytopenia (<percent>35%</percent> each), constipation and arthralgia (<percent>31%</percent> each), vomiting (<percent>30%</percent>), urinary tract infection (<percent>27%</percent>), rash (<percent>26%</percent>), leukopenia (<percent>24%</percent>), hypothyroidism (<percent>22%</percent>), and decreased appetite (<percent>21%</percent>).</p><p>For patients treated with KEYTRUDA in combination with chemotherapy with or without bevacizumab, the most common adverse reactions (≥<percent>20%</percent>) were peripheral neuropathy (<percent>58%</percent>), alopecia (<percent>56%</percent>), fatigue (<percent>47%</percent>), nausea (<percent>40%</percent>), diarrhea (<percent>36%</percent>), constipation (<percent>28%</percent>), arthralgia (<percent>27%</percent>), vomiting (<percent>26%</percent>), hypertension and urinary tract infection (<percent>24%</percent> each), and rash (<percent>22%</percent>).</p><p>In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in <percent>8%</percent> of 98 patients with previously treated recurrent or metastatic cervical cancer. Serious adverse reactions occurred in <percent>39%</percent> of patients receiving KEYTRUDA; the most frequent included anemia (<percent>7%</percent>), fistula, hemorrhage, and infections [except urinary tract infections] (<percent>4.1%</percent> each). The most common adverse reactions (≥<percent>20%</percent>) were fatigue (<percent>43%</percent>), musculoskeletal pain (<percent>27%</percent>), diarrhea (<percent>23%</percent>), pain and abdominal pain (<percent>22%</percent> each), and decreased appetite (<percent>21%</percent>).</p><p>In KEYNOTE-394, KEYTRUDA was discontinued due to adverse reactions in <percent>13%</percent> of 299 patients with previously treated hepatocellular carcinoma. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA was ascites (<percent>2.3%</percent>). The most common adverse reactions in patients receiving KEYTRUDA (≥<percent>10%</percent>) were pyrexia (<percent>18%</percent>), rash (<percent>18%</percent>), diarrhea (<percent>16%</percent>), decreased appetite (<percent>15%</percent>), pruritus (<percent>12%</percent>), upper respiratory tract infection (<percent>11%</percent>), cough (<percent>11%</percent>), and hypothyroidism (<percent>10%</percent>).</p><p>In KEYNOTE-966, when KEYTRUDA was administered in combination with gemcitabine and cisplatin, KEYTRUDA was discontinued for adverse reactions in <percent>15%</percent> of 529 patients with locally advanced unresectable or metastatic biliary tract cancer. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA (≥<percent>1%</percent>) was pneumonitis (<percent>1.3%</percent>). Adverse reactions leading to the interruption of KEYTRUDA occurred in <percent>55%</percent> of patients. The most common adverse reactions or laboratory abnormalities leading to interruption of KEYTRUDA (≥<percent>2%</percent>) were decreased neutrophil count (<percent>18%</percent>), decreased platelet count (<percent>10%</percent>), anemia (<percent>6%</percent>), decreased white blood cell count (<percent>4%</percent>), pyrexia (<percent>3.8%</percent>), fatigue (<percent>3.0%</percent>), cholangitis (<percent>2.8%</percent>), increased ALT (<percent>2.6%</percent>), increased AST (<percent>2.5%</percent>), and biliary obstruction (<percent>2.3%</percent>).</p><p>In KEYNOTE-017 and KEYNOTE-913, adverse reactions occurring in patients with MCC (n=105) were generally similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a single agent.</p><p>In KEYNOTE-426, when KEYTRUDA was administered in combination with axitinib, fatal adverse reactions occurred in <percent>3.3%</percent> of 429 patients. Serious adverse reactions occurred in <percent>40%</percent> of patients, the most frequent (≥<percent>1%</percent>) were hepatotoxicity (<percent>7%</percent>), diarrhea (<percent>4.2%</percent>), acute kidney injury (<percent>2.3%</percent>), dehydration (<percent>1%</percent>), and pneumonitis (<percent>1%</percent>). Permanent discontinuation due to an adverse reaction occurred in <percent>31%</percent> of patients; KEYTRUDA only (<percent>13%</percent>), axitinib only (<percent>13%</percent>), and the combination (<percent>8%</percent>); the most common were hepatotoxicity (<percent>13%</percent>), diarrhea/colitis (<percent>1.9%</percent>), acute kidney injury (<percent>1.6%</percent>), and cerebrovascular accident (<percent>1.2%</percent>). The most common adverse reactions (≥<percent>20%</percent>) were diarrhea (<percent>56%</percent>), fatigue/asthenia (<percent>52%</percent>), hypertension (<percent>48%</percent>), hepatotoxicity (<percent>39%</percent>), hypothyroidism (<percent>35%</percent>), decreased appetite (<percent>30%</percent>), palmar-plantar erythrodysesthesia (<percent>28%</percent>), nausea (<percent>28%</percent>), stomatitis/mucosal inflammation (<percent>27%</percent>), dysphonia (<percent>25%</percent>), rash (<percent>25%</percent>), cough (<percent>21%</percent>), and constipation (<percent>21%</percent>).</p><p>In KEYNOTE-564, when KEYTRUDA was administered as a single agent for the adjuvant treatment of renal cell carcinoma, serious adverse reactions occurred in <percent>20%</percent> of patients receiving KEYTRUDA; the serious adverse reactions (≥<percent>1%</percent>) were acute kidney injury, adrenal insufficiency, pneumonia, colitis, and diabetic ketoacidosis (<percent>1%</percent> each). Fatal adverse reactions occurred in <percent>0.2%</percent> including 1 case of pneumonia. Discontinuation of KEYTRUDA due to adverse reactions occurred in <percent>21%</percent> of 488 patients; the most common (≥<percent>1%</percent>) were increased ALT (<percent>1.6%</percent>), colitis (<percent>1%</percent>), and adrenal insufficiency (<percent>1%</percent>). The most common adverse reactions (≥<percent>20%</percent>) were musculoskeletal pain (<percent>41%</percent>), fatigue (<percent>40%</percent>), rash (<percent>30%</percent>), diarrhea (<percent>27%</percent>), pruritus (<percent>23%</percent>), and hypothyroidism (<percent>21%</percent>).</p><p>In KEYNOTE-868, when KEYTRUDA was administered in combination with chemotherapy (paclitaxel and carboplatin) to patients with advanced or recurrent endometrial carcinoma (n=382), serious adverse reactions occurred in <percent>35%</percent> of patients receiving KEYTRUDA in combination with chemotherapy, compared to <percent>19%</percent> of patients receiving placebo in combination with chemotherapy (n=377). Fatal adverse reactions occurred in <percent>1.6%</percent> of patients receiving KEYTRUDA in combination with chemotherapy, including COVID-19 (<percent>0.5%</percent>) and cardiac arrest (<percent>0.3%</percent>). KEYTRUDA was discontinued for an adverse reaction in <percent>14%</percent> of patients. Adverse reactions occurring in patients treated with KEYTRUDA and chemotherapy were generally similar to those observed with KEYTRUDA alone or chemotherapy alone, with the exception of rash (<percent>33%</percent> all Grades; <percent>2.9%</percent> Grades 3-4).</p><p>Adverse reactions occurring in patients with MSI-H or dMMR endometrial carcinoma who received KEYTRUDA as a single agent were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a single agent.</p><p>Adverse reactions occurring in patients with TMB-H cancer were similar to those occurring in patients with other solid tumors who received KEYTRUDA as a single agent.</p><p>Adverse reactions occurring in patients with recurrent or metastatic cSCC or locally advanced cSCC were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.</p><p>In KEYNOTE-522, when KEYTRUDA was administered with neoadjuvant chemotherapy (carboplatin and paclitaxel followed by doxorubicin or epirubicin and cyclophosphamide) followed by surgery and continued adjuvant treatment with KEYTRUDA as a single agent (n=778) to patients with newly diagnosed, previously untreated, high-risk early-stage TNBC, fatal adverse reactions occurred in <percent>0.9%</percent> of patients, including 1 each of adrenal crisis, autoimmune encephalitis, hepatitis, pneumonia, pneumonitis, pulmonary embolism, and sepsis in association with multiple organ dysfunction syndrome and myocardial infarction. Serious adverse reactions occurred in <percent>44%</percent> of patients receiving KEYTRUDA; those ≥<percent>2%</percent> were febrile neutropenia (<percent>15%</percent>), pyrexia (<percent>3.7%</percent>), anemia (<percent>2.6%</percent>), and neutropenia (<percent>2.2%</percent>). KEYTRUDA was discontinued in <percent>20%</percent> of patients due to adverse reactions. The most common reactions (≥<percent>1%</percent>) resulting in permanent discontinuation were increased ALT (<percent>2.7%</percent>), increased AST (<percent>1.5%</percent>), and rash (<percent>1%</percent>). The most common adverse reactions (≥<percent>20%</percent>) in patients receiving KEYTRUDA were fatigue (<percent>70%</percent>), nausea (<percent>67%</percent>), alopecia (<percent>61%</percent>), rash (<percent>52%</percent>), constipation (<percent>42%</percent>), diarrhea and peripheral neuropathy (<percent>41%</percent> each), stomatitis (<percent>34%</percent>), vomiting (<percent>31%</percent>), headache (<percent>30%</percent>), arthralgia (<percent>29%</percent>), pyrexia (<percent>28%</percent>), cough (<percent>26%</percent>), abdominal pain (<percent>24%</percent>), decreased appetite (<percent>23%</percent>), insomnia (<percent>21%</percent>), and myalgia (<percent>20%</percent>).</p><p>In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who had not been previously treated with chemotherapy in the metastatic setting (n=596), fatal adverse reactions occurred in <percent>2.5%</percent> of patients, including cardio-respiratory arrest (<percent>0.7%</percent>) and septic shock (<percent>0.3%</percent>). Serious adverse reactions occurred in <percent>30%</percent> of patients receiving KEYTRUDA in combination with chemotherapy; the serious reactions in ≥<percent>2%</percent> were pneumonia (<percent>2.9%</percent>), anemia (<percent>2.2%</percent>), and thrombocytopenia (<percent>2%</percent>). KEYTRUDA was discontinued in <percent>11%</percent> of patients due to adverse reactions. The most common reactions resulting in permanent discontinuation (≥<percent>1%</percent>) were increased ALT (<percent>2.2%</percent>), increased AST (<percent>1.5%</percent>), and pneumonitis (<percent>1.2%</percent>). The most common adverse reactions (≥<percent>20%</percent>) in patients receiving KEYTRUDA in combination with chemotherapy were fatigue (<percent>48%</percent>), nausea (<percent>44%</percent>), alopecia (<percent>34%</percent>), diarrhea and constipation (<percent>28%</percent> each), vomiting and rash (<percent>26%</percent> each), cough (<percent>23%</percent>), decreased appetite (<percent>21%</percent>), and headache (<percent>20%</percent>).</p><p>In KEYNOTE-B96, when KEYTRUDA was administered in combination with paclitaxel, with or without bevacizumab, serious adverse reactions occurred in <percent>54%</percent> of patients. Serious adverse reactions in ≥<percent>2%</percent> of patients were pneumonia (<percent>4.3%</percent>), urinary tract infection (<percent>3.9%</percent>), adrenal insufficiency (<percent>3%</percent>), hyponatremia (<percent>3%</percent>), COVID-19, decreased neutrophil count, pulmonary embolism (<percent>2.6%</percent> each), abdominal pain, anemia, colitis, diarrhea, febrile neutropenia, pyrexia, and vomiting (<percent>2.1%</percent> each).</p><p>Fatal adverse reactions occurred in <percent>3.9%</percent> of patients receiving KEYTRUDA and paclitaxel, with or without bevacizumab, including assisted suicide (<percent>0.9%</percent>), death, intestinal perforation, sepsis, COVID-19, cardio-respiratory arrest, colitis, and embolic stroke (<percent>0.4%</percent> each).</p><p>KEYTRUDA was permanently discontinued for adverse reactions in <percent>16%</percent> of patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA (≥<percent>1%</percent>) were colitis and increased alanine aminotransferase (<percent>1.3%</percent> each). Adverse reactions leading to the interruption of KEYTRUDA occurred in <percent>44%</percent> of patients. The most common adverse reactions leading to interruption of KEYTRUDA in ≥<percent>2%</percent> were urinary tract infection (<percent>3.9%</percent>), adrenal insufficiency, pyrexia, pneumonitis, upper respiratory tract infection (<percent>2.6%</percent> each), neutropenia, diarrhea, and COVID-19 (<percent>2.1%</percent> each).</p><p>The most common adverse reactions (≥<percent>20%</percent>) for patients treated with KEYTRUDA in combination with paclitaxel, with or without bevacizumab, were diarrhea (<percent>45%</percent>), fatigue (<percent>43%</percent>), nausea (<percent>41%</percent>), alopecia, peripheral neuropathy (<percent>38%</percent> each), epistaxis (<percent>31%</percent>), urinary tract infection (<percent>27%</percent>), constipation (<percent>25%</percent>), abdominal pain, decreased appetite, vomiting (<percent>24%</percent> each), hypothyroidism (<percent>21%</percent>), cough, hypertension, and rash (<percent>20%</percent> each).</p><p>For patients treated with KEYTRUDA in combination with paclitaxel and bevacizumab (N=169), decreased white blood cell count (<percent>27%</percent>), stomatitis (<percent>22%</percent>), and pyrexia (<percent>21%</percent>) were also reported as adverse reactions.</p><p><b>Lactation<br/></b>Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the last dose.</p><p><b>Pediatric Use<br/></b>In KEYNOTE-051, 173 pediatric patients (65 pediatric patients aged 6 months to younger than 12 years and 108 pediatric patients aged 12 years to 17 years) were administered KEYTRUDA 2 mg/kg every 3 weeks. The median duration of exposure was 2.1 months (range: 1 day to 25 months).</p><p>Adverse reactions that occurred at a ≥<percent>10%</percent> higher rate in pediatric patients when compared to adults were pyrexia (<percent>33%</percent>), leukopenia (<percent>30%</percent>), vomiting (<percent>29%</percent>), neutropenia (<percent>28%</percent>), headache (<percent>25%</percent>), abdominal pain (<percent>23%</percent>), thrombocytopenia (<percent>22%</percent>), Grade 3 anemia (<percent>17%</percent>), decreased lymphocyte count (<percent>13%</percent>), and decreased white blood cell count (<percent>11%</percent>).</p><p><b>Geriatric Use<br/></b>Of the 564 patients with locally advanced or metastatic urothelial cancer treated with KEYTRUDA in combination with enfortumab vedotin, <percent>44%</percent> (n=247) were 65-74 years and <percent>26%</percent> (n=144) were 75 years or older. No overall differences in effectiveness were observed between patients 65 years of age or older and younger patients. Patients 75 years of age or older treated with KEYTRUDA in combination with enfortumab vedotin experienced a higher incidence of fatal adverse reactions than younger patients. The incidence of fatal adverse reactions was <percent>4%</percent> in patients younger than 75 and <percent>7%</percent> in patients 75 years or older.</p><p>Of the 167 patients with MIBC treated with KEYTRUDA in combination with enfortumab vedotin, <percent>37%</percent> (n=61) were 65-74 years and <percent>46%</percent> (n=77) were 75 years or older. Patients 75 years of age or older treated with KEYTRUDA in combination with enfortumab vedotin experienced a higher incidence of fatal adverse reactions than younger patients. The incidence of fatal adverse reactions was <percent>4%</percent> in patients younger than 75 and <percent>12%</percent> in patients 75 years or older.</p><p><b>Additional Selected KEYTRUDA Indications in the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location><br/></b><i>Melanoma<br/></i>KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.</p><p>KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection.</p><p><i>Non-Small Cell Lung Cancer<br/></i>KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.</p><p>KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.</p><p>KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥<percent>1%</percent>] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, and is:</p><ul class=\"bwlistdisc\"><li>Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or</li><li>metastatic.</li></ul><p>KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥<percent>1%</percent>) as determined by an FDA-authorized test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.</p><p>KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.</p><p>KEYTRUDA, as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.</p><p><i>Malignant Pleural Mesothelioma<br/></i>KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).</p><p><i>Head and Neck Squamous Cell Cancer<br/></i>KEYTRUDA is indicated for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.</p><p>KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.</p><p>KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.</p><p>KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.</p><p><i>Classical Hodgkin Lymphoma<br/></i>KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).</p><p>KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.</p><p><i>Primary Mediastinal Large B-Cell Lymphoma<br/></i>KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.</p><p><i>Urothelial Cancer<br/></i>KEYTRUDA, in combination with enfortumab vedotin, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer.</p><p>KEYTRUDA, as a single agent, is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma:</p><ul class=\"bwlistdisc\"><li>who are not eligible for any platinum-containing chemotherapy, or</li><li>who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.</li></ul><p>KEYTRUDA, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy.</p><p>KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.</p><p><i>Microsatellite Instability-High or Mismatch Repair Deficient Cancer<br/></i>KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.</p><p><i>Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer<br/></i>KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test.</p><p><i>Gastric Cancer<br/></i>KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.</p><p>KEYTRUDA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test.</p><p><i>Esophageal Cancer<br/></i>KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:</p><ul class=\"bwlistdisc\"><li>in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that express PD-L1 (CPS ≥ 1), or</li><li>as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.</li></ul><p><i>Cervical Cancer<br/></i>KEYTRUDA, in combination with chemoradiotherapy (CRT), is indicated for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA).</p><p>KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.</p><p>KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.</p><p><i>Hepatocellular Carcinoma<br/></i>KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.</p><p><i>Biliary Tract Cancer<br/></i>KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).</p><p><i>Merkel Cell Carcinoma<br/></i>KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).</p><p><i>Renal Cell Carcinoma<br/></i>KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).</p><p>KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.</p><p><i>Endometrial Carcinoma<br/></i>KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.</p><p>KEYTRUDA, as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.</p><p><i>Tumor Mutational Burden-High Cancer<br/></i>KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.</p><p>This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.</p><p><i>Cutaneous Squamous Cell Carcinoma<br/></i>KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation.</p><p><i>Triple-Negative Breast Cancer<br/></i>KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.</p><p>KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.</p><p><b>Merck’s focus on cancer<br/></b>Every day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 25 novel mechanisms. With one of the largest clinical development programs across more than 30 tumor types, we strive to advance breakthrough science that will shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fresearch%2Foncology%2F&amp;esheet=54435066&amp;newsitemid=20260227462624&amp;lan=en-US&amp;anchor=www.merck.com%2Fresearch%2Foncology&amp;index=4&amp;md5=50f3f0f18c101400e297f3789179faa0\" rel=\"nofollow noopener\" shape=\"rect\">www.merck.com/research/oncology</a>.</p><p><b>About Merck<br/></b>At Merck, known as MSD outside of <location idsrc=\"xmltag.org\" value=\"LC/us\">the United States</location> and <location idsrc=\"xmltag.org\" value=\"LC/ca\">Canada</location>, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2F&amp;esheet=54435066&amp;newsitemid=20260227462624&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=5&amp;md5=6d0ba1936a699d07a10fba24bdd63ca1\" rel=\"nofollow noopener\" shape=\"rect\">www.merck.com</a> and connect with us on <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FMerck&amp;esheet=54435066&amp;newsitemid=20260227462624&amp;lan=en-US&amp;anchor=X+%28formerly+Twitter&amp;index=6&amp;md5=b4dadbee42b06fa059704c87a5e506e6\" rel=\"nofollow noopener\" shape=\"rect\">X (formerly Twitter</a>), <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=54435066&amp;newsitemid=20260227462624&amp;lan=en-US&amp;anchor=Facebook&amp;index=7&amp;md5=bdb50ed0ac44ea80d2f3b590b0fb1b72\" rel=\"nofollow noopener\" shape=\"rect\">Facebook</a>, <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=54435066&amp;newsitemid=20260227462624&amp;lan=en-US&amp;anchor=Instagram&amp;index=8&amp;md5=438f88c9216a0da8abbb8a0acf7647d1\" rel=\"nofollow noopener\" shape=\"rect\">Instagram</a>, <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=54435066&amp;newsitemid=20260227462624&amp;lan=en-US&amp;anchor=YouTube&amp;index=9&amp;md5=6f21b63d5419c808cb26593784e3de9f\" rel=\"nofollow noopener\" shape=\"rect\">YouTube</a> and <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=54435066&amp;newsitemid=20260227462624&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=10&amp;md5=4d7eb51858f74632db197bd9edb72dc0\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn</a>.</p><p><b>Forward-Looking Statement of Merck &amp; Co., Inc., <location idsrc=\"xmltag.org\" value=\"LU/us.nj.rahway\">Rahway, N.J.</location>, USA<br/></b>This news release of Merck &amp; Co., Inc., <location idsrc=\"xmltag.org\" value=\"LU/us.nj.rahway\">Rahway, N.J.</location>, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the <location idsrc=\"xmltag.org\" value=\"LC/us\">U.S.</location> Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.</p><p>Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in <location idsrc=\"xmltag.org\" value=\"LC/us\">the United States</location> and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.</p><p>The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (<a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54435066&amp;newsitemid=20260227462624&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=11&amp;md5=d7cc3418d9772c7b3fd3e3d46c4147cc\" rel=\"nofollow noopener\" shape=\"rect\">www.sec.gov</a>).</p><p><b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at </b><a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=54435066&amp;newsitemid=20260227462624&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=12&amp;md5=6eec41b51b5f73ee14e526df9b410df3\" rel=\"nofollow noopener\" shape=\"rect\"><b>http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf</b></a><b> and Medication Guide for KEYTRUDA at </b><a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=54435066&amp;newsitemid=20260227462624&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=13&amp;md5=16f3ddc059c8e878f45ab06cd40e85cf\" rel=\"nofollow noopener\" shape=\"rect\"><b>https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_mg.pdf</b></a><b>.</b></p><p><img alt=\"\" loading=\"lazy\" src=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260227462624r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"/><span class=\"bwct31415\"></span></p><p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: </span><span id=\"mmgallerylink-link\"><a href=\"https://www.businesswire.com/news/home/20260227462624/en/\" rel=\"nofollow noopener\">https://www.businesswire.com/news/home/20260227462624/en/</a></span></p><p>Media Contacts:</p><p>Julie Cunningham<br/>(617) 519-6264</p><p>Sofia DiMartino Bu<br/>(857) 274-4296</p><p>Investor Contacts:</p><p>Peter Dannenbaum<br/>(732) 594-1579</p><p>Steven Graziano<br/>(732) 594-1583</p><p>Source: Merck &amp; Co., Inc.</p></article>",
            "link": "https://www.stocktitan.net/news/MRK/keytruda-pembrolizumab-plus-paclitaxel-with-or-without-bevacizumab-xjsic08un809.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 15:15:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "KAYAK launches \"Got That Right,\" a New Brand Platform Bringing Confidence Back to Travel Planning | BKNG Stock News",
            "description": "<article class=\"article\"><div class=\"xn-content\"><p class=\"prntac\">New Ad Campaign <i>Reframes Travel Search around Reassurance </i></p><p><span class=\"legendSpanClass\"><location idsrc=\"xmltag.org\" value=\"LU/us.ma.boston\">BOSTON</location></span>, <span class=\"legendSpanClass\">Feb. 27, 2026</span> /PRNewswire/ -- <u><a href=\"https://www.kayak.com/\" rel=\"nofollow noopener\" target=\"_blank\">KAYAK</a></u>, a leading travel search engine, today unveiled a new brand platform and tagline, \"Got That Right,\" alongside a new campaign designed to tap into the most stressful moment of travel planning: the decision-making.</p><div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\"><p><a href=\"https://mma.prnewswire.com/media/2312078/KAYAK_Logo.html\" rel=\"nofollow noopener\" target=\"_blank\"><img alt=\"KAYAK.com (PRNewsfoto/KAYAK)\" loading=\"lazy\" src=\"https://mma.prnewswire.com/media/2312078/KAYAK_Logo.jpg\" title=\"KAYAK.com (PRNewsfoto/KAYAK)\"/></a></p></div><p>While <percent>66%</percent> of travelers say booking travel makes them feel stressed, most travel brands continue to focus on selling the thrill of the trip itself. KAYAK is taking a different approach by owning the moment before the trip, when uncertainty and second-guessing peak – and confidence matters most. The new platform positions KAYAK as the tool that cuts through complexity and replaces doubt with confidence, so travelers can book knowing they got it right.</p><p>\"Our research underscores the reality that travelers don't need more information, they need reassurance,\" said Carolina Montenegro, SVP of Global Brand Marketing at KAYAK. \"As travel search has become increasingly crowded and commoditized and people are bombarded by reels, reviews, stories and more - information overwhelm is real. 'Got That Right' is about giving travelers the reassurance that they've made the best choice, so they can avoid second-guessing.\"</p><p>Created in partnership with independent agency Rethink, the campaign is aimed at travelers aged 25-45, dramatizing the very real obstacles standing in the way of booking a trip.</p><p>At the center of the effort are two comedic 30-second spots.</p><ul type=\"disc\"><li><b>\"Big trip. Small screen.\"</b> playfully highlights the decision paralysis Millennials often feel when booking travel on anything other than a desktop computer – and shows how the KAYAK app cuts through the noise with clear comparisons and smart tools.<br/><br/></li><li>With one in two (<percent>50%</percent>) Americans reporting ever feeling overwhelmed by travel advice online,<b> \"Momfluencer\"</b> pokes fun at the overload of misguided online travel advice as a mom spirals into full-blown influencer brain before her daughter shows her how simple booking with KAYAK can be.</li></ul><p>Supporting 15-second vignettes will extend the idea on social media, positioning KAYAK as the tool that travelers trust to get their trip right.</p><p>\"We have more options than ever when it comes to travel searching but those options feel overwhelming versus liberating,\" said Tara Lawall, Chief Creative Officer of Rethink's <location idsrc=\"xmltag.org\" value=\"LU/us.ny.nyc\">New York</location> Office. \"People get paralyzed by choice and second-guess everything. That's the tension we saw, and it felt like a real opening for KAYAK. So we centered the work on a simple benefit, confidence and that feeling of relief when you know you got it right.\"</p><p>The campaign will run in <location idsrc=\"xmltag.org\" value=\"LB/nam\">North America</location> across TV, CTV, online video, digital out-of-home, digital audio, social, and digital channels.</p><p><b>About KAYAK</b><br/><u><a href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=3967439-1&amp;h=3162576145&amp;u=https%3A%2F%2Fwww.kayak.com%2F&amp;a=KAYAK\" rel=\"nofollow noopener\" target=\"_blank\">KAYAK</a></u>, part of Booking Holdings (NASDAQ: <u><a href=\"https://www.prnewswire.com/news-releases/kayak-for-business-launches-new-enterprise-solution-301926459.html#financial-modal\" rel=\"nofollow noopener\" target=\"_blank\">BKNG</a></u>), is a leading travel search engine. With billions of queries across our platforms, we help people find their perfect flight, stay, rental car and vacation package. We also support business travelers with our <u><a href=\"https://www.kayak.com/c/enterprise/\" rel=\"nofollow noopener\" target=\"_blank\">corporate travel solution</a></u>.</p><p>Methodology:<br/>All figures, unless otherwise stated, are from YouGov Plc. Total sample size was 1204 adults, of whom 926 travel. Fieldwork was undertaken between 3rd - 4th February 2026. The survey was carried out online. The figures have been weighted and are representative of all US adults (aged 18+).</p><p>SOURCE KAYAK</p></div></article>",
            "link": "https://www.stocktitan.net/news/BKNG/kayak-launches-got-that-right-a-new-brand-platform-bringing-sc528z6vxa65.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 15:00:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting | IRD Stock News",
            "description": "<article class=\"article\"><ul type=\"disc\"><li style=\"list-style-position:inside; margin-bottom:8pt; text-align:center;\"><em>Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months </em><br/><br/></li><li style=\"list-style-position:inside; margin-bottom:8pt; text-align:center;\"><em>Early signals of functional and structural improvement observed at one month and three months<br/><br/></em></li><li style=\"list-style-position:inside; margin-bottom:8pt; text-align:center;\"><em>12-letter BCVA gain and <percent>23%</percent> CST reduction observed in the treated eye at three months<br/><br/></em></li><li style=\"list-style-position:inside; margin-bottom:8pt; text-align:center;\"><em>Full cohort data expected in mid-year 2026</em><br/><br/></li></ul> <p>RESEARCH TRIANGLE PARK, N.C., Feb.  27, 2026  (GLOBE NEWSWIRE) -- <a href=\"https://www.globenewswire.com/Tracker?data=6SJWcmOoXPhrxg_rOmQmRe1Vx8ePHlgG_i13JHWWh9dcXf6bbmtNFCDPaPvkFRyUMzj4BhKkIdHCq7E7IiZRZ2qcp78rxWIikIKL9ODvaOw=\" rel=\"nofollow noopener\" target=\"_blank\">Opus Genetics, Inc</a>. (Nasdaq: <a class=\"symbol-link\" href=\"/overview/IRD/\" title=\"View IRD stock overview\">IRD</a>) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today new clinical data from its ongoing Phase 1/2 study of OPGx-BEST1 gene therapy, presented at the 49th Annual Meeting of the Macula Society, in San Diego, California.</p> <p>The presentation, titled “Preliminary Results from an Adult Participant in a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations,” reported 3-month results from the first (sentinel) adult participant treated in the study, highlighting positive safety, tolerability, and biological activity following subretinal administration of OPGx-BEST1.</p> <p>The sentinel participant is a 63-year-old female with Autosomal-Recessive Bestrophinopathy (ARB) disease with severe functional impairment. The data demonstrated that OPGx-BEST1 was well tolerated with no ocular inflammation, no ocular or treatment-related adverse events, and no dose limiting toxicities. Early signals of functional vision improvement were observed, including an equivalent 12-letter gain in Best Corrected Visual Acuity (BCVA) in the treated study eye. In addition, structural improvement in central subfield thickness (CST) was observed with a <percent>23%</percent> decrease in the study eye. Resolution of intraretinal fluid was also seen as early as 1-month in areas with less atrophy.</p> <p>“We are encouraged by these results from our sentinel participant, showing OPGx-BEST1 was well-tolerated and demonstrated promising initial efficacy at three months,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. Although early, this data represents an important milestone for our OPGx-BEST1 program and for patients with BEST1-related retinal diseases.”</p> <p>“BEST1-related retinal diseases represent a significant unmet medical need, with no approved treatments currently available,” said Mark Pennesi, M.D., Ph.D., study investigator at the Retina Foundation of the Southwest in Dallas, Texas. “The preliminary results from this study, including the early favorable safety profile and initial signals of functional and structural improvement, are encouraging and support continued evaluation of OPGx-BEST1 as a gene augmentation approach for patients with BEST1-associated disease.”</p> <p>Recruitment in the Phase 1/2 study is ongoing at two clinical sites in the U.S., with additional sites expected to open in Florida, Cincinnati and New York. Two participants have been enrolled to date, with 3-month results from the full Cohort 1 expected in mid-year 2026.</p> <p>The full presentation and video recording will be available on the Opus Genetics website in the <a href=\"https://www.globenewswire.com/Tracker?data=f0bFStFTGQbq1zSNfuUI6K_Ty13dzjBay7__iO8jdVSpy2nL8WIofPtnZ7ssWhUAXssuPHAh6GRW_IppxzDbqw==\" rel=\"nofollow noopener\" target=\"_blank\">Events</a> section.</p> <p><strong>About OPGx-BEST1 and the Phase 1/2 Trial</strong></p> <p>OPGx-BEST1 leverages Opus Genetics’ proprietary AAV-based gene therapy platform, designed to deliver a functional copy of the BEST1 gene directly to the retinal pigment epithelium (RPE) cells where the defective gene resides. The program builds on extensive preclinical work demonstrating restoration of BEST1 protein expression and improved retinal function in relevant disease models.</p> <p>By restoring BEST1 function, the therapy aims to address the underlying genetic cause of retinal degeneration and support preservation of photoreceptor health and visual function. BEST1-associated IRDs affect an estimated 22,000 patients worldwide and currently have no approved treatments.</p> <p>The ongoing adaptive, open-label Phase 1/2 study is evaluating single-eye subretinal administration of OPGx-BEST1 up to two dose levels in adult participants with Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB). Treatment will be administered via a single subretinal injection in one eye of each participant with two dosing cohorts.</p> <p>The primary objective is to assess safety and tolerability and identify the most appropriate dose for further clinical development, with participants followed longitudinally for long-term outcomes. The trial will also explore biological activity through functional and anatomical endpoints, including changes in visual function and retinal structure.</p> <p><strong>About Opus Genetics</strong></p> <p>Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution <percent>0.75%</percent>, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. For more information, visit <a href=\"https://www.globenewswire.com/Tracker?data=UmpBah_dckPD0-8cXR6wdbJEURvu5iKoTK8fwGxrGu5zbYa6hCbJfa-_uyv1yFO5QfdQygubBcFhuIqaaZu0ig==\" rel=\"nofollow noopener\" target=\"_blank\">www.opusgtx.com</a>.   </p> <p><strong>Forward Looking Statements</strong></p> <p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to the clinical development, clinical results, preclinical data, and future plans for Phentolamine Ophthalmic Solution <percent>0.75%</percent>, OPGx-LCA5, OPGx-BEST1, RDH12, and earlier stage programs, and expectations regarding us, our business prospects, and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, our subsequent Quarterly Reports on Form 10-Q, and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.</p> <p><strong>Contacts:</strong></p> <p><strong>Investors</strong><br/>Jenny Kobin<br/>Remy Bernarda<br/>IR Advisory Solutions<br/><a href=\"https://www.globenewswire.com/Tracker?data=8V2QE2VZP6pWEoq-Uh7o2MDifJHXQGZjrZXhklU8VPs9kOSsTVXDqH-_ItXkaA0BMYkvberbcLdmqh7pxd1G43PF6XQYqukH9O-Pk2lUQRki4YY2_0QvXY2FGfYXdtzwzJvM7AqSThBFO3xLqtRYP7CjzK5l6oFluafB4RXzvDcalTb6ERKr236P3nsXIdVUD31zyDT4YU6JRNilEG-t5fqEzcC47byhHsbq-G0Rx1vPXBlBsB-zMLSVWQRs8a0YQ-Yib4EqBvZu0cvUYhr3TcfePMs93EyoQhnh9Zdai_QFW-VV_V13TBslc5HC9GoktAem-ckTXUYsHXjpSDAZ91VlCr89SxpQeAK0VBxGGHLQcHPMB9tmz_fDicp53ISNFC1HHCLiQPbL8zaed8tErCgcX8wuzeVEmA_ZxEPYJC7F0fzCDZE_ChdrtiKeYdxu1FcRindepK8YL6RUmpkNG10yXQAZ0qw2jONrQSU6rhvj2MnlkkhNtPs1N7KP4eZRIisV2eGbpU_Bd3pRX3T2XZMtE1gU0PwmJe6Pu38dz2rTbyxw5ubLDoGrUwsB2z_NavDJiR1HLoLaqZmyVmo01Low5XKUi13eBOgjwQ7zG0Ukjbwo_KYyBpiDaDPZMulmedRVRMmq1d0l2xFNF-HzCyvIsW8FulUk5Y-2u6gNydTKsj-0jpa_rxG5xMkAzfEpyq40kRrJn5ytH69OUc5OOQaZYdCZSMvV95XJAABgK2E=\" rel=\"nofollow noopener\" target=\"_blank\">ir@opusgtx.com</a></p> <p><strong>Media</strong><br/>Kimberly Ha<br/>KKH Advisors<br/>917-291-5744<br/><a href=\"https://www.globenewswire.com/Tracker?data=zNcjUyLAPuCcDZAwzimgpIIjwWkGlTURfZLo3_8EAYoqgp-eE8SVS0mAp3BFv3HThDAAt_PddI6LtTuQ0xkF4WyzdK5cOiwegCkyXpjEFnOQehUGuG1Eqa7R1TTmBSUadaQteBaOP0fDaWSPQnfItkrRYr3V6XqQ7wZ-xbYo_zDoQJ6eVL0cF8yDsyKnBSW5dkBm1ksG7qzL5al_jAUXDWrc1leMx1HQlgSkktqH7y-AlOQMPdI2f_-RmtabFXCnlTDnA2_Xz_DgwnzgVER3yN10Z93uVDmj6IU9sp0yIHR1Czjyl4wPdg9VyOb4ZtUX4mdgbwRDk3GPQj2MswA7jtpCeNSORX7kxZpuPTRo7fGRlHnTROZhEp0hyeZWRXeX4JA6a1ogA943hox1E831nXP7bD9ExVcmg5CKZDC70CrflFl_-Ml8eU5B--iNhoe1n0e2EefZTQjjT743lRaQt6avfFsuqhXxMfQQrGR6hB1QvC6qz6CnYMGWbKPYQxCoZGwOJnIoa-OtLaw2a6PAWovpO8Yxg0IHJvSn9sKyRPwu1uKE9nIqTZibX5SQqgQoB0m_wf03XujW-fHEN2PX7c-4wkiWEbIAJKCdsSDAxNZ0PFqbdH_ari8VeFTme3zE_Eh5g_LHjskJyi-pTiOyRA_Ex4ZC3SFSMDqPyKKHqalD4sOpKlEMK_rUP8adZRdGGSh9-Tsy0c5GzcqMwH7Xjco63F0sprm7ABCTZHMXb_VvfFGW7kCMJ8LhKePVsNcroxJhpUnyfqARSaF6vgJCcFqp4fbgvdaoNOi4m8jvZsf6wyFcjAazIvmXwmrrP61YqVfRD8Q-Za32ZxD9mRienoyFjZfymDE4LvvCLeOetQc=\" rel=\"nofollow noopener\" target=\"_blank\">kimberly.ha@kkhadvisors.com</a></p> <p>Source: Opus Genetics, Inc.</p> <img alt=\"\" class=\"__GNW8366DE3E__IMG\" loading=\"lazy\" src=\"https://www.globenewswire.com/newsroom/ti?nf=OTY2MjYwMCM3NDUzNjc5IzIzMDE3NjA=\"/> <br/><img alt=\"\" loading=\"lazy\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/YjUyN2U1NzEtYjc2ZC00Y2VhLTg3YzAtN2QyMTI3NzYxM2YyLTEzMTMzMTAtMjAyNi0wMi0yNy1lbg==/tiny/Opus-Genetics-Inc-.png\"/></article>",
            "link": "https://www.stocktitan.net/news/IRD/opus-genetics-announces-initial-clinical-data-from-phase-1-2-op-gx-26n9dfn0f7es.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 15:10:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Sirios Completes Acquisition Of OVI Mining Corp | SIREF Stock News",
            "description": "<article class=\"article\"><p>Combined company is well-capitalized with an exceptional management team and portfolio of gold assets in the Eeyou Istchee James Bay region</p><p>Montreal, Quebec--(Newsfile Corp. - February 27, 2026) - Sirios Resources Inc. (TSXV: SOI) (OTCQB: <a class=\"symbol-link\" href=\"/overview/SIREF/\" title=\"View SIREF stock overview\">SIREF</a>) (\"<b>Sirios</b>\") and OVI Mining Corp. (\"<b>OVI</b>\") are pleased to announce the completion of their previously announced business combination by way of a court approved plan of arrangement under the <i>Business Corporations Act </i>(British Columbia) (the \"<b>Transaction</b>\"). Under the Transaction, Sirios acquired all of the common shares of OVI (each, an \"<b>OVI Share</b>\") outstanding immediately prior to the effective time of the Transaction, which resulted in OVI becoming a wholly-owned subsidiary of Sirios. </p><p>Following completion of the Transaction, each former holder of OVI Shares is entitled to receive 2.34 common shares of Sirios (each, a \"<b>Sirios Share</b>\") in exchange for each common share of OVI held immediately prior to the effective time of the Transaction.</p><p>Concurrent with the completion of the Transaction, Jean-Félix Lepage has been appointed Chief Executive Officer of Sirios, replacing Sirios founder, Dominique Doucet, who will transition to Executive Chairman and Head of Exploration. In addition, Sean Roosen and Laurence Farmer have joined the board of directors of Sirios (the \"<b>Board</b>\"), adding deep Québec mining and capital markets expertise to the Sirios team.</p><p>Mr. Lepage has over 15 years of experience in mining and managing operations, projects, and development activities. Prior to becoming CEO of OVI, he was Vice-President of Projects at O3 Mining Inc., where he led the Marban Project though the study and development process. His past experience also includes several different operational roles at Newmont Corporation, including managing the underground operations at the Eleonore Mine. Mr. Lepage obtained his Bachelor of Mining Engineering from Université Laval and holds a college technical degree in mineral processing from CEGEP de Thetford.</p><p><b>Jean-Félix Lepage, incoming CEO of Sirios, stated: </b><i>\"I am honoured to lead Sirios Resources as we enter this exciting new chapter. The combination of Sirios and OVI creates a stronger, well-capitalized company with an exceptional portfolio of gold assets in the Eeyou Istchee James Bay region. I look forward to working with our talented team and newly strengthened board to advance our exploration and development programs and deliver value for our shareholders.\"</i></p><p><b>Dominique Doucet, former CEO of Sirios, stated: </b><i>\"After founding and leading Sirios for many years, I am proud to see the company take this significant step forward. This transaction brings together two complementary teams and asset portfolios, strengthening our position in the James Bay gold camp. In my new role as Executive Chairman and Head of Exploration, I remain deeply committed to Sirios and look forward to focusing my efforts on advancing our exploration programs and supporting Jean-Félix and the team in building on the foundation we have established.\"</i></p><p><b>Board of Directors</b></p><p>The Board is led by Executive Chairman Dominique Doucet, and now includes Sean Roosen and Laurence Farmer, as well as Robert Ménard, Colinda Parent and Guy Le Bel. Luc Cloutier has resigned from the Board. Sirios would like to express its sincere gratitude for his years of service. </p><p><b>Dominique Doucet, former CEO of Sirios, stated: </b><i>\"On behalf of the Board, I would like to recognize and express my profound gratitude for Luc's unwavering commitment and dedication to Sirios since its founding in 1994. Luc's contributions have left an lasting mark on Sirios, and his legacy will continue to shape our path forward. On behalf of the entire Sirios team, we extend our heartfelt appreciation and wish him every success in his future endeavours.\"</i></p><p>Mr. Roosen is the founder and Executive Chairman of Osisko Development Corp., and former CEO of OR Royalties Inc. As founder, President, Chief Executive Officer, and Director of Osisko Mining Corporation, Mr. Roosen was responsible for developing the strategic plan for the discovery, financing, and development of the Canadian Malartic mine. Recognized as one of the \"Top 20 Most Influential Individuals in Global Mining,\" in 2017, he brings unmatched industry vision and strategic leadership.</p><p>Mr. Farmer is the General Counsel and VP Strategic Development of Osisko Development Corp. and the Chief Executive Officer of Electric Elements Mining Corp., prior to which he was Senior Counsel of OR Royalties Inc. Prior to joining the Osisko Group, Mr. Farmer worked in investment banking at RBC Capital Markets in London and, before that, practiced as a corporate lawyer with Norton Rose Fulbright LLP in London, England and Montréal, Canada, and brings strong transactional expertise and strategic insight into global resource development.</p><p><b>Information for Former OVI Shareholders</b></p><p>To receive the Sirios Shares to which they are entitled under the Transaction, former registered shareholders of OVI must complete, sign, date and return the letter of transmittal mailed to each OVI shareholder prior to closing. The letter of transmittal is also available on SEDAR+ (<a href=\"https://api.newsfilecorp.com/redirect/24mgXs1z5A\" rel=\"nofollow noopener\">www.sedarplus.ca</a>) under OVI's issuer profile. Former shareholders whose OVI Shares are registered in the name of a broker, investment dealer, bank, trust company or other intermediary should contact that intermediary for assistance in depositing their OVI Shares and follow its instructions.</p><p>The Transaction was unanimously approved by shareholders of OVI at a special meeting held on February 18, 2026 (the \"<b>Meeting</b>\"). Further information about the Transaction is set forth in the joint news release of Sirios and OVI dated December 11, 2025 and the management information circular prepared by OVI in respect of the Meeting which was mailed to shareholders of OVI and filed on SEDAR+ (<a href=\"https://api.newsfilecorp.com/redirect/Mqy1XtqvMm\" rel=\"nofollow noopener\">www.sedarplus.ca</a>) under OVI's issuer profile.</p><p>OVI has applied to cease to be a reporting issuer under applicable Canadian securities laws.</p><p>Pursuant to the Transaction, Sirios will issue an aggregate of 131,905,594 Sirios Shares. All 1,866,000 options to purchase OVI Shares outstanding immediately prior to the effective time of the Transaction, whether or not vested, were exchanged for 4,366,440 options to acquire Sirios Shares, with an exercise price equal to approximately <money>$0.05</money>641 per Sirios Share, subject to rounding on the exercise thereof in accordance with the plan of arrangement and which expire on November 1, 2030.</p><p>OVI owns a portfolio of properties located in the James Bay region of Québec, including a <percent>100%</percent> interest in the Corvet Est and PLEX gold projects. Certain of OVI's properties are subject to royalties and contingent cash payments, which have been assumed indirectly by Sirios as a result of the Transaction. </p><p><b>Early Warning Disclosure</b></p><p>Prior to the completion of the Transaction, Sirios held no OVI Shares. Following the completion of the Transaction, Sirios holds all of the issued and outstanding OVI Shares. An early warning report will be filed by Sirios on SEDAR+ (<a href=\"https://api.newsfilecorp.com/redirect/bg1npS1gaG\" rel=\"nofollow noopener\">www.sedarplus.ca</a>) under OVI's issuer profile in accordance with applicable securities laws. To obtain a copy of the early warning report, please contact the CEO of Sirios 438-454-5636 or <a href=\"mailto:info@sirios.com\" rel=\"nofollow noopener\">info@sirios.com</a>. Sirios's head office is located at 1400 Marie-Victorin, Bureau 210, Saint-Bruno-de-Montarville, Québec, J3V 6B9.</p><p><b>Advisors and Counsel</b></p><p>Bennett Jones LLP acted as legal counsel to OVI in connection with the Transaction. Mills Dunlop Capital Partners acted as financial advisor to OVI.</p><p>Stein Monast LLP acted as legal counsel to Sirios in connection with the Transaction.</p><p><b>About Sirios Resources Inc.</b></p><p>Sirios Resources Inc. (TSXV: SOI) (OTCQB: <a class=\"symbol-link\" href=\"/overview/SIREF/\" title=\"View SIREF stock overview\">SIREF</a>) (<a href=\"https://api.newsfilecorp.com/redirect/3KkpDHe4Ew\" rel=\"nofollow noopener\">www.sirios.com</a>) is a Québec-based mineral exploration company focused on developing its portfolio of high-potential gold properties in the Eeyou Istchee James Bay region of Canada.</p><div id=\"contactInfo\"><p><b>For more information, please contact:</b></p><p><b>Sirios Resources Inc. </b><br/>Jean-Félix Lepage, CEO<br/>438-454-5636<br/><a href=\"mailto:info@sirios.com\" rel=\"nofollow noopener\">info@sirios.com</a> <br/><b><a href=\"https://api.newsfilecorp.com/redirect/N3K1DHPxNb\" rel=\"nofollow noopener\">www.sirios.com</a> </b></p><p><b>OVI Mining Corp. </b><br/>Jean-Félix Lepage, CEO <br/>438-454-5636 <br/><a href=\"mailto:jflepage@ovimining.com\" rel=\"nofollow noopener\">jflepage@ovimining.com</a> <br/><b><a href=\"https://api.newsfilecorp.com/redirect/XEz1mSMaPQ\" rel=\"nofollow noopener\">www.ovimining.com</a></b></p></div><p><b>Cautionary Note Regarding Forward-Looking Information</b></p><p><i>This news release contains \"forward-looking information\" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as \"expects\", or \"does not expect\", \"is expected\", \"anticipates\" or \"does not anticipate\", \"plans\", \"budget\", \"scheduled\", \"forecasts\", \"estimates\", \"believes\" or \"intends\" or variations of such words and phrases or stating that certain actions, events or results \"may\" or \"could\", \"would\", \"might\" or \"will\" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.</i></p><p><i>In this news release, forward-looking statements relate to, among other things, statements regarding: the anticipated benefits of the Transaction, including potential synergies resulting from combining Sirios and OVI and the creation of a stronger, well-capitalized company; the enhanced portfolio of gold assets in the Eeyou Istchee James Bay region; the expected advancement of exploration and development programs; the ability to deliver value for shareholders; future exploration results and the potential for resource growth; the expectations for the combined entity's board, management team and operations; the roles and responsibilities of management, including those of Mr. Lepage, Mr. Doucet, Mr. Roosen and Mr. Farmer; the filing of an early warning report and the ceasing of OVI's status as a reporting issuer; and any other statements that are not historical facts.</i></p><p><i>Forward-looking statements are based on certain assumptions and analyses made by Sirios and OVI in light of the experience and perception of historical trends, current conditions, and expected future developments, and other factors they believe are appropriate. These forward-looking statements are not guarantees of future results and involve risks and uncertainties that may cause actual results to differ materially from the potential results discussed in the forward-looking statements.</i></p><p><i>Risks and uncertainties that may cause such differences include, but are not limited to: fluctuations in the price of gold and other commodities; general economic, market and business conditions; the inherent risks associated with mineral exploration, development and mining operations; risks relating to the integration of Sirios and OVI and the realization of anticipated benefits from the Transaction; the volatility of the capital markets and market conditions in general; changes in national and local government legislation, taxation, controls and regulations; environmental risks and hazards; the speculative nature of mineral exploration; risks associated with obtaining and maintaining necessary licences, permits and authorizations and complying with permitting requirements; title matters; community and Indigenous relations; uncertainty in the estimation of mineral resources; competition for, among other things, capital, undeveloped lands and skilled personnel; risks relating to insufficient funding and the requirement for additional capital; risks relating to climate change and extreme weather events; the reliance on key personnel; the potential for conflicts of interest among certain officers and directors; and the other risks described in the continuous disclosure documents of Sirios filed with the Canadian securities regulatory authorities available on SEDAR+ at <a href=\"https://api.newsfilecorp.com/redirect/DOyaPfPXn3\" rel=\"nofollow noopener\">www.sedarplus.ca</a>.</i></p><p><i>Sirios and OVI believe that the expectations reflected in forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. As such, readers should not place undue reliance on the forward-looking statements and information contained in this news release. These forward-looking statements are made as of the date of this news release and, except as required under applicable securities legislation, Sirios and OVI assume no obligation to update or revise them to reflect new events or circumstances.</i></p><p><b>Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.</b></p><p id=\"corporateLinkBack\">To view the source version of this press release, please visit <a href=\"https://api.newsfilecorp.com/redirect/rpXxQHwrq3\" rel=\"nofollow noopener\">https://www.newsfilecorp.com/release/285631</a></p><p><img alt=\"\" loading=\"lazy\" src=\"https://api.newsfilecorp.com/newsinfo/285631/375\"/></p></article>",
            "link": "https://www.stocktitan.net/news/SIREF/sirios-completes-acquisition-of-ovi-mining-19j1xcg639zu.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 15:09:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Trans Canada Gold Announces Plans for Exploration and Drilling on its Harrison Lake Gold Project, Lays Out Detailed 2026 Drilling Program Targeting Gold | TTGXF Stock News",
            "description": "<article class=\"article\"><p><strong id=\"dateline\">VANCOUVER, BC / <a href=\"https://www.accessnewswire.com/\" rel=\"nofollow noopener\">ACCESS Newswire</a> / February 27, 2026 / </strong><strong>Trans Canada Gold Corp. (TSX-V:TTG)(OTCQB:TTGXF)</strong> (\"<strong>Trans Canada</strong>\" or the \"<strong>Company</strong>\"), is pleased to provide a corporate update and announce its Spring 2026 drilling plans on the Harrison Lake Gold Project. The project is demonstrating the same characteristics as the Snowline Gold deposit situated in the Tintina Gold Belt in the Canadian, Yukon.</p><p><strong><u>2026 EXPLORATION AND GOLD DRILLING STRATEGY</u></strong></p><p>Harrison Lake Gold Project in an advanced exploration and development setting, fully permitted targeting identified gold zones, increasing its gold resource. Detailed drilling planning is currently underway on the Harrison Lake Gold Project. The Company is well positioned to capture and to capitalize on the forecasted ascending gold prices.</p><div><ul style=\"list-style-type:disc;\"><li><p style=\"text-align:justify;\"><strong><u>Phase 1-Drilling</u></strong> - 6-hole program targeting the highest-grade gold zone around intercept<strong> DDH-84-52: 102 meters grading 3.54 g/t gold.</strong></p></li></ul></div><ul style=\"list-style-type:disc;\"><li><p><strong><u>Phase 2 Drilling</u></strong> - 8-Hole drilling program targeting multiple high grade gold zones.<strong> DDH 88-76 which intersected 7.0 meters averaging 21.4 g/t and DDH 88-121 which intersected 9.0 meters averaging 13.5 g/t, </strong>are priority follow-ups.</p></li></ul><p>The Company currently has a non-compliant historical gold resource of 220,000 ounces of gold at the Harrison Lake Gold Project. These historic estimates are disclosed solely for context. The historic estimates do not conform to current NI 43- 101 standards, are not classified as current mineral resources or mineral reserves, and should not be relied upon. A qualified person has not done sufficient work to classify the historic estimates as current mineral resources or mineral reserves.</p><p><strong><u>Jenner Zone</u></strong></p><p>A summary of the estimate for the Jenner zone from Norman's 1989 study is shown as follows:</p><p>Historical Tonnage and Grade Estimate for the Jenner Zone</p><table><tbody><tr><td style=\"border:1.0pt solid black;height:24.45pt;padding:0in;vertical-align:top;width:101.5pt;\"><p>Mineralized Zone</p></td><td style=\"border-bottom-style:solid;border-border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;height:24.45pt;padding:0in;vertical-align:top;width:127.6pt;\"><p>Resource</p><p>Category</p></td><td style=\"border-bottom-style:solid;border-border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;height:24.45pt;padding:0in;vertical-align:top;width:85.05pt;\"><p>Resource</p><p>Tonnes</p></td><td style=\"border-bottom-style:solid;border-border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;height:24.45pt;padding:0in;vertical-align:top;width:77.95pt;\"><p>Grade</p><p>Au g/t</p></td></tr><tr><td style=\"border-bottom-style:solid;border-border-left-style:solid;border-right-style:solid;border-top-style:none;border-width:1.0pt;height:12.1pt;padding:0in;vertical-align:top;width:101.5pt;\"><p>Jenner Stock</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:12.1pt;padding:0in;vertical-align:top;width:127.6pt;\"><p>\"Probable Resource\"</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:12.1pt;padding:0in;vertical-align:top;width:85.05pt;\"><p>1,344,000</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:12.1pt;padding:0in;vertical-align:top;width:77.95pt;\"><p>2.67</p></td></tr><tr><td style=\"border-bottom-style:solid;border-border-left-style:solid;border-right-style:solid;border-top-style:none;border-width:1.0pt;height:12.2pt;padding:0in;vertical-align:top;width:101.5pt;\"><p>Jenner Stock</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:12.2pt;padding:0in;vertical-align:top;width:127.6pt;\"><p>\"Possible Resource\"</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:12.2pt;padding:0in;vertical-align:top;width:85.05pt;\"><p>457,000</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:12.2pt;padding:0in;vertical-align:top;width:77.95pt;\"><p>2.83</p></td></tr></tbody></table><p style=\"text-align:justify;\"><sup>*The historic estimates do not conform to current NI 43- 101 standards, are not classified as current mineral resources or mineral reserves, and should not be relied upon. A qualified person has not done sufficient work to classify the historic estimates as current mineral resources or mineral reserves.</sup></p><p><strong><u>Portal Zone</u></strong></p><p style=\"text-align:justify;\">The total amount of drilling to 1989 on the Portal Stock was 6,978 meters (22,895 feet) in 50 drill holes. Additional diamond drilling by Bema during the fall of 1988 concentrated on the eastern portion of the stock (east of 11040 E) which had produced the best gold mineralization intercepts to date.</p><p style=\"text-align:justify;\">Similar Probable and Possible categories were calculated, as for the Jenner Zone, with \"probable reserves\" defined by projection of a known drill intercept up to 15 meters outward and \"possible reserves\" defined by projection of the probable block boundaries an additional 30 meters. The resource parameters were identical to those used in the Jenner study.</p><p>Historical Resources Estimate at Portal Stock</p><table><tbody><tr><td style=\"border:1.0pt solid black;height:12.2pt;padding:0in;vertical-align:top;width:123.15pt;\"><p>Mineral Zone</p></td><td style=\"border-bottom-style:solid;border-border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;height:12.2pt;padding:0in;vertical-align:top;width:130.5pt;\"><p>Category</p></td><td style=\"border-bottom-style:solid;border-border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;height:12.2pt;padding:0in;vertical-align:top;width:81.75pt;\"><p>Tonnes*</p></td><td style=\"border-bottom-style:solid;border-border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;height:12.2pt;padding:0in;vertical-align:top;width:85.05pt;\"><p>Grade Au g/t</p></td></tr><tr><td style=\"border-bottom-style:solid;border-border-left-style:solid;border-right-style:solid;border-top-style:none;border-width:1.0pt;height:12.2pt;padding:0in;vertical-align:top;width:123.15pt;\"><p>Portal Stock</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:12.2pt;padding:0in;vertical-align:top;width:130.5pt;\"><p>\"Probable Resource\"</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:12.2pt;padding:0in;vertical-align:top;width:81.75pt;\"><p>500,000</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:12.2pt;padding:0in;vertical-align:top;width:85.05pt;\"><p>3.12</p></td></tr><tr><td style=\"border-bottom-style:solid;border-border-left-style:solid;border-right-style:solid;border-top-style:none;border-width:1.0pt;height:12.2pt;padding:0in;vertical-align:top;width:123.15pt;\"><p>Portal Stock</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:12.2pt;padding:0in;vertical-align:top;width:130.5pt;\"><p>\"Possible Resource\"</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:12.2pt;padding:0in;vertical-align:top;width:81.75pt;\"><p>157,000</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:12.2pt;padding:0in;vertical-align:top;width:85.05pt;\"><p>2.69</p></td></tr></tbody></table><p>* rounded from Norman's original numbers</p><p>Combined Jenner and Portal Zone Historical Resources Estimates</p><table><tbody><tr><td style=\"border:1.0pt solid black;height:12.2pt;padding:0in;vertical-align:top;width:73.15pt;\"><p>Mineral Zone</p></td><td style=\"border-bottom-style:solid;border-border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;height:12.2pt;padding:0in;vertical-align:top;width:120.5pt;\"><p>Category</p></td><td style=\"border-bottom-style:solid;border-border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;height:12.2pt;padding:0in;vertical-align:top;width:63.8pt;\"><p>Resource</p><p>Tonnes</p></td><td style=\"border-bottom-style:solid;border-border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;height:12.2pt;padding:0in;vertical-align:top;width:56.4pt;\"><p>Grade g/t Au</p></td><td style=\"border-bottom-style:solid;border-border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;height:12.2pt;padding:0in;vertical-align:top;width:57.0pt;\"><p>Grams</p></td><td style=\"border-bottom-style:solid;border-border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;height:12.2pt;padding:0in;vertical-align:top;width:49.6pt;\"><p>Ounces</p></td></tr><tr><td style=\"border-bottom-style:solid;border-border-left-style:solid;border-right-style:solid;border-top-style:none;border-width:1.0pt;height:24.3pt;padding:0in;vertical-align:top;width:73.15pt;\"><p>Jenner zone</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:24.3pt;padding:0in;vertical-align:top;width:120.5pt;\"><p>\"Probable and Possible\"</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:24.3pt;padding:0in;vertical-align:top;width:63.8pt;\"><p>1,801,134</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:24.3pt;padding:0in;vertical-align:top;width:56.4pt;\"><p>2.71</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:24.3pt;padding:0in;vertical-align:top;width:57.0pt;\"><p>4,876,635</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:24.3pt;padding:0in;vertical-align:top;width:49.6pt;\"><p>156,710</p></td></tr><tr><td style=\"border-bottom-style:solid;border-border-left-style:solid;border-right-style:solid;border-top-style:none;border-width:1.0pt;height:24.45pt;padding:0in;vertical-align:top;width:73.15pt;\"><p>Portal zone</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:24.45pt;padding:0in;vertical-align:top;width:120.5pt;\"><p>\"Probable and Possible\"</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:24.45pt;padding:0in;vertical-align:top;width:63.8pt;\"><p>657,753</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:24.45pt;padding:0in;vertical-align:top;width:56.4pt;\"><p>3.02</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:24.45pt;padding:0in;vertical-align:top;width:57.0pt;\"><p>1,984,324</p></td><td style=\"border-bottom:1.0pt solid black;border-left-style:none;border-right:1.0pt solid black;border-top-style:none;height:24.45pt;padding:0in;vertical-align:top;width:49.6pt;\"><p>63,766</p></td></tr></tbody></table><p><sup>*The historic estimates do not conform to current NI 43- 101 standards, are not classified as current mineral resources or mineral reserves, and should not be relied upon. A qualified person has not done sufficient work to classify the historic estimates as current mineral resources or mineral reserves.</sup></p><p><strong><u>2026 EXPLORATION OBJECTIVES</u></strong></p><div><ul style=\"list-style-type:disc;\"><li><p>The proposed 2026 drill program is comprised of 2-Phases of diamond drilling using large diameter NTW (2\"+)drilling core.</p></li></ul></div><div><ul style=\"list-style-type:disc;\"><li><p>Conduct systematic drilling along a fence in a known higher grade gold zone to demonstrate the use of metallic screen gold assaying to potentially establish higher gold grades. Recent work has demonstrated that historic gold assays may be understated by as much as 10- <percent>40%</percent> on the project.</p></li></ul></div><div><ul style=\"list-style-type:disc;\"><li><p>Update the existing geological database to modern GIS standards</p></li></ul></div><ul style=\"list-style-type:disc;\"><li><p>Identify additional gold drill targets over the 7.5 Kilometer trend in the Harrison Lake Corridor of Gold</p></li></ul><p>Tim Coupland, President and Chief Executive Officer, commented: \"We are extremely pleased to laying out our detailed drilling plans for a 14-hole drill campaign targeting previously known areas of high-grade gold mineralization. The Harrison Lake Gold Project represents a high potential gold project with a historical gold resource and high-quality database of exploration and drilling data. Trans Canada Gold is strategically positioned to expand its historic gold resource, potentially increasing its gold grade to bring these results to its existing shareholders and new investors. The Company will embark on a program to accelerate investor awareness and branding of our unique gold investment opportunity, n this precious metal super-cycle\"</p><p><strong><u>HARRISON LAKE GOLD DISTRICT SCALE GOLD PROJECT- GOLD AND EXPLORATION HIGHLIGHTS</u></strong></p><p>The Harrison Lake Gold Project contains a 7-kilometre-long ridge with diorite/ quartz bearing extensive intrusive related gold mineralization, situated near Harrison Lake, British Columbia. Historical drilling results confirm the presence of significant gold mineralization.</p><div><ul style=\"list-style-type:disc;\"><li><p>The Harrison Lake Mineral claims (5,025 ha or 7475 acre) are fully road accessible from the TransCanada Highway and Highway 7 in southwestern British Columbia, with numerous secondary logging roads and related power and rail service.</p></li></ul></div><div><ul style=\"list-style-type:disc;\"><li><p>The property covers a 7-kilometre strike length of the gold rich Harrison Lake Structural Zone, with stockwork type gold mineralization within diorite intrusions (Jenner and Portal Zones) including <strong>DDH-84-52: 102 meters of 3.54 g/t gold.</strong></p></li></ul></div><div><ul style=\"list-style-type:disc;\"><li><p>Jenner and Portal Zones include <strong>DDH 88-76 which intersected 7.0 meters averaging 21.4 g/tand DDH 88-121 which intersected 9.0 meters averaging 13.5 g/t.</strong> (Note: the intercept in DDH 88-121 is more than 50 meters vertically below the historic resource estimate and requires additional drilling).</p></li></ul></div><div><ul style=\"list-style-type:disc;\"><li><p>A corridor of similar diorite intrusions and \"gold in soil\" anomalies that extends for more than two kilometers to the south of the original discovery. Follow up drilling of some of these anomalies identified more diorite hosted stockwork type mineralization including <strong>DDH 88-130 which tested the Hill Zone and reportedly returned 30 meters averaging 3.0 g/t.</strong></p></li></ul></div><div><ul style=\"list-style-type:disc;\"><li><p>The style of mineralization is similar to the gold deposits of the Tintina Gold Belt that straddles the Yukon - Alaska border and it has also been recognized that the mineralized diorite intrusions are localized along a regionally extensive shear zone adjacent to a large diorite batholith. Snowline Gold's recent discovery of the Valley deposit clearly demonstrates the potential of these types of occurrences.</p></li></ul></div><div><ul style=\"list-style-type:disc;\"><li><p>Over <money>$10.0 Million</money> dollars in previous exploration drilling expenditures.</p></li></ul></div><div><ul style=\"list-style-type:disc;\"><li><p>The Company has assembled a strong Technical Team in place experienced in underground exploration drilling for gold.</p></li></ul></div><ul style=\"list-style-type:disc;\"><li><p>Drilling Permits have been approved and granted by the Province of British Columbia for 2026-2027.</p></li></ul><p>Michael Magrum P. Eng. is the Exploration Manager Mining, and as its key technical advisor (as a Qualified Person under National Instrument NI #43-101). Mr. Magrum will be responsible for overseeing the technical management of all Trans Canada Gold's mineral properties, and will be carrying out all requisite oversight for all new gold exploration drilling. Mr. Magrum is a seasoned geological engineer, who is recognized as professional. He prefers aggressive targeted drilling programs that have the potential to deliver multi-million-ounce gold deposits. Mr. Magrum has over 40 years of gold exploration and drilling experience, and has worked extensively in gold and mineral exploration and mining since 1971, starting his career in the Yellowknife Gold Mining Camp. The Company's option agreement is currently being reviewed by and is subject to TSX Venture acceptance of the TSX Exchange and completing the proposed drill programs will be dependent on a successful completion of the private placement announced concurrently with the property acquisition.</p><p>Michael Magrum, P. Eng, vice -president of mining for the Company and a qualified person as defined by National Instrument 43-101, has reviewed and approved the scientific and technical information used in this news release.</p><p><strong><u>ABOUT TRANS CANADA GOLD CORP. - GOLD &amp; MINERAL EXPLORATION/OIL AND GAS PRODUCTION/REVENUE PRODUCING OIL WELLS</u></strong></p><p>The Company is a Canadian discovery focused Gold Exploration company focused on acquiring and drilling advanced gold, silver and critical base metal mineral assets situated in Canada. The Company identifies, acquires and finances with its working interest partners, and Oil &amp; Gas Resource Development Exploration Company that is currently focused on developing and drilling its' production of conventional heavy oil exploration properties, increasing production capabilities, and increasing future oil production revenues through responsible exploration. The Company identifies, acquires and finances with its working interest partners, the ongoing development of oil and gas assets, primarily situated in Alberta Canada. The Company has qualified Senior exploration mining management and oil &amp; gas Geological teams of professionals, seasoned in exploration production, field exploration and drilling. The Company currently works with Croverro Energy Ltd., who has demonstrated proficiency, expected of an experienced oil and gas technical team that has proven oil production, and revenue success with large multi-lateral wells currently under their supervision. The Company has the necessary manpower in place to develop its natural resource properties and manage its production properties. The Company is committed to minimizing risk through selective property acquisitions, and responsible exploration drilling, and maximizing long term gold and strategic mineral and petroleum and natural gas resource assets.</p><p><strong><u>FOR FURTHER INFORMATION, PLEASE CONTACT:</u></strong></p><p>Tim Coupland, President and CEO<br/>Trans Canada Gold Corp.<br/>Tel: (604) 681-3131<br/><a href=\"mailto:astar@telus.net\" rel=\"nofollow noopener\">astar@telus.net</a><br/><a href=\"https://pr.report/j487\" rel=\"nofollow noopener\">www.transcanadagold.com</a></p><p>Mario Drolet<br/>President<br/>MI3 Communications Financieres Inc., Montreal Quebec<br/>Tel: (514) 904-1333<br/>Cell: 514) 340-3813<br/>E-Mail: <a href=\"mailto:Mario@mI3.ca\" rel=\"nofollow noopener\">Mario@mI3.ca</a></p><p><i><strong>Neither the TSX Venture Exchange nor its Regulation Services Provider, (as the term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.</strong></i></p><p><strong>SOURCE:</strong> Trans Canada Gold Corp.</p><br/><br/>View the original <a href=\"https://www.accessnewswire.com/newsroom/en/metals-and-mining/trans-canada-gold-announces-plans-for-exploration-and-drilling-on-its-harrison-la-1142183\" rel=\"nofollow noopener\">press release</a> on ACCESS Newswire<br/><br/><img height=\"0\" loading=\"lazy\" src=\"https://app.accessnewswire.com/img.ashx?id=1142183\" width=\"0\"/></article>",
            "link": "https://www.stocktitan.net/news/TTGXF/trans-canada-gold-announces-plans-for-exploration-and-drilling-on-04qb9xhbt7e4.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 15:00:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Booking Holdings Inc. to Present at the Morgan Stanley Technology, Media & Telecom Conference | BKNG Stock News",
            "description": "<article class=\"article\"><div class=\"xn-content\"><p><span class=\"legendSpanClass\"><location idsrc=\"xmltag.org\" value=\"LU/us.ct.noralk\">NORWALK, Conn.</location></span>, <span class=\"legendSpanClass\">Feb. 27, 2026</span> /PRNewswire/ -- Booking Holdings (NASDAQ: <a class=\"symbol-link\" href=\"/overview/BKNG/\" title=\"View BKNG stock overview\">BKNG</a>) today announced that Chief Financial Officer Ewout Steenbergen will participate in a fireside chat at the Morgan Stanley Technology, Media &amp; Telecom Conference, held in <location idsrc=\"xmltag.org\" value=\"LU/us.ca.sanfrn\">San Francisco</location>, on March 3, beginning at 9:15 am PT / 12:15pm ET. A live audio cast of the presentation will be available to the public at <a href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4628942-1&amp;h=2835367194&amp;u=https%3A%2F%2Fir.bookingholdings.com%2Fevents-and-presentations%2FEvents%2Fdefault.aspx&amp;a=https%3A%2F%2Fir.bookingholdings.com%2Fevents\" rel=\"nofollow noopener\" target=\"_blank\">https://ir.bookingholdings.com/events</a>, and a replay will be available approximately 24 hours later.</p><div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\"><p><a href=\"https://mma.prnewswire.com/media/644288/Booking_Holdings_Logo.html\" rel=\"nofollow noopener\" target=\"_blank\"><img alt=\"(PRNewsfoto/Booking Holdings Inc.)\" loading=\"lazy\" src=\"https://mma.prnewswire.com/media/644288/Booking_Holdings_Logo.jpg\" title=\"(PRNewsfoto/Booking Holdings Inc.)\"/></a></p></div><p>Source: Booking Holdings<br/>#BKNG_Corporate</p><p><b>About Booking Holdings<br/></b>Booking Holdings (NASDAQ: <a class=\"symbol-link\" href=\"/overview/BKNG/\" title=\"View BKNG stock overview\">BKNG</a>) is the world's leading provider of online travel and related services, provided to consumers and local partners in more than 220 countries and territories through five primary consumer-facing brands: <a href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4628942-1&amp;h=1213919877&amp;u=https%3A%2F%2Fwww.booking.com%2F&amp;a=Booking.com\" rel=\"nofollow noopener\" target=\"_blank\">Booking.com</a>, <a href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4628942-1&amp;h=1681088157&amp;u=https%3A%2F%2Fwww.priceline.com%2F&amp;a=Priceline\" rel=\"nofollow noopener\" target=\"_blank\">Priceline</a>, <a href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4628942-1&amp;h=539450321&amp;u=https%3A%2F%2Fwww.agoda.com%2F&amp;a=Agoda\" rel=\"nofollow noopener\" target=\"_blank\">Agoda</a>, <a href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4628942-1&amp;h=3733246272&amp;u=https%3A%2F%2Fwww.kayak.com%2F&amp;a=KAYAK\" rel=\"nofollow noopener\" target=\"_blank\">KAYAK</a> and <a href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4628942-1&amp;h=2908565343&amp;u=https%3A%2F%2Fwww.opentable.com%2F&amp;a=OpenTable\" rel=\"nofollow noopener\" target=\"_blank\">OpenTable</a>. The mission of Booking Holdings is to make it easier for everyone to experience the world. For more information, visit BookingHoldings.com and follow us on X @BookingHoldings.</p><p>SOURCE Booking Holdings</p></div></article>",
            "link": "https://www.stocktitan.net/news/BKNG/booking-holdings-inc-to-present-at-the-morgan-stanley-technology-kye9kk6hwm8x.html",
            "author": "stocktitan",
            "pub_date": "Fri, 27 Feb 2026 15:01:00 GMT",
            "source": "stocktitan",
            "kind": 1,
            "language": "en"
        }
    ]
}